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Immunoglobulin E (IgE) is fundamental to the allergic response and the functions of 
IgE are mediated by its Fc region binding to two receptors, FcεRI and CD23 (FcεRII). 
The interaction of IgE with other proteins have complicated our investigations of the 
unique role each receptor plays. To solve this, a small-scale library of IgE-Fc proteins 
was designed with two key positions, one at each receptor-binding site mutated. The 
unpredictable allosteric nature of IgE prevents rational engineering approaches, thus the 
design of a membrane-bound IgE-Fc-GFP-tagged protein allowed for the generation of 
a membrane-surface display library of stable cell lines. A FACS selection assay 
identified IgE-Fc proteins with weakened binding to a single IgE-receptor, which serves 
as a proof-of-principle for this concept. 
 
Additional studies into human CD23 and the differences between it and murine CD23 
revealed additional levels of regulation for IgE-binding not seen in other species and 
this is due to its unique properties. Human CD23 is an unusual antibody receptor, being 
a calcium dependent (C-type) lectin that has lost its carbohydrate binding capability. 
 Ca2+ binds to and increases CD23’s affinity for IgE, and one of two Ca2+ binding sites 
usually present in C-type lectins is absent in human but present in murine CD23.  To 
understand if the loss of the second Ca2+ binding site has led to a regulatory gain/loss of 
function in human CD23, a panel of CD23 mutant proteins with increasingly ‘mouse-
like’ sequences was generated. 
 
The insertion of the second Ca2+ binding site was verified by HSQC-NMR whilst 
molecular dynamic simulations provided a means of understanding the flexibility of the 
proteins. It revealed that binding of two Ca2+ ions tethers the soluble CD23 loops into 
position in the most mouse-like mutant protein, limiting possible conformations for IgE 
binding. Complementary Biacore experiments indicated that higher calcium binding 
affinity may have come at a cost of weakened IgE binding, as data in the presence and 
absence of Ca2+ showed decreased binding affinities of the proteins for human IgE. This 
regulatory difference between murine and human soluble CD23 could inform the 
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Chapter 1 Introduction 
1.1 Allergy, asthma and its prevalence in the world  
Allergy is a defined as a range of conditions following an immune system response to 
an otherwise innocuous antigen. It is a growing problem and the prevalence of allergic 
diseases has continued to rise in the industrialised world for more than 50 years 
(Pawankar et al., 2011). Across the world, school children are experiencing 
sensitization rates of 40-50% to one or more common allergens. Worldwide, the 
incidence of allergic asthma is plateauing in high income countries, whilst still rising in 
prevalence within low and middle income countries, as they adopt a more Western-type 
lifestyle (Pawankar et al., 2011). 
 
Asthma is particularly problematic in the United Kingdom, which has the highest 
prevalence rates of childhood asthma worldwide (Asthma UK)(Anandan et al., 2010). 
This corresponds to one in eleven children suffering from asthma in the UK, and has 
considerable impact on the quality of life of people with asthma. School children with 
asthma miss 254 days of school per 100 children (Asthma UK)(Mukherjee et al., 2016). 
For adults, asthma accounts for 79 days taken off work per 1000 adults, rendering dire 
financial implications for companies, with the total cost of asthma in the UK estimated 
to be about £5 billion (Mukherjee et al., 2016; Nunes et al., 2017). Better care is 
required for all these people, especially vulnerable patients with severe asthma. It was 
been estimated that better routine care could have prevented 46% of asthma deaths 
(Levy, 2015). 
 
The pharmacological management of asthma has not changed much over recent years 
for most people with asthma. Newly diagnosed patients are prescribed inhalers 
containing corticosteroids and, if symptoms worsen, they are prescribed combination 
inhalers, which contain corticosteroids combined with inhalable long-acting b2 agonists. 
If the symptoms still cannot be controlled, the doses are increased until the patient is 
given oral steroids. At this point, biologics such as monoclonal antibody treatment may 





1.2 The role of Immunoglobulin E (IgE) in asthma 
 
Allergen-specific IgE has been recognised to play a central role in allergic asthma, with 
most asthma cases due to an IgE-mediated reaction after sensitisation to an inhaled 
allergen. IgE is a glycosylated protein belonging to the immunoglobulin family of 
proteins, and was the fifth and final antibody class to be identified in humans 
(Stanworth, 1993). IgE can either be expressed as a membrane-bound part of the B-cell 
receptor (BCR) as one of five B-cell receptors isotypes or be secreted as a soluble 
protein by plasma cells. In the serum of healthy individuals, the concentration of IgE is 
limited to ~50-200 ng/ml, which is relatively low compared to other antibody isotypes 
found at ~1-10 mg/ml (Dullaers et al., 2012). 
 
Despite knowing the importance of IgE in asthma and allergies, the role of IgE in 
normal physiology is not fully understood. High levels of IgE are produced in humans 
in response to parasitic infections such as Ascaris lumbricoides (Lynch et al., 1998; 
McSharry et al., 1999) and Schistosoma mansoni (Rihet et al., 1991) although IgE is not 
critical for their removal (Harris and Gause, 2011). High IgE levels were also found in 
patients less likely to die from acute mycocardial infarction which was associated with 
delayed thrombin production in blood clotting (Szczeklik et al., 1993; Szczeklik and 
Dawson, 2000). A role for IgE in tumour surveillance has also been suggested in which 
IgE directs an immune attack on tumours by antibody-dependent cell-mediated 
cytotoxicity (Karagiannis et al., 2003; Josephs et al., 2014). Insights into the workings 
of this rare antibody are best understood in allergic asthma.  
 
Asthmatic patients, when asked about their condition, would mostly describe their 
clinical symptoms such as wheezing, coughs and chest tightening. These symptoms are 
presented as the ‘tip of the iceberg’ depicted in Figure 1-1, while the pathophysiological 
role of IgE in allergic asthma is presented in the rest of the iceberg. IgE can be seen to 
influence every layer of the iceberg at every stage of the allergic cascade (Palomares et 
al., 2017). High levels of total serum IgE are associated with a high asthma severity 
score, lung function abnormalities, a higher risk of hospital admission and a high dose 
of inhaled corticosteroids (Carroll et al., 2006; Tanaka et al., 2014). Targeting IgE has 





As indicated in Figure 1-1, there are two stages in the provocation or immediate 
hypersensitivity response; the sensitisation stage, and the re-exposure stage and IgE is 
involved in both. In the sensitisation stage, an inhaled allergen is taken up by an antigen 
presenting cell such as a dendritic cell or a B cell in the epithelium lining of the lungs or 
nose. The antigen presenting cells internalise the allergen, process it and present the 
processed allergen to other immune cells, in particular T cells, which then acquire a T 
helper type 2 (Th2) cell phenotype. The Th2 cells will interact specifically with B-cells 
through the B cell major histocompatibility complex (MHC) class II and co-stimulatory 
molecules, thereby causing the B-cell to undergo class-switch recombination (CSR) to 
induce the production of IgE antibodies (Galli and Tsai, 2012). 
 
Further future encounters with the same allergen lead to an exacerbation that can 
present in two phases: the early acute phase (that occurs within minutes), and the late-
phase reaction (that occurs within hours). In the early acute phase, allergen-caused 
crosslinking of IgE-bound to its receptor, FceRI, located on mast cells and basophils, 
results in degranulation of the cell, and the release of preformed mediators such as 
histamine, inflammatory cytokines and chemokines, and leukotrienes. These mediators 
induce the constriction of bronchial smooth muscle, thereby narrowing the pulmonary 
airways. This results in patients presenting with clinical symptoms which include 
wheezing, sneezing and rhinorrhea and/or mucus secretion.  
 
Mediators released by the early phase recruit inflammatory granulocytes and Th2 cells 
to the site of inflammation and continue into the late-phase reaction. These cells release 
toxic proteins such as eosinophilic cationic protein, major basic protein etc. and 
cytokines, resulting in increased vascular permeability, bronchial oedema and 
bronchospasms. If the immune reaction occurs without any resolution or if the allergen 
persists, the constant inflammation can evolve into the chronic phase. This phase is 
associated with airway remodelling, eosinophilia and further IgE production. IgE has 
been implicated in airway remodelling in humans by increasing the proliferation of 
airway smooth muscle, and depositing pro-inflammatory collagens and fibronectin 
(Roth et al., 2013; Redhu et al., 2013). For the patient, this results in progressive loss of 







Figure 1-1 The Iceberg model of IgE in allergic asthma. The symptoms of allergic asthma are 
indicated by the portion of the iceberg above water; whilst the pathophysiological changes of the disease 
occur in the depths of the iceberg. Changes in the submucosa, peripheral blood vessels and lymph nodes 
occurs from early onset of the disease. IgE in yellow, is present at all stages of the diseases and at al 
layers of the iceberg. ECP = eosinophil cationic protein; FcεRI = high affinity IgE receptor; FcεRII = low 
affinity IgE; GM-CSF = granulocyte-macrophage colony-stimulating factor; IFNγ = interferon gamma; 
IgE = immunoglobulin E; IL = interleukin; ILC = innate lymphoid cells; LTC4 = leukotriene C4; MBP = 
major basic protein; MCP = monocyte chemotactic protein; MRP = myeloid related proteins; PAF = 
platelet-activating factor; TGFβ = transforming growth factor beta; Th = T helper cells, TLR: toll-like 
receptors; TNFα = tumour necrosis factor alpha; Treg = regulatory T cells; TSLP: thymic stromal 




IgE plays a role in every stage of allergic asthma as depicted in Figure 1-2. It acts with a 
variety of cells from the sensitisation stage through to the late phase of the allergic 
response, and even in the chronic phase of the disease. It exerts these 
immunomodulatory effects via binding to its two receptors, the structure and function of 
which are discussed in the next sections. 
 
 
Figure 1-2 The role of IgE in all phases of allergic asthma. IgE plays a central role in the sensitisation, 
early-acute, and late phases, as well the chronic consequences of non-controlled allergic asthma. Image 
reproduced from Palomares et al. 2017. 
 
1.3 The Structure of IgE 
 
IgE is the most glycosylated antibody of all the immunoglobulin classes (Plomp et al., 
2014; Arnold et al., 2004; Dorrington and Bennich, 1978) as shown in Figure 1-3. It has 
a molecular weight of 190 kDa, of which about 170 kDa is protein and around 20 kDa is 
carbohydrate. Structurally, it shares the same molecular Y-shape as all antibodies, 
consisting of two identical heavy chains and two identical light chains. IgE differs from 
immunoglobulin G (IgG), in that the heavy e chain contains an additional domain (Ce2) 
in place of the hinge region of IgG. Unlike IgG, the native structure of IgE is not 




The fragment-antigen binding (Fab) region of IgE contains the variable domains, as 
depicted in Figure 1-3, which bind to antigens and confers the epitope-specificity of the 
antibody. The constant or fragment crystallisable (Fc) regions of IgE impart its effector 
functions (Figure 1-3). IgE mediates its immune functions by binding through the Ce3 
domain of the Fc region to its receptors: the high affinity receptor, FceRI, and the low 
affinity receptor FceRII or CD23. Simultaneous engagement of both receptors by IgE is 
prevented by an intrinsic allosteric mechanism (Dhaliwal et al., 2012; Borthakur et al., 
2012). 
 
Figure 1-3 The structure of IgE. A cartoon representation of the domain structures of IgE showing the 
inter- and intra-molecular disulphide bridges, and the sites of N-linked glycosylation. Image reproduced 
from Gould and Sutton 2008.  
 
1.3.1 Membrane IgE 
 
Comparing membrane-bound IgE to soluble IgE, additional domains are observed in the 
membrane-bound structure as illustrated in Figure 1-4. These additional domains 
include the extracellular membrane proximal domain (EMPD), the transmembrane 
domain, and the cytoplasmic tail, which are all found complexed with the signalling 
chains Iga and Igb; together they form the B cell receptor (BCR). The EMPD is found 
between the Ce4 domain and the transmembrane domain. In humans, the EMPD has 
two isoforms, which differ in length by 52 amino acids, which are involved in 
stabilising inter e chain disulphide bridges. The short isoform has an EMPD length of 
14 amino acids, whilst the long isoform has an EMPD length of 66 amino acids, 
rendering the latter isoform at least twice as long as the EMPD from any other 





contains 4 cysteines, unlike other antibodies, which only contain one cysteine. 
Furthermore, it is proposed to have a different disulphide bonding pattern, in which two 
cysteines form an intramolecular bond, while the remaining cysteines form 
intermolecular bonds as expected (Bestagno et al., 2001).  
 
 
Figure 1-4 Membrane IgE as part of the BCR and soluble IgE. V = variable domain, Ce = epsilon 
constant domain, EMPD = extracellular membrane proximal domain, TM = transmembrane domain, CT 
= cytoplasmic tail. The two forms of IgE are synthesised by different cells.  
 
The EMPD isoforms bind to differently glycosylated Iga proteins; the long form 
associates with the completely glycosylated Iga protein, whereas the short form 
associates with a glycoform which is partially sensitive to endoglycosidase H (Batista et 
al., 1996). The cell membrane expression changes too, with the short isoform 
transported to the cell surface at a higher rate, while transport of the long isoform is less 
efficient (Batista et al., 1996). The signalling pattern of the two isoforms also differs, 
with the kinetics of protein tyrosine phosphorylation varying, although still 
phosphorylating the same substrate proteins. Cross-linking of the short isoform leads to 
inhibition of B-cell growth, whereas signalling through the long form does not affect 
cell proliferation (Batista et al., 1996).  
 
The importance of the long EMPD is not fully understood since it is not found in mice. 
























engagement of an IgE BCR (Poggianella et al., 2006). Its length might give an 
advantage to the conformational space the IgE-Fabs can explore, or the type of allergens 
it can bind to. Alternatively, the EMPD may play a role in the IgE repertoire 
determination or in the formation of memory IgE cells (Zuidscherwoude and van Spriel, 
2012; Haniuda et al., 2016). The domain has been targeted therapeutically to prevent the 
production of soluble IgE, and is being considered as a second generation anti-IgE 
candidate (Feichtner et al., 2008; Vigl et al., 2017). The exact role of the EMPD in 
allergic disease is however, yet to be fully explored, with its three-dimensional structure 
not yet known.  
 
The hydrophobic transmembrane region of membrane-bound IgE is similar in sequence 
to other immunoglobulins, with the cytoplasmic tail of IgE not expected to signal 
without its chaperone proteins Iga and Igb. However, it has been suggested that the 
cytoplasmic tail may contribute to signalling (Yang et al., 2016).  
 
1.3.2 IgE as a flexible protein 
  
IgE is a very flexible protein that can bend such that the Ce2 domains fold back over the 
Ce3-4 domains or extend all the Fc domains (Drinkwater et al., 2014). In solution or 
when bound to its receptors, IgE is found in a symmetrically bent conformation (Zheng 
et al., 1992). IgE can, however, extend from its bent conformation, and ‘flip’ to a bent 
conformation on its other side. A proposed timeline of IgE unbending, determined by 
molecular dynamics, can be observed in Figure 1-5. This movement is not a simple 
hinge movement, as it consists of the (Ce2)2 domains twisting relative to the Ce3-4 
domains, and may involve local disorder or unfolding of domains or linker regions to 
accommodate such large-scale motions (Drinkwater et al., 2014).  
 
The reason behind IgE’s flexibility can perhaps be understood in terms of allergen-
binding. A bent IgE structure, bound to FceRI, is optimally positioned for allergen 
capture, and crosslinking, which triggers the allergic response. In constrast, an extended 
IgE molecule is beneficial for allergen capture when IgE is part of the BCR because the 
Fab arms can sample a greater range of conformational space, thus ensuring B-cell 





Figure 1-5 IgE-Fc unbending. Theoretical conformations of IgE-Fc found in energy minima of 
molecular dynamics simulations illustrate a possible pathway for the IgE-Fc unbending process. This 
process involves twisting and bending in an asymmetrical fashion. Image adapted from Drinkwater et al. 
2014. 
 
1.4 IgE and its Receptors: The high affinity receptor, FceRI 
 
FceRI, when activated by allergen cross-linked IgE, causes mast cell and basophil 
degranulation as shown in Figure 1-6A. This interaction is fundamental to the allergic 
response; as seen in FceRI deficient mice, local or systemic anaphylactic responses 
were abolished when compared to wild type (WT) mice (Dombrowicz et al., 1993; 
Kinet, 1999). The FceRI protein is a membrane-bound complex expressed as a tetramer 
on mast cells and basophils. It is composed of one a subunit, one b subunit and two g 
subunits as depicted in Figure 1-6B. The alpha subunit contains one transmembrane 
domain, and two Ig-like domains (D1 and D2) (Garman et al., 1998; Kinet, 1999). D2 
contains two asymmetric binding sites for one IgE-Fc molecule, so that each Ce3 
domain of IgE-Fc binds to one FceRI receptor (Garman et al., 2000). The b and g 
subunits contain Immunoreceptor tyrosine-based activation motifs (ITAMs) involved in 
signal transduction. The human high affinity receptor can also be expressed without the 
b subunit as a trimeric ag2 receptor, which is expressed on many more immune cells 








Figure 1-6 The role of FceRI and its arrangement of subunits. A) FceRI is involved in mast-cell 
degranulation. Image reproduced from Wright et al. 2015. B) A schematic diagram of the FceRI tetramer 
(Kindt et al., 2007). Image reproduced from Kuby Immunology, sixth edition, 2007. 
 
The D1 and D2 domains of FceRI fold back to reveal a hydrophobic ‘ridge’, which is 
the IgE binding site, allowing for a 1:1 binding stoichiometry. There are in fact, two 
hydrophobic sub-sites on Ce3 of IgE that bind to FceRI with high affinity (Ka ~ 1010 M-
1) (Garman et al., 2000) as depicted in Figure 1-7. The high affinity coupled with the 
slow dissociation rate (koff ~ 10-5 s-1) (Holdom et al., 2011) ensures that FceRI present 
on mast cells is saturated with bound IgE, even in the absence of antigen. Combined 
with local production of IgE in the tissues and rebinding of IgE, the IgE stays associated 
for most of the cell’s life span so that the cells are always primed for the Th2 cell 
response. These characteristics of IgE are unique among the antibodies classes; IgG has 
as lower affinity and faster koff rate constant for its receptors when compared to IgE 
(Maenaka et al., 2001). 
 
Although the extracellular domains of the a subunit contain seven N-linked 
glycosylation sites, and the Ce3 domain of IgE is also glycosylated, the interaction 
between FceRI and IgE-Fc is strictly protein based. The key IgE residue involved in 
FceRI binding in subsite 1 is R334, involved in a salt bridge and hydrogen bonding at 
the interface as shown in Figure 1-7A. The R334S mutation has a pronounced effect on 
the affinity of IgE-Fc for FceRI, reducing affinity by 50-fold (Henry et al., 1997; Hunt 
et al., 2008) The second subsite shown in Figure 1-7B, is characterised by a ‘proline 
sandwich’. Pro426 of IgE-Fc is placed between Try87 and Trp110 of the a subunit D2 




A)                                                   B) 
  
Figure 1-7 IgE binding to FceRI; interactions at both subsites. Green = IgE-Fc, blue = FceRI, orange 
= hydrogen bonds. A) Ce3 domain binds via two salt bridges (Arg334-Glu132 and Asp362-Lys117) to a 
single chain of FceRIa. B) The proline sandwich at site 2, with Pro426 of Ce3 packed between Trp87 
and Trp110 of the receptor (blue). PDB file: 1F6A. 
 
Inhibiting the IgE-FceRI interaction has been proven to be clinically efficacious as 
demonstrated by the first generation anti-IgE biologic Xolair® (Omalizumab), further 
discussed in section 1.6. 
 
1.5 IgE and its Receptors: The low affinity receptor, FceRII or CD23 
 
CD23 differs from most other immunoglobulin receptors, as it belongs to the C-type 
(calcium-dependent) lectin superfamily. As a membrane-bound protein, CD23 is a 
member of the type II transmembrane glycoprotein family, and as a trimer composed of 
three lectin domains, followed by a triple a-helical coiled-coil stalk, as illustrated in 
Figure 1-8A. The stalk is distanced from the membrane by a short extracellular 
sequence before the single transmembrane domain, while the intracellular part of the 
protein contains a short N-terminal cytoplasmic tail. The stalk region is susceptible to 
proteolysis by proteases such as A Disintegrin And Metalloproteinase Domain- 
containing protein 10 (ADAM10), and the major house dust mite protease allergen Der 
p I, to release soluble fragments pictured in Figure 1-8B & C (Lemieux et al., 2007; 
Shakib et al., 1998). Der p I cleaves CD23 at two sites: one site is located in the stalk at 
Ser155-Ser156, and the second site is located in the C-terminal tail that binds to CD21 
(CR2), at Glu298-Ser299, as depicted in Figure 1-8A (Schulz et al., 1997). The 

















DerCD23 retains its binding activity to CD21, which is a membrane glyco-protein 
expressed on B-cells (Nadler et al., 1981). The ectodomain of CD21 is composed of 15 
(Weis et al., 1988; Gilbert et al., 2006) or 16 (Pochon et al., 1992) short consensus 
repeat domains with a total length of 38 nm. CD21 on B cells upregulates IgE 
production by binding to soluble CD23 (Aubry and Pochon, 1992), as discussed further 
in section 1.5.3. 
 
    
Figure 1-8  Membrane CD23 and its soluble forms. A) Membrane-bound CD23, the scissors denote 
where the protease Der p I cleaves the protein. B) Soluble trimeric CD23 C) Soluble derCD23. Images 
adapted from Gould and Sutton 2008. 
 
Human membrane CD23 is expressed on a range of cells, including T and B cells 
(Kikutani et al., 1989; Armitage et al., 1989) monocytes (Vercelli et al., 1988), 
follicular dendritic cells, intestinal epithelial cells (Yu et al., 2003), and bone marrow 
stromal cells. In mice, membrane CD23 expression is limited to B cells, follicular 
dendritic cells (Richards and Katz, 1990) and enterocytes (Yu et al., 2003). The coiled-
coil stalk of membrane CD23 is protected from proteolysis when bound to soluble IgE, 
which leads to a reduction in the synthesis of IgE, as shown in Figure 1-9. Soluble 
trimeric CD23 fragments through interactions with CD21, increase IgE synthesis, as 
shown in Figure 1-9, whereas soluble monomeric CD23 reduces IgE synthesis. These 
multiple roles of CD23, dependent on the oligomerisation and soluble or membrane-
bound state of the protein, demonstrate the importance of CD23 in regulating IgE 






A    B   C  
  
Figure 5.3 The structure of CD23 and its soluble forms. A) Membrane-bound CD23 with 
cytoplasmic N terminal regions, which include a signal motif required for endocytosis. The 
trimeric coiled-coil stalk supports the IgE binding ‘head’ domains shown in red with the α4β5-
integrin binding sites at the base of the head domain and the C-terminal tail to which CD21 
binds. Adapted from Gould and Sutton 2008. B) Soluble CD23 C) derCD23  
 
 
The Fc region of IgE is capable of binding to two molecules of monomeric soluble CD23 and 
thus can link two separate CD23 fragments; this interaction can polymerise to form a 
signalling platform for the survival and differentiation of B cells [11]. The soluble form of 
CD23 can also promote T-cell differentiation in a process known as facilitated antigen 
presentation. Different regions of CD23 are capable of binding to various other ligands apart 
from IgE; the C-terminal tail binds to the complement receptor CD21 (CR2) which once 
bound to sCD23 is capable of enhancing IgE synthesis as shown in Figure 5.4. Mouse CD23 
lacks the C-terminal tail and does not bind to CD21, and has a shorter stalk region than 
human CD23 [26,27]. CD23 also binds to the integrins CD11b, CD11c and the α4β5-integrin, 
interactions that are crucial for human B cell survival and highlight the cytokine-like ability 
of sCD23 [15].  
  




C-type lectins usually bind to carbohydrate, and CD23 is unusual in this respect, in that 
it binds to its ligands via protein-protein interactions. IgE is the principal ligand for 
CD23, however, human CD23 also binds to domains 1 and 2 of the complement 
receptor CD21 (CR2) (Aubry and Pochon, 1992), MHC class II proteins (Kijimoto-
Ochiai, 2002), the vitronectin receptor (αVβ3-integrin) (Hermann et al., 1999) and the 
CD11b, CD11c and α4β5-integrins, interactions that are crucial for human B cell 
survival (Acharya et al., 2010). A putative carbohydrate binding site to CD23 on CD21 
domains 5-8 has been described (Aubry et al., 1994) but this has not been confirmed 




Figure 1-9  The roles of membrane-bound and soluble CD23. CD23 regulates soluble IgE (sIgE) 
production. Membrane CD23 binds to sIgE to reduce IgE synthesis. Soluble CD23 interacts with 
membrane IgE and CD21 to upregulate IgE synthesis. Image reproduced from Wright et al. 2015. 
 
As previously mentioned, CD23 has various roles dependent on its oligomerisation 
state, and this also has an impact on the affinity for its interactions with its ligands. A 
single head domain of CD23 binds to IgE with a KA of ~106-107 M-1. Due to their low 
binding affinities, C-type lectins often enhance their overall affinity for a ligand by 
oligomerising, to create an avidity affect (Taylor and Drickamer, 2003). The affinity of 
trimeric CD23 for IgE had a KA of ~108-109 M-1, approaching the affinity for FceRI for 




1.5.1 The Structure of derCD23 as a C-type lectin  
 
C-type lectins (CTLs), found on a plethora of cells, characteristically bind 
carbohydrates in a calcium-dependent manner. The functional versatility of this protein 
fold, depicted in Figure 1-10A, enables a wide range of interactions; from cell adhesion 
molecules to pathogen recognition receptors in innate immunity (Cambi et al., 2005; 
Zelensky and Gready, 2005; Drickamer and Taylor, 2015).  The head domain of CD23 
contains the C-type lectin-like domain (CTLD), as shown in Figure 1-10B. This domain 
has four conserved cysteine residues labelled C1-C4 in Figure 1-10, two of which form 
a cysteine bridge at the base of the long-loop region (Zelensky and Gready, 2003). The 
long-loop region begins and terminates at the same point of the core domain and 
encompasses loop 1 to loop 4 of the CTLD structure (Zelensky and Gready, 2005). It is 
also the region involved in calcium-dependent carbohydrate binding.  
 
Calcium ions tend to bind to the long-loop region at two locations, namely the primary 
and auxiliary binding sites. Structures of CTLDs reveal that they are capable of binding 
to zero, one, two or three calcium ions. The primary site is involved in carbohydrate 
binding (Zelensky and Gready, 2005). CD23 in many species is predicted to bind to two 
calcium ions based on sequence analysis. Human CD23 is unusual in that it only binds 
to one calcium ion at the primary site with an affinity of 1.5 mM (Hibbert et al., 2005; 
Yuan et al., 2013). The residues in the auxiliary binding site of human CD23 are 
positively charged, as shown in Figure 1-11, unlike the residues in CD23 of other 
species, meaning that they are unlikely to co-ordinate a calcium ion. 
 
The calcium-dependent carbohydrate interactions of CTLs can be divided into two 
groups, based on their glycan-specificity. CTLs containing a QPD tripeptide motif 
preceding loop 4, bind to galactose and N-acetylgalactosamine, while CTLs with an 
EPN motif are specific binders for  mannose, N-acetylglucosamine, glucose and L-
fucose (Lee et al., 2011). Human CD23 lacks both motifs, however murine CD23 
contains the EPN motif. In human CD23, the asparagine of the EPN has been 
substituted with a threonine residue, causing the loss of the carbonyl group that 
coordinates calcium ions for glycan binding. In fact, human CD23 is unable to bind to 
38 
 




Figure 1-10 Structural comparison of a typical CTLD and WT human derCD23. Yellow spheres = 
calcium ions, orange = cysteine bridges, blue = long loop region. P = primary calcium binding site, A = 
auxiliary calcium binding site. a helices and b strands are numbered according to convention. A) A 
cartoon representation of a typical CTLD, DC-SIGN, pdb file: 1K9I. B) A cartoon representation of WT 
human derCD23, pdb fie: 4G9A.  
 
The loss of carbohydrate binding in human CD23, coupled with the loss of calcium 
binding in the “auxiliary” binding site, may have freed those co-ordinating residues to 
make additional contacts with other ligands, such as IgE. This may have resulted in 
stronger binding to IgE, which in the context of allergy, may be a factor in determining 






































Figure 1-11 The calcium binding site of human derCD23. The principal calcium-ion-binding site 
(blue) and the “auxiliary” site (orange) in wild-type human CD23. Calcium ion shown in yellow, residues 
and loops labelled, pdb file: 4G9A.  
 
1.5.2 CD23 interactions with IgE 
 
Calcium is not essential for CD23 binding to human IgE-Fc, but enhances the affinity of 
derCD23 for IgE-Fc by 30-fold (Hibbert et al., 2005; Yuan et al., 2013). The protein 
interface of the derCD23/Ce3-4 interaction is illustrated in Figure 1-12. CD23 binds to 
IgE with a 2:1 stoichiometry, in contrast to the 1:1 stoichiometry seen between IgE and 
FceRI. Loops 1 and 4 contribute to IgE binding; loop 1 consists of derCD23 residues 
Leu226 to Glu231 while loop 4 consists of residues Arg253 to Glu257. The poor 
surface complementarity means that the interaction is dominated by salt bridges, and 
hydrogen bonds (Dhaliwal et al., 2012). Binding of IgE-Fc (consisting of the Ce2, Ce3 
and Ce4 domains) to derCD23 involves the same residues as that of  the derCD23/Ce3-
4 interaction, but with an additional hydrogen bond between His216 of derCD23 and 















Figure 1-12 Calcium-free IgE binding to derCD23. Red = derCD23, green = IgE, orange = salt bridges, 
green = hydrogen bonds, blue = a hydrogen bond found in 5 out 6 molecules in the crystallographic unit 
cells. PDB file: 4EZM. 
 
In the presence of calcium, loop 4 of derCD23 makes additional contacts with Fce3-4, 
as depicted in Figure 1-13. Two new salt bridges form between Asp227(derCD23) and 
Arg440 of Fce3-4, and Asp258(derCD23) and Arg440, as well as two new hydrogen 
bonds between Gln255(derCD23) and Arg440, and Cys273 (derCD23) and Ser437 of 
Fce3-4, despite the two hydrogen bonds between Ser254(derCD23) and Arg440 being 
lost (Yuan et al., 2013). Thermodynamically, without calcium, the derCD23/Fce3-4 
interaction is highly temperature-dependent, however, in the presence of calcium, it less 
so. The binding affinity of derCD23 for Fce3-4 changes by two-fold with vs without 















Figure 1-13  IgE binding to calcium-bound derCD23. Red = derCD23, green = IgE, orange = salt 
bridges, green = hydrogen bonds, blue circle = areas of difference, compare with Figure 1-12. PDB file: 
4GKO. 
 
The FceRI and CD23 binding sites on IgE are allosterically linked (Dhaliwal et al., 
2012). This means that binding of one receptor to IgE-Fc is transmitted through the 
protein to the other functional binding site, allowing for the regulation of IgE activity. 
This activity might have evolved to prevent CD23 crosslinking IgE-bound to FceRI on 
mast cells and basophils, which would result in systemic anaphylaxis (Gould and 
Sutton, 2008). The different orientations of the Ce3 domains and the clashes that arise 
























Figure 1-14 The steric clashes that arise when both IgE receptors are modelled to bind to Fce3-4. 
Orange spheres = clashes when FceRI is modelled onto the derCD23-Fce3-4 complex. Green spheres = 
when derCD23 is modelled onto the FceRI - Fce3-4 complex. A) The Ca trace of the derCD23-Fce3-4 
‘open’ complex shown in blue with FceRI in red. B) The Ca trace of the FceRI-Fce3-4 ‘closed’ complex 
in red with derCD23 in blue. Image reproduced from Dhaliwal et al. 2012. 
 
1.5.3 The Role of CD23 in IgE homeostasis 
 
Membrane and soluble CD23 play two distinctly differing roles in regulating IgE 
synthesis. As a trimeric soluble protein, human CD23 binds to membrane-bound IgE, 
and CD21 on B cells, thereby increasing IgE synthesis as depicted in the left-hand side 
of Figure 1-15. When CD23 is membrane bound, it is capable of binding to allergen-IgE 
complexes, which results in the reduction of IgE synthesis, as seen in the right-hand 
side of Figure 1-15. CD23 also has a role in buffering against the accumulation of 
soluble IgE; when bound to the antibody, the binding site to FceRI is blocked by CD23, 
rendering IgE incapable of binding to mast cells, and thus avoiding triggering the 





This conclusion was veriﬁed experimentally in solution using
acceptor ﬂuorophore-labeled IgE-Fc or Fcε3-4 and competitively
displacing either donor ﬂuorophore-labeled derCD23 by un-
labeled sFcεRIα, or labeled sFcεRIα by unlabeled derCD23
(Fig. 4). It can be seen that sFcεRIα readily and completely dis-
places derCD23 from the complex with either IgE-Fc or Fcε3-4.
Similarly, derCD23 can displace sFcεRIα almost completely from
either IgE-Fc or Fcε3-4, but at very much higher concentrations as
Fig. 2. Salt bridges and hydrogen bonds at the derCD23–Fcε3-4 interface. The H-bonds associated with the four salt bridges are shown in red, additional H-
bonds present in all six independent interactions are shown in green, and a further H-bond present in ﬁve of six molecules is shown in yellow.
Fig. 3. Composite images of the derCD23 and sFcεRIα complexes with Fcε3-4 to show the mutual incompatibility of their binding modes. (A) derCD23–Fcε3-4
and sFcεRIα–Fcε3-4 (Protein Data Bank ID code 1F6A) complexes superposed on their (Cε4)2 domain pairs. The receptors are shown as surfaces (derCD23, light
and dark blue; sFcεRIα, red), and the Fcε3-4 structures are shown as Cα traces (in corresponding lors). Th closed (derCD23-binding) and open (sFcεRIα-
binding) conformations of the Cε3 domains may be seen. (B) Steric clashes between the sFcεRIα structure (red Cα trace) and both chains of the derCD23-Fcε3-4
complex (blue) are indicated (orange surfaces). (C) Steric clashes of both derCD23 molecules (blue Cα traces) with the sFcεRIα–Fcε3-4 complex (red) are in-
dicated (green surfaces).
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Figure 1-15 Positive and negative mechanisms of IgE regulation by CD23. The co-ligation of 
membrane IgE, CD21 and soluble CD23 upregulates IgE synthesis. Membrane CD23 and IgE co-ligates 
with IgE-allergen complexes to negatively regulate IgE synthesis. Homeostasis (in the middle panel) is 
achieved by CD21 and CD23 competing for membrane IgE. Image reproduced from Gould and Sutton 
2008. 
 
This dual regulatory mechanism only appears to operate in humans, since in mice, 
CD23 is unable to bind to CD21. Without a CD21 homotypic interaction, only the 
negative-feedback mechanism is likely to function in mice, and this agrees with data 
showing the up-regulation of IgE synthesis in CD23-deficient mice (Yu et al., 1994). 
These precise mechanisms are still being debated, and could be resolved if the correct 
tools could be produced to probe these long-standing questions (Conrad et al., 2007). 
 
1.5.4 The Role of CD23 in receptor-mediated endocytosis 
 
Receptor-mediated endocytosis is a cellular method of selectively internalising ligands 
such as nutrients, pathogens, toxins and many other ligands as illustrated in Figure 1-16. 
Once internalised, the ligand and receptor dissociate, allowing the receptor to be 
recycled and returned to the plasma membrane, while the ligand is processed in the 
lysosomal pathway. A number of different protein families can act as receptors for this 
process, including C-type lectins such as membrane CD23, which traffics IgE-allergen 
complexes for allergen presentation (Carlsson et al., 2007). The CTL endocytic 
receptors all contain a common model for calcium-dependent binding, in which the co-






Figure 1-16 A model of receptor-mediated endocytosis. Ligands bound to membrane-bound receptors 
are internalised by a clathrin-dependent pathway. In the early endosome, calcium efflux and proton 
influx causes ligand dissociation. The receptors cluster to one region of the endosome and pinch off to be 
recycled back to the plasma membrane. The sequestered ligands fuse with late endosomes/lysosomes and 
the decrease in pH results in ligand processing or digestion by lysosomal enzymes. Image reproduced 
from Andersen & Moestrup 2014.  
 
Upon internalisation, the ligand dissociates from the receptor due to a rapid decrease in 
calcium concentrations of about 100-fold or more and a drop in pH (Gerasimenko et al., 
1998). This point of the pathway has the lowest calcium concentrations. The ligand and 
receptor are segregated into different lysosomal compartments, and the part containing 
the ligand fuses with a late-endosome/lysosome, leading to further acidification, and an 
decrease in calcium concentrations followed by lysosomal enzymes digesting the 
ligand.  In this context, calcium can be considered a switch for endocytic receptors. 
Calcium turns endocytic receptors, such as CD23, ‘on’ upon binding at high calcium 
concentrations at the plasma membrane. It then, turns endocytic receptors ‘off’ by 
dissociating when the calcium rapidly drops in the endosomal pathway (Andersen and 
Moestrup, 2014). It is not clear if the low calcium concentration may also induce 
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aggregation or influence the recycling of endocytic receptors (Andersen and Moestrup, 
2014).  
 
1.5.5 The Role of CD23 in Facilitated Antigen Presentation 
 
The Th2 cell response in allergy is well documented, especially during the late-phase 
reaction. These cells are activated by MHC class II, and co-stimulatory molecules found 
on antigen presenting cells (APCs) such as dendritic cells, macrophages and B cells. 
These APCs sample extracellular antigens from the environment by three main 
methods: phagocytosis, pinocytosis and receptor-mediated endocytosis. A variation of 
receptor-mediated endocytosis, unique to allergy and involving CD23, is known as 
facilitated antigen presentation (FAP). 
 
FAP is a more specific method of T-cell antigen presentation, enabling T-cell activation 
at antigen concentrations 100-1000 fold lower than regular antigen uptake by APCs 
(van der Heijden et al., 1995; van Neerven et al., 2006). During this process, an 
allergen-bound IgE binds to membrane-bound CD23, which initiates receptor-mediated 
endocytosis and results in the internalisation of the complex (Engeroff et al., 2017). 
Inside the endosome, an efflux of calcium and a change in pH causes the allergen-IgE 
complex to dissociate, and the allergen is proteolytcically cleaved into peptides. The 
processed allergen peptides are then loaded onto MHC class II molecules for 
presentation at the B-cell surface as illustrated in Figure 1-17. The receptor, CD23, is 
then recycled to the cell membrane.  It has also been observed that CD23 can co-express 
with MHC class II molecules on the B-cell membrane, and it is then recycled alongside 






Figure 1-17 CD23-mediated IgE-facilitated allergen presentation. The cartoon depicts the process of 
capture of allergen-IgE complexes by membrane CD23 on the surface of B cells and the resulting 
presentation of the processed allergen to the allergen-specific T-cell. This process results in the further 
production of allergen-specific IgE. Image reproduced from Wilcock et al. 2007.  
 
FAP has been demonstrated in vivo in both mice (Heyman et al., 1993; van der Heijden 
et al., 1995) and humans (Klunker et al., 2007; Poulsen, 2008), and studies have 
explored methods of inhibiting the process. Van Neerven and colleagues have 
demonstrated that blocking antibodies induced during immunotherapy were capable of 
inhibiting IgE FAP-mediated T-cell activation (van Neerven et al., 1999). In this paper, 
the authors suggest that blocking antibodies (allergen-specific IgG antibodies) 
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prevented the allergen-IgE complex binding to CD23, thus halting the FAP process. 
This observation was confirmed by Wachholz and colleagues (Wachholz et al., 2003). 
 
FAP is also related to the phenomenon of epitope spreading, in which a B cell 
simultaneously processes an unrelated antigen or a different epitope of the same 
antigen, and presents it to a T-cell, leading to the production of antibodies directed 
against both antigens, as illustrated in Figure 1-18. It has been proposed that this 
mechanism might be partially responsible for allergy expansion in which a patient 
originally allergic to one allergen becomes allergic to multiple allergens (Mudde et al. 
1995b; Mudde et al. 1995a). 
 
 
Figure 1-18 CD23–dependent epitope spreading. B cells recognize and present specific antigen X to 
specific T-cells. IgE-allergen-Y complexes bound to CD23 are internalised via endocytosis along with 
MHC class II molecules. Peptides generated from the allergen processing are loaded onto MHC II, and 
presented to T cells via the T-cell receptor (TCR). The allergen-specific T cells can differentiate to Th2 
cells and together with IL-4 production can induce class switch recombination (CSR) to IgE in the B cell 
leading the B cells to secrete new IgE antibodies. Image reproduced from Gould & Sutton, 2008.  
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1.5.6 Epitope Spreading and Allergen Immunotherapy  
 
A possible method of limiting epitope spreading is via a treatment called allergen 
immunotherapy (AIT). AIT is the administration of increasing doses of an allergen to an 
allergic patient in a controlled environment, thereby inducing immunological tolerance. 
This treatment provides people with allergy with an alternative to allergen avoidance or 
pharmacotherapy, furthermore it has long-lasting effects with demonstrable clinical 
efficacy (Durham et al., 1999; Fitzhugh and Lockey, 2011). During AIT, IgE 
production is suppressed, whilst IgG4 production is increased, which is beneficial due to 
the non-inflammatory properties of IgG4 and its inability to activate mast cells and 
basophils (Fujita et al., 2012). The role of IgG4 is not limited to the early phase allergic 
response, and it might also be involved in inhibiting the late phase response by blocking 
FAP (Wilcock et al., 2006).  
 
 
Figure 1-19 The allergic response is modified by allergy immunotherapy. A) The standard allergic 
response. B) The immunological response modified by AIT. Immunological tolerance is induced through 
the synthesis of IgG blocking antibodies and regulatory T cells. Image reproduced from Larsen et al. 
2016. 
 
The mechanisms behind epitope spreading and AIT are not yet fully understood, and the 
roles of the IgE receptors in these processes need to be further elucidated. Better 
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understanding of these processes can lead to more efficient and safer treatments. The 
first step in unravelling the roles of the IgE receptors would be to create appropriate 
tools to probe the possible mechanisms. Tools which target FceRI or CD23 would be 
beneficial in determining the individual roles of each IgE receptor. An entire protein 
tool-box could be created by designing an IgE surface display library, which could be 
screened and selected for IgE proteins which bind to one receptor but not the other, to 
explore these pathways.  
 
One instance in which the new tools could be used, could be to trigger protective 
immunity with AIT. An engineered IgE that cannot bind to FceRI will not induce mast 
cell degranulation and thus limit the most dangerous side-effect of anaphylaxis. 
However, the IgE could still bind to allergen and CD23 and thus the complex could be 
processed and presented on APCs. This might instruct T cells to activate B cells so that 
they produce more IgG4 blocking antibodies, thus enhancing the effect of AIT and 
regulating the immune system by increasing levels of T regulatory cells. 
 
Harnessing epitope spreading to produce IgG4 blocking antibodies provides an 
opportunity for therapeutic intervention in AIT. Controlling epitope spreading is also of 
interest in IgE-mediated anti-cancer therapies. In this context, it would be desirable for 
epitope spreading to be limited so that it cannot induce the spreading of tumour 
antigens. IgE has potent effector functions and is proven to be a safe biologic (Jensen-
Jarolim et al., 2010) being developed in the field of Allergo-oncology.  
 
The nascent field of Allergo-oncology attempts to harness the Th2-domainted allergic 
reaction, described in section 1.2, to eradicate cancerous cells by establishing an 
‘allergic-response’ to the tumour (Singer and Jensen-Jarolim, 2014). The mechanisms 
of cancer cell death are dependent on IgE-Fc to trigger antibody-dependent cell-
mediated cytotoxicity and antibody-dependent cell-mediated phagocytosis (Karagiannis 
et al., 2007; Jensen-Jarolim et al., 2010; Karagiannis et al., 2012). The absence of an 
IgE-equivalent of the inhibitory FcγRIIb receptor also provides IgE with an additional 
advantage, in that it avoids the suppressive effects experienced by IgG in the tumour 





A modified IgE able to bind to FceRI but not CD23 would be unable to induce epitope 
spreading, and may provide a safer substitute for IgE-mediated anti-cancer therapeutics 
(Josephs et al., 2014). It would prevent the immune system reacting to other epitopes 
similar to the cancer antigen or to unrelated cancer antigens delivered in the same 
‘allergic’ context.  
 
1.5.7 The role of CD23 in receptor-mediated transcytosis 
 
The lung epithelium is the first defensive barrier to the external environment and 
inhaled allergens. It is also immunologically active, and can secrete a wide range of 
cytokines and chemokines to recruit immune cells upon sensing allergens, as well as 
secreting host-defence proteins such as lysozyme and defensins. Dysregulation of the 
epithelial barrier can increase its permeability to allergens because tight junctions 
connecting the epithelial cells are disrupted (Mattila et al., 2011). Tight junctions can 
also be bypassed by a form of receptor-mediated immunoglobulin transport known as 
transcytosis, illustrated in Figure 1-20.  
 
CD23 is constitutively expressed in human airway epithelial cells and can bind to IgE-
allergen complexes in the airways. Furthermore, it is able to bypass the epithelial cell 
tight junctions to transport the complexes into the mucosa, where the IgE-allergen 
complexes are released (Palaniyandi et al., 2011). In the mucosa, the IgE-allergen 
complexes are then able to bind subepithelial immune effector cells such as mast cells, 
causing degranulation and allergic inflammation. This transport is bidirectional, when 
CD23 is found on the basal side of the epithelial cells, it binds to IgE and creates a 
positive feedback loop to support an influx of inflammatory cells (Palaniyandi et al., 
2015) . This mechanism of allergen uptake is believed to explain the immediate onset of 
clinical symptoms after allergen contact. 
 
These insights also have an impact on food allergies, as CD23 is also expressed on 
intestinal epithelial cells (Tu et al., 2005). IgE is also synthesised locally within the 
gastrointestinal tract, and the pathogenesis of food allergies is described in Figure 1-20. 
This finding has been identified in both humans (H. Li et al., 2006)  and mice (Yu et al., 
2003), highlighting the importance of CD23 and soluble IgE in mucosal immunology. 
Usually immunoglobulin A and its receptor, the polyimmunoglobulin receptor (pIgR), 
are associated with mucosal defence, however, CD23’s role in transcytosis is similar to 
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that of pIgR. CD23 can also be compared to the neonatal Fc receptor for 
immunoglobulin G (FcRn), which transports IgG across epithelia in a bidirectional 
manner (Baker et al. 2010). 
 
 
Figure 1-20 The role of CD23 on intestinal epithelial cells in the pathogenesis of food allergies. A) 
IgE-allergen complexes are captured by membrane CD23 expressed on intestinal epithelial cells. The 
captured complexes are transported across the epithelial membrane into the mucosa, where they are 
released, binding to FecRI on mast cells and dendritic cells, resulting in activation of the early phase of 
the allergic response.  B) IgE antibodies are secreted by plasma cells in the mucosa which are then 
transported into the gut lumen by CD23. In the gut lumen, the IgE is free to bind to allergens, thus 
perpetuating the allergic cycle. C) The tight-junctions of the epithelial cells are disrupted by the allergic 
inflammation mediated by IgE. Allergens from the lumen can freely pass into the mucosa and crosslink 
IgE-bound to FceRI on mast cells and dendritic cells, exacerbating the food allergy. Image reproduced 
from Gould and Sutton 2008.  
 
1.5.8 Other biological roles of calcium in human CD23 transport 
 
An alternative pathway of vesicular trafficking involving IgE-allergen complexes and 
CD23 is the exosome pathway. Exosomes are tiny membrane bound particles ranging 
from 30 – 150 nm in size (Li et al., 2006; Keller et al., 2006). B cell derived exosomes 
(bexosomes) contain ADAM10, CD23 and IgE-allergen complexes, and can transfer 
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these components from B cells to dendritic cells, as illustrated in Figure 1-21 (Martin et 
al., 2014). This too is a calcium sensitive process, just like receptor-mediated 




Figure 1-21 A model of CD23 endosomal trafficking and exosome formation. IgE-allergen complexes 
bound to membrane CD23 are internalised in a clathrin-dependent pathway, and trafficked into the 
endosomal pathway. The increasing acidity grants ADAM10 greater accessibility to CD23, resulting in 
cleavage and/or sorting into exosomes. The multivesicular bodies (MVB) fuse with the plasma 
membrane to release the contained exosome into the external environment. Image reproduced from 
Mathews et al. 2010. 
 
1.5.9 Differences between human and murine CD23 
 
Mice are the experimental tool of choice for most immunologists, and the study of their 
immune responses has yielded many discoveries, and greater understanding of the 
human immune system. However, there are several differences between human and 
murine CD23 that must be considered when using mice as preclinical models of human 




Human and murine derCD23 have a 70% protein sequence identity, and murine CD23 
is expected to have a very similar protein fold to human derCD23 based on Swiss-
model predictions (since no structure of murine CD23 exists). Murine derCD23 refers 
to the equivalent range residues in murine CD23 as der p I is not able to cleave murine 
CD23 since the Ser155-156 cleavage site is absent (Schulz et al., 1997; Bettler et al., 
1989). However, murine CD23 can still be cleaved to form soluble CD23 (Bartlett et al., 
1995). Structurally, one key difference is the tail region of the CTLD. This region in 
human derCD23 binds to CD21, however, those residues are absent in murine CD23. 
There is no similar adhesion between CD23 and CD21 in mice. Furthermore, murine 
derCD23 is also unable to bind to an integrins due to lacking the Arg172 equivalent 
residue, which is critical for an integrin binding of human CD23 (Edkins et al., 2012).  
 
Murine CD23 is expected to bind to two calcium ions based on amino acid sequence 
analysis and comparisons to related CTLs. This is in contrast to human CD23, which 
has been demonstrated to bind to only one calcium ion per CTLD (Wurzburg et al., 
2006; Yuan et al., 2013). In addition, murine CD23 has been shown to bind to murine 
IgE, however both calcium ions must be present for binding to occur, otherwise no 
interaction will be achieved (Richards and Katz, 1990). This contrasts with human 
derCD23, which can bind to human IgE without calcium, whilst in the presence of 
calcium, its affinity is further enhanced by 30-fold (Hibbert et al., 2005; Yuan et al., 
2013). 
 
Murine CD23 contains the ‘EPN’ carbohydrate binding motif, and other CTLs with this 
motif have sugar-binding specificities for mannose, N-acetylglucosamine, glucose and 
I-fucose (Lee et al., 2011). Indeed, carbohydrate interactions with mannose, N-
acetylglucosamine and galactose have been reported (Richards and Katz, 1990). This 
contrasts with human CD23, which despite earlier studies, was linked to mannose and 
galactose binding (Kijimoto-Ochiai and Toshimitsu, 1995; Wurzburg et al., 2006). 
More sensitive assays conducted since have not detected any specific binding for human 
CD23 to glycans (Hibbert 2005; 





If the allergic response is considered an abnormal immune response, could these 
differences between mice and humans, summarised in Table 1-1, make Homo sapiens 
more susceptible to allergies? Could these differences also be targets of therapeutic 
worth? 
   
Murine CD23 Feature Human CD23 
2 Number of Ca2+ ions binding 1 
 IgE binding Ca2+ dependent?  - but Ca2+ enhances 
binding 
 CD21 binding  
 Carbohydrate binding  
 Integrin binding  
Table 1-1 Summary of the differences between murine and human CD23. 
 
1.5.10 Calcium as a regulator of CD23 
 
As mentioned in section 1.5.4, calcium can act as a switch for endocytic receptors. In 
the context of CD23, which regulates IgE synthesis, could calcium be ‘fine-tuning’ 
CD23’s response to IgE? (Yuan et al., 2013). The extracellular concentration of calcium 
ranges between 1 and 1.5 mM, and with derCD23’s affinity for calcium at 1.5 mM, it is 
most likely that calcium is bound to CD23, thus increasing its affinity for IgE-Fc by 30-
fold. This might profoundly influence interactions between soluble trimeric CD23 and 
membrane IgE, influencing IgE synthesis in B cells (McCloskey et al., 2007; Cooper et 
al., 2012). Furthermore, it might also enhance binding of allergen-IgE complexes to 
membrane CD23, thus promoting facilitated antigen presentation, as described in 
section 1.5.5.  
 
Could this calcium ‘switch’ sensitivity be unique to humans? The requirement for 
calcium in murine CD23 differs, as detailed in section 1.5.9, therefore the role of CD23 




1.6 Targeting IgE therapeutically  
 
Despite the central role of IgE in allergic diseases, it took over two decades to develop a 
licensed anti-IgE treatment, marketed as Xolair® (Omalizumab) (Incorvaia and Mauro, 
2015). The difficulty in producing anti-IgE agents came in the selection of molecules 
that do not cross-link IgE bound to FceRI on mast cells and basophils. It is of vital 
importance that crosslinking of IgE is avoided so that the allergic response is not 
triggered, since anaphylaxis is a risk that may culminate in death. With IgE-Fc shown to 
bind to both of it receptors at the Ce3 region, it was known that this domain could be 
targeted to sterically hinder binding to FceRI. 
 
Solving the structure of IgE, FceRI and CD23 gave greater insight into the mechanisms 
of IgE binding as well as revealing the allosteric control behind these interactions that 
prevented simultaneous binding of both receptors to IgE (Borthakur et al., 2012; Wright 
et al., 2015; Davies et al., 2017). The large conformational changes that occur in IgE, as 
described in section 1.3.2 , alongside the allosteric control of the receptor binding sites 




1.7 Aims of this thesis 
 
This thesis presents two main projects on the theme of protein engineering of IgE and 
its receptor, CD23.  
 
The first two results chapters address CD23 and its auxiliary nonfunctional calcium 
binding site. To examine the mutations that have occurred during evolution and their 
impact on IgE binding, the “auxiliary” calcium binding site residues were selectively 
mutated back to those found in murine CD23, in order to restore calcium binding. 
Probing these mutant proteins may determine whether the loss of the second calcium 
ion conferred a gain-of-function, such as increased affinity for IgE, in human CD23.  
 
To achieve these aims, the following objectives were set:  
 
• Generate a panel of human derCD23 mutants that may restore calcium binding 
to the “auxiliary” binding site by site-directed mutagenesis.  
 
• Express the recombinant human derCD23 proteins, refold and purify them. 
 
 
• Analyse the calcium stoichiometry and calcium-binding thermodynamic 
parameters of the mutated human derCD23 proteins. 
 




• Determine the geometry and structural basis of additional calcium binding by 
solving the structures of the mutant proteins.  
 
• Build a molecular dynamics system to explore the conformations of the mutant 




The third results chapter focuses on the development of an IgE surface display library, 
similar to phage display but using mammalian cells. This provides a range of mutant 
IgE proteins to overcome designing and mutating individual or sets of residues. 
Screening assays were designed to select IgE-Fc mutants that can bind to one receptor 
and not the other, and vice versa. For this project, the following objectives were set: 
 
• Establish a mammalian transfection protocol for the mammalian cell display 
system. 
 
• Identify key residues to substitute in IgE-Fc and design a proof-of-principle IgE-
Fc surface display library. 
 
• Design and optimise assays to screen the IgE-Fc surface display library. 
 
It is anticipated that these mutant IgE-Fc proteins may be used to probe the role of each 








Chapter 2 Methods and Materials  
2.1 DNA Manipulation Techniques 
2.1.1 PCR materials and software 
The low-copy pET5a plasmid contained the gene for derCD23, which coded for the 
amino acids Ser156 to Glu298 (using the Swiss-Prot accession code: P06734 numbering 
scheme). In addition the pET151-GA-tri vector coded for a trimeric triCD23 construct 
(McCloskey et al., 2007), which included a 30-residue synthetic stalk sequence and 
CD23 residues 136-321 separated by the HindIII cleavage site (with the same 
numbering scheme). Both plasmids contained an ampicillin resistance gene for the 
selection of positively transformed host cells and were kindly provided by Dr Rebecca 
Beavil. 
 
2.1.2 DNA primers 
All oligonucleotides were synthesised by MWG Eurofins or Integrated DNA 
Technologies. Vector maps and sequences were created in Snapgene Viewer (Snapgene 
software v 3.0.3 from GSL Biotech). 
 
2.1.3 Gene Synthesis 
The membrane IgE construct as detailed in Appendix A, was manufactured as a double 
stranded 1923 bp DNA gBlock® gene fragment (Integrated DNA Technologies). 
 
2.1.4 DNA Sequencing 
15 µl of purified DNA sample (between 50 ng/µl and 100 ng/µl) had 2 µl of T7 forward 
primer added (5’-TAATACGACTCACTATAGGG-3’ at 10 µM) and sequenced using 
the Mix2Seq (Eurofins) service. Sequencing results were aligned by ClustalW or 
Clustal Omega software (EMBL-EBI).  
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2.1.5 DNA purification and quantification 
Plasmid DNA was purified using the Monarch® Nucleic Acid Purification Kit (NEB) 
as per manufacturer’s instructions. The concentration of eluted DNA was quantified by 
a NanoDrop ND-1000 spectrophotometer at 260 nm. Plasmid DNA was stored at -
20°C.  
 
2.1.6 DNA purification of the membrane IgE library 
The membrane IgE library plasmids were purified using the Plasmid Maxi Kit (Qiagen) 
as per manufacturer’s instructions. The concentration of the extracted DNA was 
quantified by the NanoDrop ND-1000 spectrophotometer at 260 nm. The pooled 
plasmid DNA was stored at -20°C. 
 
2.1.7 Site-Directed Mutagenesis of derCD23 
Initially the Quickchange Lightning Site-Directed Mutagenesis Kit (Agilent 
Technologies) was used to perform site-directed mutagenesis of derCD23 to produce 
the first mutation (N225D) as per manufacturer’s instructions. However, optimisation 
with the polymerase Phusion™ Flash High Fidelity PCR MM (Thermo) replaced the 
Quikchange lightning kit for the subsequent steps, whilst using the same cycling 
conditions as described in Table 2-1. The primers used are listed in Table 2-2 while the 




Cycles Temperatures (°C) Time 
1 95 2 mins 
 
18 
95 20 seconds 
60 10 seconds 
68 2.5 mins 
1 68 5 mins 
Table 2-1 Cycling conditions for site-directed mutagenesis. 
 
N225D F CCTGGATTGGCCTTCGGgAtTTGGACCTGAAGGGAGAG  
N225D R CTCTCCCTTCAGGTCCAAcTaCCGAAGGCCAATCCAGGAGCC  
K229E F GGCCTTCGGgatTTGGACCTGgAaGGAGAGTTTATCTGGGTGG  
K229E R CCACCCAGATAAACTCTCCtTcCAGGTCCAAatcCCGAAGGC  
S252N F CTGGGCTCCAGGGGAGCCCACCAaCCGGAGCCAGGGCGAGGAC  
S252N R CTGGGCTCCAGGGGAGCCCACCAaCCGGAGCCAGGGCGAGGAC  
T251N & S252N F CTGGGCTCCAGGGGAGCCCAaCAaCCGGAGCCAGGGCGAGGAC 
TG  
T251N & S252N R CAGTCCTCGCCCTGGCTCCGGtTGtTGGGCTCCCCTGGAGCCCAG  
R253G & S252G F GGGCTCCAGGGGAGCCCAaCAaCgGcgGCCAGGGCGAGGACTGC  
R252G & S252G R GCAGTCCTCGCCCTGGCcgccGtTGtTGGGCTCCCCTGGAGCCC  
 
Table 2-2 A list of primers used for site-directed mutagenesis. Mutations are shown in lower case. F = 







A)                                                                       B) 
Quantity Reagent Quantity Reagent 
5 µl 10x reaction buffer 5 µl Phusion Master Mix 
10 – 100 ng dsDNA template 0.5 µM Primer 1 
125 ng Primer 1 0.5 µM Primer 2 
125 ng Primer 2 20 ng dsDNA template 
1.5 µl dNTP mix Up to 10 µl ddH20 
1 µl QuikSolution reagent   
Up to 50 µl ddH20   






 Table 2-3 Reagents required for the derCD23 mutagenesis PCR. A) QuikChange Lightening Site-
Directed Mutagenesis kit. B) The optimised PCR. 
 
2.1.8 Dpn I digestion of the amplification products  
Template DNA was removed by Dpn I treatment; briefly: 1 µl of Fast digest Dpn I 
(Thermo), was added to 2 µl of the PCR product, 2 µl 10x Fast Digest buffer (Thermo) 
and 15 µl dH2O. The reaction was mixed well and incubated at 37°C for 10 min.  
  
2.1.9 Agarose Gel Electrophoresis  
DNA products were analysed by agarose gel electrophoresis. 0.8% agarose gels were 
made by dissolving 0.4 g agarose (Bioline) in 50 ml of 1 x TBE running buffer (90 mM 
Tris, 90 mM Boric acid, 2 mM EDTA pH8). The gel was cooled until hand hot before 
adding 5 µl of Gel red nucleic acid stain (Biotum). The solution was poured into a 
casting tray with a well comb added and allowed to set. The set gel was transferred to 
an electrophoresis tank and covered in x1 TBE running buffer. The gel comb was 
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removed and 10 µl GeneRuler 1kb DNA ladder (Fermentas) molecular weight marker 
was loaded. DNA samples were prepared by adding 5x loading dye solution 
(Fermentas) and mixing well before loading onto the gel. The gel was run at 100 V until 
the desired separation and visualized with UV light in the Biorad Gel Dock™ XR+ Gel 
System (Biorad) and a digital photograph was taken of the image.  
 
2.1.10 Competent Cell Transformation 
10 µl NEB 10-beta competent E. coli cells (NEB) or One Shot® Top10 chemically 
competent E.coli cells (Thermo) had 0.5 µl of DNA added, with the tube flicked to 
gently mix the solution. The solution was incubated on ice for 30 mins before heat 
shocking the cells at 42°C for 30s. The cells were then returned to ice for 2 mins before 
adding 200 µl of SOC media (Invitrogen). After 1 hr of incubating the cells at 37°C 
with shaking at 200 rpm, the cells were plated onto LB agar petri dishes containing (100 
µg/ml) ampicillin and left to propagate at 37°C overnight. 
 
2.1.11 Zero blunt® TOPO® PCR cloning   
Due to limited stock of the designed membrane IgE construct (section 2.1.3, Figure 
5-5), the gBlock® was first cloned into a pCR-blunt-II-TOPO vector (Invitrogen) so 
that it could be replicated and sub-cloned easily. The reagents for the reaction were 
provided in the Zero blunt® TOPO® PCR cloning kit (Invitrogen). Briefly, 0.5 µl of 
gBlock® DNA, 1 µl salt solution, 1 µl pCR-blunt-II-TOPO vector with 3.5 µl dH2O 
was mixed gently. The reagents were incubated for 5 mins at room temperature and 1 µl 
was used to transform One Shot® Top10 chemically competent E.coli cells 




2.1.12 GeneArt® Seamless Cloning and Assembly Kit  
The GeneArt® Seamless Cloning and Assembly Kit (Thermo) was used for the 
insertion of the designed membrane IgE construct (Plasmid map shown in Figure 5.5) 
into the pcDNA™5/FRT (Thermofisher) vector. The pcDNA™5/FRT vector for 
mammalian cell transfection contained an ampicillin resistance gene for vector 
propagation and a hygromycin resistance gene for cell transfection selection. The 
membrane IgE construct was manufactured as a gBlock® gene fragment (Integrated 
DNA Technologies, sequence provided in Appendix A). The primers were designed 
based on manufacturer’s recommendations and are listed in Table 2-4. The reagents for 
both the insert and vector PCR included 0.5 µl of vector (~20 ng) or insert DNA, 10 µl 
of Phusion Master Mix, 0.2 ng of forward primer, 0.2 ng of reverse primer and 7.5 µl of 
dH2O. The cycling conditions differed for the two PCRs with the vector PCR having the 
following cycling conditions: (98°C initial denaturation for 10 s, followed by 30 cycles 
of denaturation at 98°C for 1 s, annealing at 72°C for 5 s and extension at 72°C for 75 s, 
followed by 1 cycle of final extension at 72°C for 1 second), whilst the insert PCR 
consisted of the following conditions: 98°C initial denaturation for 10 s, followed by 
denaturation at 98°C for 1 s, annealing at 58°C for 5 s and extension at 72°C for 30 s 
followed by 1 cycle of final extension at 72°C for 1 second. 
 
4 µl of the PCR was mixed with loading gel to be checked on a 0.8% agarose gel and 
the remaining PCR was cleaned-up with the Monarch PCR-clean-up kit (NEB). For the 
GeneArt reaction, 4 µl of the purified vector reaction and 8 µl of the purified insert 
reaction were combined with 2 µl of dH2O, 4 µl 5x reaction buffer and 2 µl of 10x 
enzyme mix. The reaction was incubated at room temperature for 30 mins, and 1 µl of 
the reaction was used to transform 10 µl of One Shot® Top10 chemically competent 
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E.coli (Thermo) as described in section 2.1.10. Colonies were checked by colony PCR 
prior to sequencing as described in the next section, 2.1.13.  
 
Vector F GCAGATATTTAAGGTTGGTACCGAGCTCGGAT 
Vector R AATTCCAGGTTTAAACGCTAGCCAGCTTGGGT 
Insert F GTTTAAACCTGGAATTCGCCCTTATGGACTGG 
Insert R  AAGCTTAAATATCTGCAGAATTCGCCCTTCTA 
Table 2-4 A list of primers used for the GeneArt Seamless Cloning and Assembly Kit. F = forward 
primer. R = reverse primer. Primer sequences listed in the 5’ to 3’ format.  
 
2.1.13 Colony PCR  
Transformed E.coli colonies on agar plates were tested prior to sequencing to see if they 
contained the desired plasmid DNA sequence. For the membrane-IgE constructs, colony 
PCR primers specific for the insert are listed in Table 2-5 and PCR conditions are 
detailed in Table 2-6. When all the solutions of Table 2-7 had been added to the PCR 
tube, the chosen E.coli colony on the agar plate was lightly brushed with a pipette tip 
and then mixed well into the PCR reagents. This method left most of the E.coli colony 
intact and available for future experiments. The resulting PCR product was run on a 
0.8% agarose gel to visualise results.  
 
TM Colony ACTCTTCCTGCTCAG 
M13 Reverse CAGGAAACAGCTATGAC 




Cycles Temperature (°C) Time (mins) 
1 94 5 
 94 1 
30 52 2 
 72 5 
1 72 10 
Table 2-6 Cycling conditions for colony PCR. 
 
Quantity Reagent 
5 µl 2x ReadyMix Taq PCR mix (Sigma) 
4 µl ddH20 
10 µM Primer 1 
10 µM Primer 2 
+ Brush of a colony  
Table 2-7 Reagents required for colony PCR. 
 
2.1.14 Mutant IgE-Fc Library Generation  
The membrane IgE-Fc library was made using the construct made in section 2.1.12. The 
plasmid had mutations introduced at two sites, R334 and P426. To make sure that all 
the amino acids were evenly coded for at those sites, and to avoid stop codons, the ‘22-c 
trick’ was used. The ‘22-c trick’ uses degenerate primers that represent the 22 unique 
codons for all the amino acids and no stop codons. The degenerate primers, listed in 
Table 2-8, were mixed in a 12 NDT : 9 VHG : 1 TGG primer ratio (Kille et al., 2013). 
For the PCR, the (10 pmoles) of each forward and reverse primer mixture were mixed 
with 20 ng of plasmid pcDNA™5/FRT/memIgE template and 10 µl of Phusion™ Flash 
High Fidelity PCR Master Mix (Thermo) in a total of 20 µl of dH2O. The PCR 
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conditions used are listed in Table 2-9.  The PCR product was treated with Dpn I as 















Table 2-8 A list of degenerate primers used for the generation of the mutant IgE-Fc library. F = 
forward primer. R = reverse primer. Primer sequences listed in the 5’ to 3’ format. Degenerate bases 
highlighted in blue, follow the International Union of Pure and Applied Chemistry (IUPAC) designation. 
H = A or C or T. B = C or G or T. V = A or C or G. D = A or G or T. N = A or C or G or T.  
 
Cycles Temperatures (°C) Time 
1 95 2 mins 
 
18 
95 20 seconds 
60 10 seconds 
68 2.5 mins 
1 68 5 mins 




2.1.15 Quick Quality Control (QCC) 
10 colonies were randomly picked from each agar plate and their plasmid DNA was 
purified as described in section 2.1.5 before being sent for sequencing as detailed in 
section 2.1.4. The nucleotide base distribution of each mutated base was estimated by 
comparing the sequenced results to the original WT bases. The values were converted to 
pie charts using Microsoft Excel (v 14.7.1, Microsoft Corporation) and compared to the 
expected values. The 22-c trick method expects 27%(A) + 27%(C) + 27%(G) + 19%(T) 
at the first nucleotide position, 32%(A) + 18%(C) + 18%(G) + 32%(T) at the second, 





2.2 Protein Methods 
2.2.1 Protein expression of derCD23 proteins in E. coli 
BL21 DE3 competent E. coli cells (Invitrogen) were thawed slowly on ice, prior to the 
addition of 0.5 µl of plasmid DNA and transformed as described earlier in section 
2.1.10. One pipette tip’s streak of cells from the plate was used to inoculate a 20 ml 
starter colony of LB and ampicillin 100 µg/ml; ~5 hours later this colony was poured 
into 0.5 L of ZYP-5052 rich autoinduction medium (928 ml of ZY, 1 x 5052, 1 x NPS 
and 50 µg/ml of ampicillin as described in Table 2-10, Studier 2005) in 2L Erlenmeyer 
baffled flasks. The cultures were grown shaking at 37°C at 200 rpm for ~ 48 hours. To 
confirm expression of the desired protein, 250 µl samples were extracted for SDS-
PAGE analysis. The cells were harvested by centrifugation at 4000 g for 20 mins, and 
the supernatant was discarded. The pellet was left in the -80°C freezer over night to for 





Name Reagent Amount 
ZY N-Z-amine AS 10g 
Yeast Extract 5g 
dH2O 925mL 
50 x 5052 Glycerol  250 g 
Glucose 25 g 
α-Lactose 100 g 
 dH2O  730 ml 
20 x NPS (NH4)2SO4 0.5 M 
KH2PO4 1 M 
Na2HPO4 1 M 
 dH2O Up to 1 L 
Table 2-10 ZYP-5052 autoinduction medium – 1L stock solutions. Reagents for the 50x 5052 and the 
20x NPS were added to the dH2O in the order listed (Studier, 2005). 
 
2.2.2 15N labelled protein expression of derCD23 in E.coli  
Performed the same way as in section 2.2.1 but with 15N ammonium sulphate for the P-
5052 minimal autoinduction medium (Studier, 2005). 
 
2.2.3 Protein Expression of triCD23 in E. coli 
BL21 DE3 competent E. coli cells (Invitrogen) were thawed slowly on ice, prior to the 
addition of 0.5 µl of plasmid pET151-GA-tri DNA and transformed as described earlier 




2.2.4 SDS-PAGE gel electrophoresis analysis  
Protein purity was assessed by a 16% Tris-SDS mini-gel, prepared as stipulated in 
Table 2-11 (Laemmli, 1970). Typically, 2 – 20 µg of pure protein or 20 µl of sample 
was mixed with 5x non-reducing sample buffer (5x non-reducing SDS sample buffer: 
0.313 M Tris-HCl pH 6.8, 10% SDS, 50% glycerol and 0.05% bromophenol blue), with 
1 µl of β-mercaptoethanol added for reducing gels. This sample was then boiled for 3 
mins. 5 µl SeeBlue Plus2 Pre-stained Protein Standard (Invitrogen) was loaded into the 
first well followed by the samples. The mini-gel was run at 120 V in SDS running 
buffer (25 mM Tris, 192 mM Glycine, 0.1% SDS, pH 8.3) until the blue dye had 
reached the end of the gel. Gels were extracted and the stacking gel removed to allow 
for staining with Instant Blue Comassie Stain (Expedeon) for 30 mins until the protein 
bands were clearly visible. Stained gels were washed with dH2O before capturing the 
image on the Bio-Rad gel dock and the Bio-Rad ImageLab software (Bio-Rad v5.2.1). 
‘Separating Gel’ Volume (µl) 
Lower Tris 2000 
Acrylamide 2500 
dH2O 5300 
10 % ammonium persulphate 50 
TEMED 10 
‘Stacking Gel’ 
Upper Tris 1250 
Acrylamide 1000 
dH2O 3180 
10 % ammonium persulphate 50 
TEMED 10 




2.2.5 Extraction of inclusion bodies 
derCD23 is expressed in inclusion bodies, not as a soluble protein, to extract the 
inclusion bodies from the E.coli, the cell pellet was first removed from the -80 °C 
freezer and thawed prior to resuspension in 20 ml Phosphate buffered saline (PBS, pH 
7.4: 0.14 M NaCl, 2.7 mM KCl, 1.5 mM KH2PO4, 8 mM Na2HPO4, pH 7.4) with 
added protease inhibitor cocktail tablet (Roche). The solution was passed through a cell 
disruptor twice at a pressure of 20 KPSI (CF Range, Constant Systems Ltd.) with the 
product collected on ice. The cooled product was centrifuged at 20450 rcf for 20 min to 
separate the inclusion bodies, with the supernatant discarded. The inclusion bodies were 
resuspended in inclusion body wash buffer (50 mM Tris pH 7.5, 100 mM NaCl, 0.5% 
octylphenoxypolyethoxyethanol (Igepal), 0.1% Sodium-azide) and centrifuged at 20450 
rcf for 20 mins with the supernatant discarded. The washing with the inclusion body 
wash buffer was repeated for a total of 5 times. 
 
2.2.6 Solubilisation of the inclusion bodies  
After the final centrifugation step at 20450 rcf for the inclusion body wash process, the 
supernatant was discarded and the inclusion body pellet was resuspended in 5 ml of 20 
mM Tris, 6M Guanidinium hydrochloride, pH 7.5 and left rotating at room temperature 
overnight at 200 rpm. Insoluble contaminants were removed by centrifuging the 
solution at 20450 rcf. The concentration of the solubilised protein was quantified by a 
NanoDrop ND-1000 spectrophotometer at 280 nm and the absorbance was divided by 
2.786 (the absorbance per cm for 1 mg/ml at 280nm) to gain the actual mg/ml value, 
before storing the sample in the -80°C freezer.  
 
2.2.7 Extraction and solubilisation of triCD23 from inclusion bodies 
TriCD23 inclusion bodies were washed as described in section 2.2.5, however, after the 
final wash, the inclusion bodies were solubilised in 100 ml of 6 M Guanidine 
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hydrochloride, 20 mM sodium phosphate, 500 mM NaCl, 20 mM imidazole and 10 mM 
DTT, pH 7.4. The solubilised protein was quantified by a NanoDrop ND-1000 
spectrophotometer at 280 nm and the absorbance was divided by 1.65 (the absorbance 
per cm for 1 mg/ml at 280nm) to gain the actual mg/ml value. The protein was stored in 
a -80°C freezer as 90 mg aliquots.  
 
2.2.8 DerCD23 protein refolding  
To recover biologically active recombinant protein a protocol based on Taylor et al., 
1992 was followed. 20 mg of the solubilised derCD23 protein was reduced with 
Dithiothreitol (DTT), added to a final concentration of 1 mM and incubated at room 
temperature for 1 hour. The sample was then diluted ten-fold into 6 M Guanidine, 0.5 M 
Tris-Acetate pH 8.6 and 100 mM oxidised glutathione and incubated at 4°C, stirring for 
24 hours. This sample was then slowly diluted into 2 L of ice-cold refolding buffer 100 
mM Tris-Acetate pH 8.6, 3 mM cysteine and 2 mM CaCl2 using a peristaltic pump at a 
setting of 0.5 (~ 100 µl/min) to avoid precipitation. The protein continued to refold at 
4°C with constant slow stirring, in the dark for 48 hours. 
 
2.2.9 TriCD23 protein refolding 
One aliquot of frozen solubilised triCD23 from section 2.2.7, was thawed and spun 
briefly to remove debris. To refold the protein, a protocol modified from section 2.2.8 
was used. The solubilised protein was slowly diluted into 1L of refold buffer (1 M 
Guanidine hydrochloride, 0.4 M arginine, 50 mM CHES, 1:2 ratio of reduced to 
oxidised glutathione, pH 9) using a peristaltic pump at a setting of 4.0 (~800 µl/min). 




2.2.10 Protein purification by hydrophobic interaction chromatography (HIC)  
The refolded derCD23 proteins were purified by HIC. First, ammonium sulphate 
precipitation was performed to remove unwanted protein. 400 g (approx. 1.5 M) of 
ammonium sulphate was slowly added to 2 L of the refolded protein with constant 
stirring and allowed to dissolve fully. Then the solution was filtered through a 0.45 
micron filter fitted with a pre-filter disk by vacuum filtration. The filtered solution was 
connected to an ÄKTA Prime System (Amersham) fitted with a 10 ml Phenyl Sepharose 
6 Fast Flow (high sub) column equilibrated in buffer A (1.5 M (NH4)2S04, 25 mM Tris-
Cl pH 7.5, 2 mM CaCl2). The experiment ran at a flow rate of 10 ml/min. The derCD23 
proteins were eluted into 10 ml fractions into buffer B (25 mM Tris- HCl pH7.5, 2 mM 
CaCl2), with a gradient elute program The column flow-through was kept with more 
ammonium sulphate added to it (to a total of approx. 2 M), before filtering and passing 
the solution over the HIC column again. A maximum of three ammonium sulphate cuts 
were performed (max. of 2.5 M ammonium sulphate added).  
 
2.2.11 Protein Purification by Immobilised Metal Ion Affinity Chromatography 
(IMAC) 
The refolded his-tagged triCD23 protein were purified by IMAC. First, 200 ml of the 
refold solution was diluted to 1 L with dH2O to reduce the pH of the refold solution to 
pH 7.4. A 1 ml HisTrap FF crude column (GE Healthcare Life Sciences) was connected 
to an ÄKTA Prime System (Amersham) and equilibriated with binding buffer (20 mM 
sodium phosphate, 500 mM NaCl, 20 mM imidazole pH 7.4).  The experiment ran at a 
flow rate of 1 ml/min using the ion exchange gradient elute method program. The 
protein was eluted into twenty 1 ml fractions in a 0-500 mM imidazole gradient using 





2.2.12 Protein concentrating  
DerCD23 proteins were concentrated using a 5000 MWCO centrifugal concentrator 
(Vivaspin) spun at 3901 rcf at 4˚C for 20 min intervals. TriCD23 was concentrated 
using an Amicon 10 000 MWCO centrifugal concentrator (Millipore) spun at 3901 rcf 
at 4˚C for 5 min intervals to about 4 mg/ml. The concentrator tube was inverted three 
times between spins with constant monitoring of the protein concentration throughout. 
Flow-through was checked for protein content to check the membrane was not leaking 
and discarded if fine. Concentrated protein was decanted and stored in 1.5 ml 
microcentrifuge tubes at -20 ˚C. 
 
2.2.13 Analytical Gel Filtration  
To assess the integrity of the protein, a small sample was passed through an analytical 
gel filtration Superdex 200 10/300 GL column (GE Healthcare) to measure impurities 
or/and aggregation. 100 µg of protein was diluted into 100 µl of running buffer (Tris 
Buffered Saline TBS, pH 7.5: 25 mM Tris-HCl pH 7.5, 125 mM NaCl, 0.05% azide w/v 
for derCD23 proteins, and PBS, pH 7.4: 0.14 M NaCl, 2.7 mM KCl, 1.5 mM KH2PO4, 
8 mM Na2HPO4, pH 7.4, 0.05 % azide w/v for all other proteins). The Gilson HPLC 
system was equilibrated in the same buffer the protein was diluted in. A flow rate of 
0.75 ml/min was used and protein was detected by absorbance at 280 nm. 
Chromatograms were analysed with Trilution®LC software (Gilson). 
 
2.2.14 Size Exclusion Chromatography (SEC) 
The concentrated triCD23 protein was further purified by SEC on a Superdex 200 
column 10/300 GL column (GE Healthcare). The column was equilibrated in 0.5 M 
Tris, 100 mM NaCl pH 7.5 and the protein was loaded onto the system in 500 µl 
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aliquots and run at 0.75 ml/min. The protein was eluted into 200 µl fractions collected 
between 10 and 30 mins in Tris buffer (0.5 M Tris, 100 mM NaCl pH 7.5).  
 
2.2.15 Buffer exchange  
Samples were dialysed by placing the concentrated protein sample into 3.5 kDa MWCO 
dialysis tubing (Fisher Scientific Ltd) pre-rinsed in dH2O. The tubing was transferred 
into a large beaker containing the end buffer of choice. Samples were dialysed 
overnight at 4°C with stirring, and carefully removed from the dialysis tubing with 
pipettes. Protein samples had their concentration determined before storage at 4°C for 
further use.  
 
2.2.16 Co-transfection of pcDNA5/FRT/Fcε-GFP-V5-His vectors and pOG44 Flp-
recombinase vector 
As recommended for the transfection reagent FuGene (Promega), briefly: the day before 
the transfection, half a 24-well plate (Flat round well, tissue culture 24-well Nunc™ 
plate, Thermo) was plated at a density of 8 x 104 cells/well with FlpIn HEK293 cells, 
and the second half at a density of 4 x 104 cells/well in 500µl of complete growth 
medium (DMEM + 10% Fetal Bovine Serum). For a single protein transfection in 
duplicate, 0.11 ug of pcDNA5-FRT vector and 0.99 ug of pOG44 DNA (Thermofisher 
lot no. 1542822 and 417309) were added in a combined total volume of 52 µl of sterile 
deionized water. pcDNA™5/FRT/CAT is the positive control (Thermofisher lot no. 
468373) and is also co-transfected with pOG44. Using a 3:1 Fugene to DNA ratio, 3.3 
µl of FuGene was carefully added. This was achieved by avoiding touching the sides of 
the 1.5ml microcentrifuge tube with the tip of the pipette. The solution was vortexed for 
20 seconds, and spun-down to recover all the solution in the base of the 1.5 ml 
microcentrifuge tube. After 10 minutes incubation at room temperature, 25 µl of 
complex was added per well (one at the higher density and one at the lower cell density) 
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and mixed thoroughly. Cells were returned to the incubator and after 48 hours the cells 
were split into 6-well plates containing complete media with 50 µg/ml hygromycin 
(Invitrogen hygromycin B in PBS, lot no. HY068-L11) for selection. A month later 
successfully transfected cells form loci in the wells which can be expanded.  
 
2.2.17 Large-scale transfection of FlpIn cells for the creation of the memIgE-Fc 
library  
As recommended for FuGene (Promega), briefly: the day before the transfection, a T75 
flask was seeded at a density of 8 x 105 cells/well with FlpIn HEK293 cells in 22 ml of 
complete growth medium (DMEM + 10% Fetal Bovine Serum). For a single 
transfection of the whole library, 2.5 ug of the pooled pcDNA5-FRT-IgE-Fc-GFP 
mutant vectors and 22.5 ug of pOG44 DNA (Thermofisher lot no. 1542822 and 
417309) were added in a combined total volume of 1163 µl of sterile deionized water. 
Using a 3:1 Fugene to DNA ratio, 74 µl of FuGene was carefully added. This was 
achieved by avoiding touching the sides of the 1.5ml microcentrifuge tube with the tip 
of the pipette. The solution was vortexed for 20 seconds, and spun-down to recover all 
the solution in the base of the 1.5 ml microcentrifuge tube. After 10 minutes incubation 
at room temperature, 1125 µl of complex was added to the flask and swirled to mix 
thoroughly. Cells were returned to the incubator and after 48 hours the cells were split 
into a T175 flask containing complete media with 50 µg/ml hygromycin (Invitrogen 
hygromycin B in PBS, lot no. HY068-L11) for selection. A month later successfully 








2.2.18 Cell Lines 
Cell Line Name Species Cell Type Growth Medium 
FlpInä 
HEK293 




DMEM + 10% FBS + Zeocin  
Post-transfection: DMEM + 10% FBS + 
1% PSG + 50 µg/ml hygromycin (no 
Zeocin) 
 
WEHI cells  Mouse  B-cells DMEM + 10% FBS + Geneticin + b-
mercaptoethanol 
 
Table 2-12 Cell lines used in the experiments. DMEM = Dulbecco’s Modified Eagle’s Medium. FBS = 
fetal bovine serum, PSG = penicillin-streptomycin-glutamine. 
 
2.2.19 Thawing Cell lines 
Cells were extracted from the liquid nitrogen store and thawed quickly in a water bath 
at 37°C and were immediately transferred to a T25 flask containing 5 ml of pre-warmed 
medium (DMEM and 20% FBS).  
 
2.2.20 Passaging Cell lines 
Medium from adherent cells was decanted and the cells were subsequently washed 
twice with Gibco™ PBS (Thermo) before 5 ml of trypsin was added to the T175 flask. 
The trypsin-covered flask was left to incubate at 37˚C for 2 – 5 mins until cells started 
to detach. At this point, the trypsin was neutralised with media and split accordingly 
into new flasks. New T175 flasks, which contained fresh media and correct antibiotics 
were mixed well by pipetting the cells up and down before leaving the cells to grow in 




Suspension cells (For WEHI cells): A few mls of cells was removed directly from the 
flask and transferred into a new flask with fresh media at a 1:4 ratio. 
 
2.2.21 Freezing Cells 
Medium from cells was removed and washed twice with Gibco™ PBS (Thermo) and 
trypsinsed. Cells were counted and resuspended at a density of at least 3 x 106 cells/ml 
in freezing media (FBS + 10% DMSO). 1 ml aliquots were divided into freezing nunc 
vials and were stored in the Mr Frosty™ Freezing Container (Fisher Scientific) at -80˚C 
for 24 hours to allow slow freezing before being moved into liquid nitrogen storage. 
 
2.2.22 Determination of Cell Numbers 
10 µl of cells were extracted and mixed with 10 µl of trypan blue before adding 10 µl of 
the mix to a haemocytometer. An average was taken of the cells in the quarters of the 
haemacytometer and multiplied by the dilution factor to define the cells/ml density.  
 
2.2.23 Antibiotic Cell Culture Kill Curve 
The optimum concentration of hygromycin antibiotic used for selection of a stably 
transfected FlpIn HEK293 cell line expressing the protein of interest was determined by 
a kill curve. FlpIn HEK293 cells were plated at a density of 8 x 104 cells/well for half a 
plate, and 4 x 104 cells/well for the second half of the plate in 500 µl of complete 
growth medium (DMEM + 10% Fetal Bovine Serum). The hygromycin antibiotic 
(Invitrogen hygromycin B in PBS, lot no. HY068-L11) was added at a range of 
concentrations: 0, 25, 50, 100, 150 and 200 µg/ml and monitored for 2 weeks. 50 µg/ml 




2.2.24 Epifluorescence Microscopy  
Transfected cells grown in plates were checked for GFP fluorescence by an Axiovert 
200M inverted microscope (Zeiss). Tissue culture plates were placed on the microscope 
stage platform and cells were examined at 10x optical zoom. Cells were located in the 
brightfield channel before switching to the GFP channel (LEJ EBQ 100 isolated 
mercury discharge lamp power supply, GFP filter – EX BP 469/38) with images 
captured with the AxioVision software v4.4. Images were processed with ImageJ v1.49 
(Wayne Rasband, NIH, USA).  
 
2.2.25 Flow Cytometry 
Cells were harvested, washed twice with Gibco™ PBS (Thermo), and re-suspended at 1 
x 106 cells/ml in FACS buffer (Gibco™ PBS pH7.4 + 10% FBS) and 100 µl was 
aliquoted into FACS tubes. The cells were stained with either antibody, or labelled 
protein reagent (triCD23-Alexa488, triCD23-Alexa647 or ag-fusion protein-Alexa647) 
at 1 ug/ml and incubated on ice for 30 mins. The cells were then washed twice and re-
suspended in 1 ml of FACS buffer for analysis. Cells were analysed either on the Attune 
NxT Acoustic Focusing Cytometer (Lasers: BRVX) or Guava Easy Cyte Plus™ 
CytoSoft 5.2.7. For the Attune, the voltage parameters were kept constant as follows: 
FSC 170 V, SSC 330 V, BL1 250 V, BL3 400 V, RL1 350 V. Flow cytometry data was 
analysed in FlowJo version 10.2. 
 
Antibodies: For the positive control: anti-human IgE-PerCP Cy5.5, clone MHE-18, 





2.2.26 Protein Fluorophore labelling  
Proteins were labelled with either Alexa647 (Monolith NT™ Protein Labelling Kit) or 
Alexa488 (AlexaFluor™ 488, Thermo) according to manufacturer’s instructions. 
Briefly, proteins were first dialysed into a primary amine-free buffer e.g. PBS (PBS pH 
7.4: 0.14 M NaCl, 2.7 mM KCl, 1.5 mM KH2PO4, 8 mM Na2HPO4, pH 7.4). The 
fluorophore was reconstituted, and added to the protein and mixed slowly. The protein 
and fluorophore were incubated rotating at room temperature and covered in tin foil to 
block out any light for 30 mins. To remove free dye, the mix was passed over an 
equilibrated PD-10 desalting column and eluted into fresh dialysis buffer into 0.5ml 
fractions. The degree of labelling (D.O.L) was determined using Equation 1.  
 
 !.#. $ = 	 '()*	+	,-	[/012345]e789 
 
Equation 1 Degree of labelling equation. D.O.L = degree of labelling, Amax = the absorbance of dye 
solution measured at the wavelength maximum, DF = dilution factor, edye = molar extinction coefficient 
of the fluorescent dye.  
 
As fluorescent dyes also absorb at 280 nm, to adjust for the contribution of the dye to 
the A280, a correction factor was used for each dye as described in Equation 2.  The 
correction factors used for alexa647 were 0.03 and 0.11 for Alexa488.  
 




Equation 2 Correction factors used to calculate protein molarity. A280 = the absorbance of the protein-
dye at 280 nm. Amax = the absorbance of the dye solution measured at the wavelength maximum, CF = 




2.2.27 Protein Biotinylation 
IgE-Fc was biotinylated with the EZ-link® Sulfo-NHS-LC-Biotin, No-weigh™ 
(Thermo) kit as per manufacturer’s recommendation. Briefly, biotin was resuspended in 
dH2O to 10 mM and added to IgE-Fc in at a 1:1 molar ratio. The mixture was incubated 
on ice for 2 hours and purified by SEC on the Superdex 200 10/300 GL column (GE 
Healthcare) at a flow rate of 0.75 ml/min. The protein was eluted into 10 mM HEPES, 
150 mM NaCl, pH 7.4, 0.05% Na-Az. The 0.5 ml fractions containing the biotinylated 
protein were pooled and stored at 4°C. 
 
2.2.28 Other protein materials/Gifted proteins  
ag-fusion protein; the soluble fragment of the high-affinity IgE receptor α-chain fused 
to the Fc region of IgG4 (Shi et al., 1997), and FceRI were kindly provided by Dr 
Rebecca Beavil. 
 




2.3 Biophysical Methods  
2.3.1 Isothermal Titration Calorimetry (ITC) 
ITC is a technique that provides experimental details about the energetic components of 
protein interactions. ITC complements structural studies to yield parameters such as 
binding constants (KB), stoichiometry (n), enthalpy (DH) and entropy (DS) of binding. It 
measures the change in heat associated with a chemical reaction in relation to the 
reference cell, triggered by the mixing of 2 reagents, such as a titration of a ligand into a 




Figure 2-1 The basic principle of Isothermal Titration Calorimetry. A schematic representation of the 
isothermal titration calorimeter (left) and a characteristic titration experiment and analysis (right). The 
instrument consists of two cells in an insulated jacket and a power supply to maintain the temperature 
between the two cells. Injections of the ligand (calcium) from the stirring syringe into the sample cell 
(protein) cause a change in the temperature, which is measured and recorded as a titration thermogram 
(upper right). The raw data is integrated (blue circles) and plotted against the molar ratio to be fitted with 
a curve that corresponds to a model which considers n binding sites and gives thermodynamic properties 
of the reaction. Image reproduced from (Chengcheng et al., 2015). 
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Isothermal Titration Calorimetry
Isothermal titration calorimetry is a label-free, powerful, and
highly sensitive technique for studying molecular interactions
in solution. This method has been applied quite extensively
to investigate the interaction of a macromolecule (in general,
a protein) with small ligands (Sigurskjold, 2000; Velazquez-
Campoy and Freire, 2006), other proteins (Pierce et al., 1999;
Velazquez-Camp y et al., 2004), and nucleic acids (Matulis
et al., 2000) as well as with drugs (Ward and Holdgate, 2001;
Boonsongrit et al., 2008) and metal ions (Zhang et al., 2000),
relies on the fact that such an interaction is accompanied by a
heat eﬀect. It does not rely on the presence of chromophores or
fluorophores, nor does it require an enzymatic assay. A number of
parameters such as enthalpy of binding (!H), entropy of binding
(!S), association constant (Ka), binding stoichiometry (n), free
energy of binding (!G), and potential site–site interactions
(cooperativity) can be obtained from a single calorimetric
titration, providing a full hermodynami description of a
interacting system (Figure 7).
Isothermal titration calorimetry has been one of the
most common tools used for investigating interactions of
protein association with nucleic acids. Recent advances in ITC
instrumentation and data analysis software like the Omega
ITC, MCS ITC, VP-ITC, Auto-ITC, Nano ITC-III, and ITC200
instruments have facilitated the development of experimental
designs. It also can provide an informative thermodynamic
when used in conjunction with complementary techniques
such as X-ray crystallography, NMR spectroscopy, small angle
x-ray scattering (SAXS), circular dichroism spectroscopy (CD),
intrinsic fluorescence, and immunoisolations. Many particularly
interesting reports employ ITC, with a focus on protein
interactions with nucleic acids. Zhou et al. (2008) have utilized
ITC in their study of the role of E. coli proline utilization A
(PutA) flavoprotein, which acts as the transcriptional repressor of
proline utilization genes putA and putP. ITC of PutA binding to
the optimal oligonucleotide (O2) revealed a strongly endothermic
interaction in Tris buﬀer but a weakly exothermic interaction in
phosphate buﬀer. Kozlov and Lohman (2012) employed ITC to
analyze the interaction about E. coli SSB and D. radiodurans SSB
binding to ssDNA, respectively. Crane-Robinson et al. (2009) and
Gilbert and Batey (2009) present an overview of ITC experiments
on protein/DNA complexes, with detailed descriptions of the
experimental methodologies. This review concentrates on the
thermodynamics of interaction of protein DNA binding domains
with DNA duplexes, and gives a thorough description of the joint
implementation of ITC and diﬀerential scanning calorimetry
(DSC) to provide a thorough description of the binding process.
In spite of the widely using, there remain some important points
to the use of ITC that should always be considered. Just as
Falconer said in two eviews about ITC (Falconer et al., 2010;
Falconer and Collins, 2011), several aspects of ITC data collection
have been outlined in the reviews.
As more and more correlative analyses are performed
and databases increased their informative capacity, ITC
FIGURE 7 | Basic principle of isothermal titration calorimetry. Schematic representation of the isothermal titration calorimeter (left) and a characteristic titration
experiment (upper right) with its evaluation (lower right). In (upper right) picture, the titration thermogram is represented as heat per unit of time released after
each injection of the ligand into the protein (black), as well as the dilution of ligand into buffer (blue). In (lower right) picture, the dependence of released heat in each
injection versus the ratio between total ligand concentration and total protein concentration is represented. Circles represent experimental data and the line
corresponds to the best fitting to a model considering n identical and independent sites. The syringe is inserted in the sample cell and a series of injections are made
(Freyer and Lewis, 2008; Martinez et al., 2013).
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When studying protein interactions, choosing the experimental protein concentration is 
dependent on the c-value as defined by Equation 3.  
 
A = 	@:2QR  
Equation 3 The ITC parameter C. n = number of binding sites per protein molecule, Pt = protein 
concentration in the measurement cell, KD = The dissociation constant.  
 
This c value affects the shape of the binding isotherm in the processed data, as shown in 
Figure 2-2. To obtain a sigmoidal shaped binding isoform, necessary for good estimates 
of n, c is required to be between 20 and 100. If c is below 20, then thermodynamic 
parameters can only be obtained if one is fixed during the curve fitting process (Dutta et 
al., 2015). The following ITC experiments were conducted using historic experimental 
settings as detailed in (Yuan et al., 2013) which had low c-values. 
 
 
Figure 2-2 The importance of the c value for binding isotherms. Simulated binding isotherms for a 1:1 
system were generated. For low c values (c < 5), the binding isotherm loses the S-shape and thus 
thermodynamic parameters cannot be determined. At high c values ( c > 1000), some thermodynamic 
parameters can be determined such as the stoichiometry (n) and DH. In optimum values of c ( 20 < c < 
100), all thermodynamic parameters such as KD, DH, DS and n can be obtained from the sigmoidal 




 3. If necessary, run a blank titration of ligand into the buffer and 
buffer into protein to correct for any heat change due to con-
tribution from dilution of the protein and/or GAG samples.
 4. An important aspect of an ITC experiment is choosing the 
proper concentration for protein and ligand. The choice of pro-
tein concentration depends on the “c” value as given by Eq. 1:
 c n t d= P K/  (1)
where, Pt is the protein concentration in the measurement cell; 
“n” is the number of binding sites per protein molecule. Please 
note that multiple binding sites are present usually on the GAG 
and not on the protein. Thus the value of n could be <1. The 
shape of the binding isotherm depends on the  value. The c 
value should be between 20 and 100 to obtain a sigmoidal 
shape of th  bindi g isotherm in order to get a good fit to esti-
mate Kd, ΔH, ΔS, and n. If the c value is very high (~1,000), 
one can get an estimate of ΔH and n, but not of the other 
parameters. If the c value is <5, then the shape of the binding 
isotherm does not permit accurate estimation of the thermody-
namic parameters unless one of them is already known (such as 
the stoichiometry) and is not varied during the fitting process.
A simulation plot of heat released vs. mole ratio explains 
the importance of c value (Fig. 1). If the Kd and n are not 
Fig. 1 Simulated binding isotherm for a 1:1 system to show the importance of c 
value. The data were generated using the model proposed by Wiseman et al. [10] 
using ΔH = −50 kcal/mol. For low c values (<5), the binding isotherm loses the 
S-shape and thus determination of the thermodynamic parameters is not pos-
sible. At high c values (~1,000), ΔH and stoichiometry (n) can be inferred from 
the shape of the binding isotherm but th  data cannot be fitted to determine the 
other thermodynamic parameters
Amit K. Dutta et al.
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2.3.2 Isothermal Titration Calorimetry Measurements  
WT human derCD23, mutant B and mutant C were initially dialyzed against 10 mM 
Tris pH 6.8, 125 mM NaCl and 10 mM EDTA to remove the bound Ca2+ present in the 
refold buffer. This was followed by extensive dialysis against 50g/L Chelex-100-
pretreated 10 mM Tris pH6.8, 125 mM NaCl buffer. The 10 mM Tris pH6.8, 125 mM 
NaCl buffer was filtered with a 0.22 micron filter spun at 8736 rcf and was used to 
dilute the protein (if required) and to establish the baseline for the iTC200 
microcalorimeter (Microcal, GE Healthcare) by titrating 20 mM CaCl2 into the buffer. 
For the protein experiment, 20 mM CaCl2 diluted in buffer was titrated into 400 µl of 50 
or 500 µM derCD23 protein, measured at 25°C. Data was analysed using the MicroCal 
ITC-ORIGIN Analysis Software (Microcal, GE Healthcare). 
 
2.3.3 Surface Plasmon Resonance (SPR) 
SPR is a spectroscopic technique that measures the binding between molecules in 
solution (the analyte) to an immobilised molecule (the ligand) in real time. The 
immobilised molecule is bound to a planar metal surface, usually gold. Gold can be 
regarded as plasma, it is a medium with an equal concentration of negative and positive 
charges, of which at least one charge type is mobile. Plasma has a natural oscillation 
frequency, the plasma frequency, and plasma oscillations are known as plasmons. A 
plasma oscillation along the surface of the metal is a known as a surface plasmon as 
illustrated by ksp in Figure 2-3. A surface plasmon can couple with a photon (kx), from 
the polarised light shone at the gold layer. The polarised light encounters an interface 
(between the gold layer and the analyte solution, which is of low refractive index (n2)) 
at a specific angle (q), and is totally reflected within the prism. The electromagnetic 
component of the polarised light combined with a surface plasmon of the same 
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wavevector, leads to the enhancement of the evanescent wave (E). This results in a dip 
of light intensity observed (Ritzefeld and Sewald, 2012).  
 
A change in the refractive angle results in an angular shift of the position of the light dip 
echoed in the reflective curve, as shown in Figure 2-4, the change between phase 2 to 3. 
These shifts in the refractive index are directly proportional to the mass being 




Figure 2-3 The principle of Surface Plasmon Resonance. E = evanescent field amplitude, n2 = 
refractive index of medium with lower refractive index, ksp = wavevector of surface plasmon, kx = 
wavevector of photon. Insert = the change in refractive index. Image reproduced from Ritzefeld and 
Sewald 2012.  
 





















Figure 1: General principle of SPR. See text for details. n2 (refractive index of medium with lower refractive index), E (evanescent field
amplitude), ksp (wavevector of surface plasmons), kx (wavevector of photon).
specific angle (Θ). This phenomenon is called total internal
reflection (TIR). Although a total reflection occurs, the
electromagnetic field component penetrates over a short
distance into the medium of low refractive index. The
resulting evanescent wave attenuates exponentially. If the
interface is coated with a thin layer of metal (e.g., gold),
a dip in the intensity of the polarized light will be visible
(Kretschmann-Reather ATR configuration). Electrons are
oscillating at the plasma frequency within the surface of
the conductor. The quantization of this oscillation is called
plasmon. The surface plasmons can couple with the photons
of the polarized light, if the wavevector of the photon
(kx) equals the wavevector of the surface plasmons (ksp).
Coupling of both quasiparticles leads to an enhancement of
the evanescent field amplitude (E). This phenomenon, called
surface plasmon resonance, results in the observed dip of the
light intensity. The wavevector of the plasmons depends on
the refractive index of the conductor and the neighboring
medium of low refractive index (n2). The wavevector of the
photon depends on the wavelength of the polarized light
and the angle of incidence (Θ). In conclusion, the refractive
index n2 can be determined by measuring the intensity of
the reflected light at diﬀerent angles of incidence (Θ), if the
wavelength of the polarized light and the refractive index of
the conductor are both known [9, 10].
2.2. Using SPR for Interaction Analysis. In most practical
applications of SPR, the Kretschmann-Reather ATR method
that was already described in the last section is used. In
this setup, a thin metal film (typically around 50 nm thick
gold layer) is evaporated onto the glass prism and kept in
direct contact with the medium of lower refractive index (n2)
[10, 11]. In order to evaluate the interactions of a protein
with a nucleic acid that results in the formation of a protein-
DNA complex, one of the two interaction partners has to
be immobilized on the surface of the conductor (“ligand”
in Figure 1) [12]. In most cases, a sensor chip with preim-
mobilized streptavidin is used to immobilize biotinylated
oligonucleotides (more details concerning immobilization
will be discussed below). The other interaction partner (e.g.,
the protein = “analyte” in Figure 1) is injected into the
running buﬀer that passes the surface at a constant flow. In
Biacore instruments, the resulting change in concentration
of molecules at the gold surface due to the formation of the
protein-DNA complex is measured in resonance units (RUs)
and can be described according to (1):









In this equation, n is the changing refractive index at the
surface, X is a multiplier to convert n to RU, RII is the
refractive index increment of the protein that is binding to
the immobilized oligonucleotide, and c is the concentration
of the protein. In general, 1000 RU correspond to a change
in angle of 0.1◦, or a protein concentration of 1 ng·mm− 2
(alternatively 10mg·mL− 1) [13, 14]. One set of problems
that is connected to the RII has to be mentioned when using
the correlation of RU and protein concentration. The RII
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SPR machines are built using microfluidics with various numbers of channels to allow 
parallelisation of the experiments. One channel is always the reference channel in which 
no molecules are immobilised to it, this allows for changes caused by analyte flow to be 
substracted from the experimental channels. The difference between the two channels is 
plotted on a sensorgram, depicted in Figure 2-4. The process is repeated with different 
concentrations of analyte to obtain KD values.  
 
 
Figure 2-4 The phases of a Surface Plasmon Resonance experiment. The red line shows a typical SPR 
sensorgram divided into five phases. In this example, the interactions between an antibody and an antigen 
were measured. 1) The antibody is bound to the gold film and the baseline is established. 2) The analyte 
(the antigen) is flowed over the film, some of the antigen binds to the antibody in the association phase. 
This change in the refractive index, causes a variation of the specific angle (q) corresponding to change 
of mass of the surface. 3) In the equilibrium phase, the association and dissociation of the antigen from 
the antibody occur at equal rates. 4) In the dissociation phase, the analyte flow is stopped and the antigen 
dissociates from the antibody. During this process, a regeneration buffer is added to remove all the 
analyte from the antibody. 5) The surface has re-generated and has returned to its baseline. This process 
is repeated for different concentrations of analyte. Measurements taken during the steady-state of the 
equilibrium phase, (X), are plotted against the analyte concentration to give a binding curve, used to 
determine the KD. Image reproduced from Weistron 2014.  
 
2.3.4 Preparation of the Surface Plasmon Resonance Chip 
The CM5 sensor chip (GE Healthcare) and the streptavidin chip (GE Healthcare) were 
prepared at 25°C. The carboxymethyl groups on the CM5 chip in all flow channels were 




N-hydroxysuccinimide (NHS) in a 1:1 ratio. The derCD23 proteins had been dialysed 
into HBS/Ca2+ (HEPES pH 7.4, 150 mM NaCl, 4 mM CaCl2) and were diluted into 10 
mM Na-acetate pH 4.5 with 0.005% (v/v) surfactant P-20 for amine coupling to the 
measurement channels. The coupling density was limited to ~70-100 RU. Free ester 
groups in all channels were blocked with 1 M ethanolamine-HCl pH 8. Biotinylated 
IgE-Fc was dialysed into HBS/Ca2+ (HEPES pH 7.4, 150 mM NaCl, 4 mM CaCl2) and 
immobilised on a streptavidin chip by biotin covalent linkage at two densities (~400 RU 
for the lower density and ~800 RU for the higher density).   
 
2.3.5 Surface Plasmon Resonance Measurements  
The CD23 proteins and IgE-Fc were dialysed into either HBS (HEPES pH 7.4, 150 mM 
NaCl, 10 mM EDTA) or HBS/Ca (HEPES pH 7.4, 150 mM NaCl, 4 mM CaCl2) which 
were also used as the running buffer with 0.005% (v/v) surfactant P-20 added. 
Experiments were performed on the Biacore T200 instrument (GE Healthcare) at 25°C 
with the flow rate set to 20 µl/mins using conditions previously optimised for derCD23, 
(Yuan et al., 2013). Binding of Fce3-4 to immobilised derCD23 was collected at a range 
of concentrations: 8000, 4000, 2000, 1000, 500, 250, 125, 62.5 and 31.2 nM with a 90 s 
association phase followed by a 5 min dissociation phase. Binding of derCD23 proteins 
to immobilised IgE-Fc were collected at a different range of concentrations: 40, 20, 10, 
5, 2.5, 1.25, 0.63 and 0.32 µM respectively. The raw data was processed with standard 
double referencing data subtraction methods before analysing the rates of equilibrium in 
Microcal Origin (OriginLab).  
 
2.3.6 Nuclear Magnetic Spectroscopy (NMR) 
NMR relies on the observation that atoms with an odd number of protons or neutrons 
spin about an axis and generate their own magnetic field. Such atoms that magnetic 
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moment include hydrogen (1H), carbon (13C) and nitrogen (15N) and are found in 
biological samples as shown in Figure 2-5A. An NMR machine consists of a very 
strong magnet and when a biological sample is placed inside the magnet, the atoms with 
magnetic moment adopt one of two states; they either align with or against the magnetic 
field (Figure 2-5B). A specific radiofrequency wave is applied to the sample and the 
atoms with magnetic moment ‘flip’ to their other state (Figure 2-5C). When the 
radiofrequency wave is discontinued, the atoms relax and release radiofrequency waves 
which provide information on the location and chemical environment of the atoms 
(Figure 2-5D) (Bothwell and Griffin, 2011).   
 
The data collected is processed and analysed to give a spectrum (one dimensional) 
(Figure 2-5E). An additional radiofrequency wave (e.g. one with a wavelength targeted 
for 1H and the second to target 15N) will provide data for a two-dimensional spectrum. 
 
 
Figure 2-5 An example of an NMR experiment. A) Nuclei (blue circles) in a sample have random 
magnetic moment in a sample. B) The sample is placed inside the NMR magnetic and the nuclei either 
align with the magnetic field (up arrow) or against the magnetic field (down arrow). C) A radiofrequency 
is applied to the experiment. D) The nuclei relax and emit electromagnetic radiation (wavy lines). E) The 





2.3.7 1H-NMR Spectroscopy 
A pure protein sample, of at least 90 µM in TBS, pH 7.5 (25 mM Tris-HCl pH 7.5, 125 
mM NaCl), had 5% D2O was added, to confirm correct protein refolding. 
Measurements for one-dimensional 1H-NMR analysis were taken at a proton frequency 
of 500 MHz at 35°C with all experiments performed using a 500 MHz NMR machine 
(Bruker DMX500) using conditions previously optimised for derCD23 (Hibbert et al., 
2005). 
 
2.3.8 1H - 15N HSQC NMR Spectroscopy Titrations 
A 0.5ml sample of 15N labelled protein (please refer to section 2.2.2) with 5% D2O 
added, was used to collect titration spectra. Protein samples with concentrations 
between 350 µM and 400 µM were stored in a buffer containing 25 mM Tris, 125 mM 
NaCl, pH 6.8. Samples were spun at 15000 g for 10 mins to remove debris, and were 
transferred to Shigemi NMR tubes (Shigemi Corporation). Measurements were taken at 
35°C with all experiments performed using a 500 and 700 MHz NMR machine (Bruker 
DMX500, DMX700). For calcium titration experiments, CaCl2 was added at step-wise 
increments until saturation was seen. For carbohydrate titration experiments, mannose 
was added at step-wise increments until saturation was seen. Data was processed in 
TopSpin3.5pl6 (Bruker) and analysed in SPARKY (T. D. Goddard and D. G. Kneller, 
SPARKY 3, University of California, San Francisco). 
 
2.3.9 Glycan Array  
The RayBio Glycan Array 100 [4 sample kit] (RayBiotech, Inc. lot no: 042817 30056) 
was performed as per manufacturer’s instructions. The PBS buffer pH 8.0, was also 
prepared according to the manufacturer’s instructions as stated here: 0.6 g KCl, 24 g 
NaCl, 0.6 g KH2PO4 and 3.45 g Na2HPO4 were dissolved in 2500 ml of ddH20 with the 
pH adjusted to pH 8 and the final volume adjusted to 3000 ml with ddH20. In brief, the 
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calcium-free wild type derCD23, mutant B and mutant C proteins were initially 
dialyzed into 1x PBS, pH8.0 buffer with 3 buffer exchanges, and biotinylated by 
incubating the reaction solution at room temperature with gentle rocking for 30 min. 
The reaction solution was mixed every 5 min by gentle tapping. 3 µl of stop solution 
was added to each reaction solution tube, and immediately dialysed into the same 1X 
PBS, pH8.0 buffer.  
 
The printed glycan array glass slide was air-dried and subsequently blocked with kit 
sample diluent E for 30 mins at room temperature. This was followed by incubation 
with the protein samples and dH2O as a negative control, with gentle rocking overnight 
at 4°C. Samples were decanted from the wells, and each well was washed 5x 5 mins 
with 800 µl of 1x Wash buffer I, and 2x 5 mins with 800 µl of Wash buffer II, with both 
sets of washes at room temperature with gentle shaking. To each well, 400 µl of Cy3 
equivalent dye-conjugated streptavidin was added. The whole glass slide was covered 
with plastic adhesive strips, and incubated in aluminium foil to avoid exposure to light 
at room temperature for 1 hour with gentle rocking.  
 
Next, the samples were decanted from the wells and washed 5x 5 mins with 800 µl of 
1x Wash buffer I at room temperature with gentle shaking. The slide assembly was 
disassembled and gently placed into the slide washer tube, and covered with 1x Wash 
buffer I and incubated at room temperature for 15 mins with gentle rocking. This was 
followed by a single wash with 1x Wash buffer II for 5 mins. The glass slide was 
washed with dH2O for 5 mins and the signals were acquired and processed using the 
LuxScan™ 10K Microarray scanner (Capital Bio) and the LuxScan 10K software. The 
RayBio Analysis Tool for GA-Glycan-100 (RayBiotech, Inc.) was used to analyse the 




To repeat the results in the presence of calcium, the glycan array was washed first with 
PBS-Tween at room temperature with gentle rocking for 20 mins. Next the array was 
washed with Wash Buffer 1 and then with Wash buffer II, both at room temperature 
with gentle shaking for 20 mins. The glycan array was air-dried and repeated, starting at 
the blocking step. The array was incubated with the same protein samples, except with 4 
mM CaCl2 added to the samples and incubated overnight at 4°C with gentle rocking. 





2.4 X-ray Crystallography  
In order to determine the 3D structure of a protein at atomic level, samples and data 
must be processed in a different manner to light microscopy. First samples are prepared 
by growing protein crystals from pure protein, the individual protein molecules are 
aligned in a repeating three-dimensional pattern to create a lattice. To collect data, X-
rays (which are close in wavelength to the distance of an atomic bond) are shone at the 
protein crystal and diffraction is collected.  
 
The diffraction pattern represents scattering constructive waves off a crystal lattice, 
described as waves which are an integer apart with the same amplitude. These 
conditions are known as Bragg’s Law as described in Equation 4, and Figure 2-6 
displays the conditions required for diffraction. The diffraction of measurable X-rays 
from the minimum spacing (d) of crystal lattice planes gives the definition of resolution 
which is measured in Å. The resolution is often used as a measure of quality and 
describes the minimum distance between neighbouring structural features in an 
electron-density map. The higher the resolution, (the lower the value in Å), the smaller 
the spacing (d) between features in an electron-density map which results in more 
independent reflections and a better-defined structure.  
 
n λ = 2d sinΘ 
 
Equation 4 Bragg’s Law of diffraction. n = an integer, λ = the wavelength of the incident X-rays, d = 




Figure 2-6 Bragg’s Law. Diffraction is created when diffracted X-rays exhibit constructive interference 
when the distance between paths ABC and A’B’C’ differs by an integer number of wavelengths (λ).  
 
In a diffraction pattern, the amplitude of a wave can be derived from experimentally-
measured intensities of the diffracted beams. The phase of the wave cannot be 
determined and thus in macromolecular X-ray crystallography various techniques are 
used to overcome this ‘phase problem’. The most commonly used technique is called 
molecular replacement, in which a similar solved structure is used to approximate a set 
of phases which is then compared to the experimental observations and further refined.  
 
2.4.1 Pre-crystallisation trials  
The pre-crystallisation test (PCT) (Hampton research) determines if the protein 
concentration for crystallisation screening is appropriate. Trials were run as per 
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2.4.2 Crystallisation Screens  
Commercial screens were used to investigate the conditions required for protein 
crystallisation. The Hampton Index HT (Hampton Research), PEG and JCSG (Qiagen) 
screens contain 96 different reservoir solutions, differing in precipitant, salt and buffer. 
The screens were prepared in polystyrene MRC 96-well plates in a sitting-drop vapour 
diffusion method with 100 nl or 200 nl of concentrated protein (stored in TBS buffer, 25 
mM Tris-HCl pH 7.5, 125 mM NaCl, 0.05% azide w/v) dispensed into the wells with 
the Mosquito Liquid Handling robot (TTP Labtech). 100 nl or 200 nl was then removed 
from the reservoir and added to the protein well also with the Mosquito Liquid 
Handling robot (TTP Labtech). The plates were incubated at 18°C, and were checked 
for crystal growth regularly. Photographs of the crystals were taken using NIS elements 
software (Nikon).  
 
2.4.3 Salt detection with the PX scanner  
Grown crystals can either be salt or protein based. To discriminate between the two, 
their X-ray diffraction qualities were assessed. Sealed crystallisation plates were 
inserted into the PX-scanner (Agilent Technologies) and exposed to X-rays to quantify 
their diffraction properties.  Results were visualised in CrystalEyes software.  
 
2.4.4 Crystallisation Optimisation  
The initial crystal growing conditions for mutant B were found in the commercial 
crystallisation screen JSCG: 0.1M sodium-cacodylate pH 6.5 and 1M tri-sodium-citrate. 
These conditions were systematically changed and optimised in a 6 by 4 grid format. 
The grid conditions ranged from 0.8 - 1.3 M tri-sodium-citrate and pH 6-6.75 sodium-
cacodylate, and in the second round of optimisation, this was refined to 0.8 – 1.1 M tri- 
sodium-citrate, with a duplicate grid containing an added 5% glycerol. Plates were 
incubated at 18°C and took a week to grow.  
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2.4.5 Cryo-cooling crystals in cryoprotectant  
To suppress ice formation, cyroprotectant was added to the protein crystal well, before 
mounting the crystals onto nylon cryo-loops for data collection. For most of the crystal 
growing conditions, the cryoprotectant was the reservoir solution + 20% glycerol, 
alternatively if the crystals had been soaked with calcium first, the solution would also 
have worked as a cryoprotectant. Once the protein crystals were mounted onto the cryo-
loop, the crystal was flash-cooled in liquid nitrogen (Teng, 1990), and stored in liquid 
nitrogen until data collection. 
 
2.4.6 Calcium soaking of crystals  
The crystal plate seal was broken briefly to add CaCl2 directly to the protein well in a 
drop-wise fashion and immediately re-sealed. The plate was left to incubate at 18°C for 
4 days before cryo-cooling the crystals as described above. Three different calcium-
containing solutions were used: 1.1 M tri-sodium-acetate, 0.1 M Na-cacodylate pH 7.1, 
10 mM CaCl2 with either 20% or 16.7% glycerol or 1.35 M tri-sodium-acetate, 0.1 M 
Na-cacodylate pH 7.1, 10 mM CaCl2. 
 
2.4.7 Data Collection  
Data was collected at Diamond Light Source (Synchrotron) using X-ray radiation at 
beamline I04 for the WT human derCD23, beamline I04-1 for mutant B and beamline 
I02 for mutant C. All data was collected at cryo-temperatures of 100 K, maintained by a 
stream of nitrogen.  
 
2.4.8 Data processing  
The raw data collected at the Synchrotron was first inspected with iMosflm (Leslie et 
al., 2011). The data was indexed and the unit cell parameters defined, and refined before 
integration with the accurate cell parameters. Pointless was run on the data to determine 
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the space group before scaling and merging the data in SCALA. The protein structures 
were solved by molecular replacement using PDB file: 4J6J, crystal form A as the 
search model. Refinement was conducted in PHENIX (Adams et al., 2010) and 
alternated with manual model-building in COOT (Emsley et al., 2010). Structures were 
validated using the POLYGON tool in PHENIX. Data is measured in Å; the lower the 
number of Å, the higher the resolution, which provides more detail about the structure 
of the protein 
 
2.4.9 Graphics software used for structure visualisation 
Figures were generated using PyMol (The PyMol Molecular Graphics System, v 
1.7.4.3, Schrodinger, LLC) with specific codes for visualising clashes (show_bumps.py 
written by Thomas Holder) and for the Porcupine plots (modevectors.py written by 
Sean Law and Srinivasa, Michigan State University). Codes were accessed from the 
PyMol wiki (www.pymolwiki.org). 
 
Figures exhibiting electron density were created in CCP4mg molecular graphics 
software (McNicholas et al., 2011). 
 
2.4.10 Graph graphics software 






2.5 Molecular Dynamics Simulations  
 
2.5.1 System Preparation  
All MD simulations were set up using the AMBER14 software suite (Case et al., 2014); 
coordinates for a monomer of derCD23 were chosen from chain A of the asymmetric 
unit of the crystal structure PDB 4G9A. This model was also used as the base for the 
mutant proteins generated in PyMol. All the structures were then processed by 
pdb4amber (Case et al., 2014) to remove water molecules, build disulphide bonds and 
assign amber specific residue identifiers. The online tool H++ 
( http://biophysics.cs.vt.edu/H++ version 3.2) (Anandakrishnan et al., 2012; Gordon et 
al., 2005) was used to determine the protonation state of the histidine residues, which 
were manually renamed in the pdb text file. Another amber14 tool; reduce (Word, et. al. 
1999) added protons to the model and determined optimum geometry of each residue. 
The previous tools remove all non-covalently bound ions so calcium was modelled 
using Yasara v16.3.8 (Elmar Krieger). The calcium ions were modelled on the positions 
of calcium ions in another C-type lectin protein, DC-SIGN, pdb file: 1SL4.  
 
Parameter files were generated using AMBER14SB and force fields 
frcmod.ionsjc_tip3p and frcmod.ionslm_1264_tip3p for the ions. The protein was 
solvated in the TIP3PBOX model with a 10 Å layer of water. The total charge of the 
protein was neutralized with counterions and the average size of the monomer 
simulations is ~ 22700 atoms which is ~7000 residues in a 58.6 Å by 60.4 Å by 82.9Å 






Figure 2-7 A schematic overview of the MD simulation set-up.  
 
2.5.2 Running Molecule Dynamic Simulations  
Simulations were performed using pmemd.cuda in AMBER14 program (Case et al., 
2014) with a time-step of 2fs. Firstly, the system is minimized with protein constrained 
to equilibrate the solvent, then the entire system is minimized followed by a slow 
heating step to bring the system to 300K. Next, the system was relaxed, initially with 
the protein heavy atoms restrained, followed by the protein released in a NTP ensemble. 
The systems were subjected to 1 µs MD simulations at a constant temperature of 300K, 
controlled by Langevin dynamics and Berendsen barostat for pressure control. Please 




2.5.3 Calcium Ion binding plots  
The trajectories were analysed to produce calcium ion binding plots in the Ipython 
notebook Jupyter (Perez and Granger, 2007). Details of the python script are found in 
Appendix D.  
 
2.5.4 Trajectory Analysis  
Mdcrd files were converted to dcd files using the CPPTRAJ program (Roe and 
Cheatham III, 2013), which also removed non-alpha carbon atoms. Calcium ion 
distances were also calculated in CPPTRAJ. The data was analysed with the R-based 
program Bio3d (please refer to Appendix E for script)(Grant et al., 2006), where 
structures were aligned with the exclusion of the termini as they radically altered the 
PCA (residues 15-125).  
 
Principal component analysis (PCA) was conducted in Gromacs (version 5.1.3) 
(Abraham et al., 2015). PCA is a statistical technique to find the principal components 
of a set of data (Kerrigan, 2013). The principal component is not a standard x- or y-axis 
but an axis that describes the most variance. This is useful to know, since it is able to 
reduce data dimensions, simplifying it as well as making data easier to visualise. For 
MD trajectories, the principal component reveals the most important motions in 
proteins.  
 
Files were converted into a Gromacs compatible files by CCPTRAJ and PARMED 






Chapter 3 Calcium studies of derCD23 
3.1 Introduction 
The type II transmembrane glycoprotein and C-type lectin CD23/FceRII is responsible 
for a plethora of biological responses (Acharya et al., 2010). In the context of asthma, 
CD23’s role in IgE homeostasis is considered essential, alongside its roles in enhanced 
antigen presentation, and gut lumen transcytosis that lead to epitope spreading (Gould 
and Sutton, 2008). When examining the structure of CD23, it becomes apparent that 
unlike most antibody receptors, which are members of the immunoglobulin gene super-
family, CD23 is a C-type lectin (Fridman, 1991). C-type lectins usually bind to 
carbohydrate via calcium ion interactions, such as mannose-binding protein (Weis, 
1992), a member of the CTL family, and they frequently bind to two or more calcium 
ions (Drickamer, 1999). Uncommonly for a C-type lectin, human CD23 binds to IgE via 
protein-protein-interactions and only binds to one calcium ion, whereas an alignment of 
human CD23 sequences from other species and homologous proteins predicts two 
calcium-ion binding sites (Zelensky and Gready, 2003)(Zelensky and Gready, 2005).  
 
This divergence of the primate and rodent lineages regarding calcium ion binding is 
shown in Figure 3-1, which displays calcium-coordinating residues in the auxiliary 
calcium-binding site (as stated in chapter 1) of human CD23 and in Figure 3-2. In 
primates, these residues have been substituted by residues with an opposite charge so 
that they no longer co-ordinate a calcium ion. In mice, calcium ions are mandatory for 
CD23 to bind to the ligand IgE via protein-protein interactions (Richards and Katz, 
1990) while in humans, calcium is not vital for non-carbohydrate CD23-IgE interactions 
(Richards and Katz, 1990; Hibbert et al., 2005) In the presence of calcium, two 
additional salt bridges are formed between the human CD23-IgE complex which results 
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in a temperature-dependent 30-fold increase in affinity (Yuan et al., 2013). Considering 
the spatial proximity of the principal calcium-binding site to the IgE-binding-residues 
within loop 4 (Arg 253 to Glu 257) and loop 1 (Leu 226 to Glu 231) of human CD23 in 
Figure 3-2, it is clear how disordering or ordering of the loops by calcium could affect 
loop conformation and affinity of CD23 to IgE. 
 
         220       230       240       250       260       270 
      .         .         .         .         .         . 
Human    GSWIGLRNLDLKGEFIWVDGSHVDYSNWAPGEPTSRSQGEDCVMMRGSGRWNDAFCDR 
Gorilla  GSWIGLRNLDLKGEFIWVDGSHVDYSNWAPGEPTSRSQGKDCVMMRGSGRWNDAFCHR 
Pig      GSWIGLRDLDIEGEFIWMDEKPLDYSNWQPGEPNDAGQGEHCVMMQASGQWNDAFCGS 
Dog      GTWIGLRDLDREGEFIWMDENPLNYSNWRPGEPNNGGQGEDCVMMQGSGQWNDAFCGS 
Rat      ESWIGLQDLNMEGEFVWPDGSPVGYSNWNPGEPNNGGQGEDCVMMRGSGQWNDAFCRS 
Mouse    DSWIGLQDLNMEGEFVWSDGSPVGYSNWNPGEPNNGGQGEDCVMMRGSGQWNDAFCRS 
       EPN  
Figure 3-1 A sequence alignment of the principal and auxiliary calcium binding sites of CD23 in 
various species. The principal binding site residues are highlighted in blue and the auxiliary calcium 
binding site resides are highlighted in magenta. The green residue E257 is involved in both calcium 
binding sites. The EPN carbohydrate binding motif is highlighted in yellow. The amino acid numbering 
scheme is shown above the sequences.  
 
Human CD23 has an affinity for calcium of 1.5 mM, and this is close to physiological 
calcium concentrations in blood, ranging between 1 and 1.5 mM (Yuan et al., 2013). 
This signifies that the calcium-bound and calcium-free CD23 might be in equilibrium 
and thus confer sensitivity to calcium-facilitated ligand interactions. Calcium-bound 
membrane-CD23 binds to allergen-bound IgE, and undergoes receptor-mediated 
endocytosis, where the change in calcium concentrations in endosomes (to ~10 µM) 
(Andersen and Moestrup, 2014) results in the release of IgE and the allergen. The loss 
of the auxiliary calcium-binding site in human CD23 might result in decreased 
sensitivity to IgE-allergen binding, and downstream this may affect the release of the 
102 
 
ligand within the endosome and the subsequent processing and presentation of the 
allergen to the immune system. This reduction in calcium sensitivity might be enough to 
tip the scales such that the ligand (allergen-bound IgE) is released into a different 
vesicle (a late endosome rather than an earlier vesicle) and this might be enough for the 
ligand to embark on a different route of enzymatic digestion, and display on MHC class 
II molecules. The different peptides presented to naïve T-cells might deviate the 
immune response from Th1 cells to the Th2 cell response, which recruits IgE-producing 
B cells, mast cells and eosinophils, all involved in allergic inflammation and thus 
resulting in an increased chance of an asthmatic reaction (Mudde et al., 1995a). In this 
context, calcium is posing an additional layer of regulation over IgE. 
 
Figure 3-2 Important residues in WT human derCD23. Blue carbon atoms = the principal calcium-
ion-binding site, orange = “auxiliary” non-functional calcium-binding site, green carbon atoms = E257, a 
residue involved in both principal and “auxiliary” sites, pink carbon atoms = residues involved in IgE 
binding, yellow carbon atoms = additional residues involved in IgE binding upon calcium binding, 
striped yellow and orange carbon atoms = D258 a residue part of the “auxiliary” calcium binding site and 
























This has led to the hypothesis which suggests human CD23 may have lost its ability to 
bind a second calcium ion in the auxiliary calcium-binding site, in order to enhance its 
binding to human IgE. To test this hypothesis, a set of mutations was designed in 
human derCD23 that would enable the restoration of the auxiliary calcium binding site, 
and this focused on mutating the residues shown in Figure 3-3. 
 
 
Figure 3-3 The calcium binding site of human derCD23. The principal calcium-ion-binding site (blue) 
and “auxiliary” site (orange) in wild-type human CD23. Calcium ion shown in yellow, residues and loops 
labelled, pdb file: 4G9A.  
 
3.1.1 Mutation Design Rationale  
 
Residues to be mutated were selected based on the alignment of human WT and mouse 
WT derCD23 as shown in Figure 3-1. The proteins have 70% sequence identity and 
comparisons to other C-type lectin structures imply that residue E257 is involved in 













mutant proteins were designed as illustrated in Figure 3-4. Each set of mutants were 
designed in a consecutive fashion so that it would only take a single set of additional 
primers to add the extra mutations into the DNA for the next mutant. In mutant A, 
(Figure 3-4A) the mutations introduced cause a charge reversal from mostly postively 
charged side chains in the WT protein, to amino acid residues containing carboxylate 
groups to aid calcium ligation, as most calcium ions in proteins are chelated by oxygen-
containing groups (Yang et al., 2003). Mutant B has an additional mutation T251N 
(Figure 3-4B), because although it is involved in the principal calcium-binding site, the 
asparagine is conserved in C-type lectins and is part of the ‘EPN’ carboyhdrate binding 
motif. Residues R253 and S254 are not involved in calcium ion co-ordination, however 
they were mutated to glycines as found in the mouse CD23 sequence, which increased 
the flexibility of loop 4 depicted in  mutant C Figure 3-4C. We speculated that these 




Figure 3-4 Models of the mutant proteins, focusing on the calcium binding sites. derCD23 in grey, in 
blue – mutations N225D, K229E and S252N, in green – additional mutation T251N, and in pink 
additional mutations R253G and S254G. Carbon atoms coloured either blue, green or magenta, red = 
oxygen, blue = nitrogen. Yellow spheres = calcium ions (predicted places). 
 
 
A B C 
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3.2 Results  
3.2.1 Production of WT human derCD23 and human derCD23 mutants  
 
The pET5a vector containing the human WT derCD23 sequence was provided by Dr. 
Rebecca Beavil and was transformed into BL21 cells for protein expression. DerCD23 
is a proteolytically cleaved fragment of CD23 which contains the C-type lectin domain 
and no glycosylated residues (Hibbert, 2005). For the auxiliary calcium-binding site 
mutants, the DNA was first mutated with the primers as described in the mutation 
design rationale and section 2.1.7.  
 
3.2.2 Expression of human and mutant derCD23 
 
Human WT and the mutant derCD23 proteins were grown in autoinduction medium, 
which negates the dependency to induce protein expression by ITPG as cells begin 
protein expression once all the glucose in the media has been consumed and the E.coli 
begin feeding on lactose (Studier, 2005).  All the derCD23 recombinant protein is 
expressed as insoluble inclusion bodies, as shown in Figure 3-5. The insoluble inclusion 
bodies must first be washed to remove traces of lipid and carbohydrate contaminants 
from the E.coli cells, to improve protein purity before solubilising the protein for the 




Figure 3-5 15% SDS-PAGE of wild type derCD23 stained with Comassie Stain. M = Molecular 
weight markers, lane 1 = insoluble fraction, lane 2 = soluble fraction, lane 3-7 = inclusion body washes, 




Protein expressed as inclusion bodies take longer to produce than soluble proteins. The 
recombinant protein is produced at a greater density within the inclusion body and thus 
its potential yield is higher. The refold process is slow as derCD23 must correctly form 
all four of its disulphide bonds at 4°C, in the dark, and the oxidised-glutathione and the 
light-sensitive cysteine in the buffer would promote denaturation and reduction of the 
protein. To achieve correct folding, a method modified from Taylor et al. (1992) was 
utilised in which the protein was slowly diluted into a large volume of refold buffer, to 





7.2 Small-scale expression and refolding of recombinant wild type derCD23 protein 
 
Expression of WT derCD23 and its purification strategy was confirmed by a small-scale 
experiment: 100 ml autoinduction media culture was harvested after 24 hours of growth at 
37°C and expression of WT derCD23 was analysed by SDS-PAGE as shown in Figure 7.4. 
An intense Coomassie Blue stained band was observed migrating at ∼16 kDa in the insoluble 
fraction which was not seen in the soluble fraction, which meant that derCD23, was expressed 
in insoluble inclusion bodies. Inclusion bodies are misfolded protein aggregates that are easily 
isolated and the protein contained in them can be re-folded to biologically active protein. First 
the inclusion bodies must be washed to remove lipids and carbohydrate contaminants; the 
different salt concentration of the buffer for these washes has caused disparate separation of 
the proteins on the SDS-PAGE gel in Figure 7.4.  
 
 
Figur  7.4. 5  SDS-PAGE gel staine  with Instant Blue assie Stain (Exped on) of 
wild type d CD23. M = Molecular weight markers, lane 1 = insoluble fracti n, lane 2 = 






3.2.4 Purification  
 
The derCD23 construct does not have a purification tag at either terminus and thus 
hydrophobic interaction chromatography (HIC) was chosen to purify the protein as 
depicted by the chromatogram in Figure 3-6. The mutations introduced into derCD23 
involved charge reversals that could have altered the isoelectric point, whilst the 
hydrophobicity would remain similar and allow for the same conditions of purification 
of all the derCD23 proteins. The eluted proteins were very pure, as indicated by the 
single bands in Figure 3-7, and HPLC SEC analysis revealed the derCD23 proteins to 




Figure 3-6 Chromatogram of derCD23 purified by HIC. The protein solution (blue line = UV 
absorbance at 280 nm) was loaded onto a 10ml phenyl sepharose 6 fast flow column (GE Healthcare), 
equilibrated in buffer A (1.5 M ammonium sulphate, 25 mM Tris, 2 mM CaCl2 pH7.5) and eluted in a 
step-wise gradient of buffer B (25 mM, 2 mM CaCl2 pH7.5), run at 10 ml/min. A = column equilibration, 
B = sample load, C = column wash, D = column elute with fractions shown on x-axis. * = A single peak 




The purity of collected protein solution from HIC column was confirmed using HPLC. Compared with first batch, the amount of 
protein made in second batch was enhanced, but aggregation appeared in both batches according to HPLC results (Figure 7.3). 
However, there were only one peak appearing at early stage in the first batch, but two peaks appearing in the second batch and 
one of them was at the expected time range (Figure 7.3). The purification method for the third batch was same as that for the 







Figure 3-7 16% SDS-PAGE of purified wild type and mutant derCD23 proteins stained with 
Comassie Stain. M = Molecular weight markers, WT = WT derCD23 sample, A = mutant A, B = mutant 
B, C = mutant C. 2 µg of each protein was run on the gel. The single band indicates a pure protein sample 




Figure 3-8 Chromatographic profiles of derCD23 proteins determined by analytical gel filtration 
HPLC using a Superdex 200 column. Between 100-140 µg of purified derCD23 was injected onto a 
Superdex 200 10/300 GL column equilibrated with TBS-Ca2+ buffer (pH 7.5), flow rate = 0.75ml/min. 
The well resolved monomeric peaks at 22 mins indicate a highly pure homogenous protein. If additional 
















































The yields of folded protein from both the mutants and WT human derCD23 were 
similar, except for mutant A. As mutant A did not express as well as the other derCD23 
mutant proteins at either 37°C or 18°C, it was considered to be an exception. As such, 
the majority of experiments conducted, utilised mutants B and C alongside the WT 
protein. Not all the solubilised inclusion bodies were used for the re-fold step as 
described in section 2.2.6, as an estimated 50 mg/L could be purified from 1 L of 
autoinduction medium. For one round of refolding and protein purification, that used 
part of the total isolated inclusion bodies, the yield of purified derCD23 protein was at 
about 12% of the total protein within the inclusion bodies. 
 
3.2.5 Calcium affinity of the derCD23 proteins 
 
To confirm that the proteins had folded properly, a 1H NMR experiment was performed; 
the spectra are shown in Figure 3-9. The presence of the four characteristic leucine and 
isoleucine methyl peaks upfield of 0 ppm indicated that the derCD23 proteins were 
correctly folded, this finding was indicative of buried sidechain-protons packed next to 
aromatic residues in the hydrophobic core of the protein. The lack of peaks in this area 
would indicate that the protein has not folded into its tertiary structure. This finding was 
important, as prior research has documented that changes in the hydrophobic core are 
capable of decreasing calcium affinity, even when residues are distant from calcium-
binding sites (Quesenberry and Drickamer, 1992). Chemical shift perturbations upon 
calcium binding can also be detected in Figure 3-10 with the small peak at -0.4 ppm not 
detected upon addition of 4 mM CaCl2. The leucine and isoleucine methyl peaks 
experienced peak narrowing with the addition of calcium ions, which meant that the rate 
of exchange for the protons increased as the chemical microenvironment altered.  
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Larger chemical shift perturbations upon addition of 4 mM CaCl2 could be detected in 
the mutant proteins, especially in mutant C as shown in Figure 3-11. The peaks at 0.25 




Figure 3-9 1D-1H NMR spectra of wild type and mutant derCD23 proteins in the presence of 4 mM 
CaCl2. Black = WT human derCD23, red = mutant A, green = mutant B, blue = mutant C. The leucine 
and isoleucine methyl group protons are labelled, labels taken from BMRB database entry 6732, 
(Hibbert, 2005).   
  
 
Figure 3-10 1D-1H NMR spectra of wild type derCD23 with and without calcium. Black = zero 
CaCl2, red = with 4 mM CaCl2. The leucine and isoleucine methyl group protons are labelled, labels 













Figure 3-11 1D-1H NMR spectra of mutant C with and without calcium. Black = zero CaCl2, red = 
with 4 mM CaCl2. The leucine and isoleucine methyl group protons are labelled, labels taken from 
BMRB database entry 6732, (Hibbert, 2005). 
 
A similar experiment by SEC HPLC, in which calcium was titrated into the mobile 
phase, indicated a conformational change upon calcium binding for mutant C, which 
displayed a dramatic change in elution time as Figure 3-12. Upon addition of calcium, 
the hydrodynamic radius of the protein changed as the protein appeared to become 
smaller and more compact, since the protein eluted at a longer time point. The shape of 
the chromatographic peak also changed from a monodisperse single peak at 15.8 mins 
to two peaks spanning a wider base at 17 mins. This change was not seen in the WT or 
the other mutant derCD23 proteins (first three graphs of Figure 3-12) suggesting that 
the one-calcium bound state known for WT human CD23 could not be detected by SEC 
HPLC. The two peaks of mutant C might correspond to the two-calcium bound state 
and the apo-protein, alternatively, perhaps the second-calcium binding site in the mutant 
proteins is less sensitive and is unable to bind to second calcium at 2 mM Ca2+. Changes 
such as these have also been observed in other CTLs as reported by Gingras et al., 
(2011), Sulmann et al. (2014) and Holla and Skerra (2011). The change in 
hydrodynamic radius could be explained by the calcium ion constraining the loops into 







become more spherical than oval-like in shape and passing through the column beads at 


























Figure 3-12 Chromatographic profiles of WT and mutant derCD23 calcium titrations. WT and 
mutant derCD23 proteins were run in calcium-free TBS on an analytical superdex 200 10/300 GL gel 
filtration column (GE Healthcare) at 4°C. All proteins were subjected to the same increasing step-wise 
concentrations of Ca2+ added to the sample and mobile phase from 0 (dark blue) to 2 mM CaCl2 (light 
blue), flow rate = 0.75 ml/min. 
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3.2.6 Calcium binding assays 
 
The size of a calcium ion (van der Waals radius of 0.231 nm) as a ligand, compared to a 
protein (~4.5 nm for derCD23) is 20 times smaller. The small size, and mass of the 
calcium ion (40 g/mol) means that this mass is below the detection limit for SPR. The 
mutant derCD23-calcium interaction could be investigated by the highly sensitive 
technique, Isothermal titration calorimetry (ITC),  considered the gold standard for 
quantitative measurements of biomolecular interactions (Krainer and Keller, 2015).  
 
The low affinity (KD for calcium of 1.5 mM) and low protein concentration (50 µM, 
based on the WT human derCD23 experiments documented in Yuan et al. 2013) 
resulted in a low c value defined by equation 1 in section 2.3.1. ‘C’ is defined as the 
protein concentration divided by the dissociation constant, KD. Under low c-value 
conditions, the isotherm binding curve is hyperbolic in shape, rather than sigmoidal as 
reported in section 2.3.1. In these circumstances, the stoichiometry or n value is fixed as 
a constant value during the fit. For the WT derCD23 protein titrated with calcium, n 
was fixed at 1 as was found by the X-ray crystallographic studies (Wurzburg et al., 
2006; Yuan et al., 2013). 
 
Figure 3-13A shows calcium binding to WT human CD23 with a KD value of 0.63 mM, 
which is within the expected experimental range given standard errors, and using the 
same set-up as used by Yuan et al 2013. The ITC binding isoform curve results from 
plotting the analysed heat released per injection vs the molar ratio of titrant to the 
protein. In both figures Figure 3-13A and B, the molar ratio is quite high since the 
concentration of Ca2+ is increased so that the isotherm curve can reach some degree of 
saturation. Curve-fitting to the Wiseman isotherm can be difficult for systems with low 
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c values (please refer to Figure 2-2, Turnbull and Daranas, 2003) as such, for both the 
WT and mutant B derCD23 proteins, the stoichiometry value, n, was assumed to be 1 
and kept constant during the curve-fitting process. Mutant B, in Figure 3-13B, bound to 
calcium about 3-fold tighter than WT human derCD23 with a KD of 0.22 mM, as 
summarised in Table 3-1, although the affinity remained in the mM range which is 
typical for a CTL. 
 
 
Figure 3-13 Calorimetric titration of 20mM calcium to WT and mutant B derCD23. Top panel of 
each graph: Heat generated by each injection of Ca2+ at each time interval. Bottom panel of each 




free buffer.  Black curve and squares = derCD23 protein. A) 20 mM Ca2+
 
was titrated 
into 50µM apo WT derCD23. B) 20 mM Ca2+ titrated into 50µM mutant B derCD2. Both proteins 
measured at 25°C and fitted to a 1:1 binding event curve and plotted against the molar ratio of Ca2+ to 
protein (concentration range 0 –  20 mM). 
 
The experiment with Mutant C was limited by the protein concentrations that could be 
achieved. At 500 µM of protein, or 10-fold more concentrated than in Figure 3-13, a 
	 16	
	 	








protein.	A)	 20	mM	Ca2+	was	 titrated	 into	50μM	apo	WT	derCD23.	B)	20	mM	Ca2+	 titrated	




The	 experiment	 with	Mutant	 C	 was	 limited	 by	 the	 protein	 concentrations	 that	 could	 be	
achieved.	At	500	µM	of	protein,	or	10-fold	more	concentrated	than	 in	Figure	1-12,	a	very	
different	binding	 isoform	could	be	 seen	 in	 Figure	1-13	with	at	 least	 two	different	binding	
events.	The	biphasic	shape	of	this	curve	is	similar	to	those	of	proteins	reported	to	bind	to	













Figure 7.20 Experimental set up for ITC and calorimetric titration of 20mM calciu  to 
WT derCD23. A) The calcium is titrated into the protein sample in the cell an  the heat 
generated from this reaction is measured in relation to the reference ell. Image adapted fro  
Zhou et al., 2011. B) Top panel: Heat generated by each inj ction of titrant at each tim  
interval. Bottom panel: Integration of each peak and the effective amount of heat produced. 
Red squares = 20 mM Ca2+ buffer into Ca2+ free buffer. Black curve and squares = WT 
derCD23. 20 mM Ca2+ was titrated into 50µM WT derCD23 measured at 25°C and fitted to a 
1:1 binding model and plotted against the molar ratio of ligand to protein (concentration range 
0 – 20mM). 
 
 
ITC identified that mutant 3b bound to calcium 3-fold more tightly than wild type derCD23 
although the affinity remained relatively low in the mM range as shown in Figure 7.21. The 
hyperbolic shape of the isotherm in Figures 7.20 and 7.21, rather than a complete sigmoidal 
curve, is typical for a low-affinity interaction, unfortunately these curves cannot provide any 
data on the stoichiometry. The equivalence point at which the curve shows an inflection point 
is the point from which the stoichiometry can be inferred and unfortunately the curves do not 








increase the sensitivity. For instance, the temperature of the experiment was dropped to 10°C 
and the concentration of the calcium titrant were halved which enabled more accurate 
detection of the given heats as shown in Figure 7.21. This provided better quality data but was 
not enough to determine if two calcium ions were binding.  
 
 
Figure 7.21 Calorimetric titration of calcium mutant 3b measured by ITC. Top panel of 
each graph: Heat generated by each injection of titrant at each time interval. Bottom panel 
of each graph: Integration of each peak and the effective amount of heat produced. Red 
squares = 10 or 20 mM Ca2+ buffer into Ca2+ free buffer. Black curve and squares = derCD23. 
A) 10 mM Ca2+ trated into 50µM mutant 3b derCD23 at 25°C measured at 25°C and fitted 
to a 1:1 binding model. B) 20 mM Ca2+ titrated into 50µM mutant 3b derCD23 at 25°C 
measured at 25°C and fitted to a 1:1 binding event curve and plotted against the molar ratio of 
ligand to protein (concentration range 0 – 10 or 20mM). 
   
At 500 µM of mutant 4, at ten times the amount of protein of the initial experiment, ITC data 








20 mM Ca2+ 







very different binding isoform could be seen in Figure 3-14 with at least two different 
binding events which were fitted to a 2:1 binding model. The biphasic shape of this 
curve is similar to those of proteins reported to bind to two metal ions as documented by 
Henzl et al. (2008), Zhang et al. (2009), and Brautigam (2015). Early in the titration at 
the low molar ratio, the higher affinity calcium-binding site was occupied first, followed 
by the lower affinity site, until saturation.  
 
Thermodynamic parameters were measured by taking the measurements for mutant B 
and fixing them in a sequential binding site model. This meant that the higher affinity 
calcium-binding site had a similar KD value to mutant B of 0.22 mM, as reported in 
Table 3-1. This binding event was enthalpically favourable with a –TΔS of 1.30. This 
suggests that as the calcium ions bind to the mutant C protein, counterions and water 
molecules are being displaced. The second, lower affinity calcium-binding site has a KD 
value of 1.10 mM, and is enthalpically unfavourable due to the positive enthalpy term. 






Figure 3-14 Calorimetric titration of calcium mutant C measured by ITC. Top panel: Heat 
generated by each injection of Ca2+ at each time interval. Bottom panel: Integration of each peak and the 




free buffer. Black curve 
and squares = mutant C. 10 mM Ca2+
 
titrated into 500 µM mutant C derCD23 measured at 25°C and 
fitted to a 2:1 binding model and plotted against the molar ratio of ligand to protein (concentration range 
0 – 10mM). 
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data, existing data was modelled in the Origin Microcal software, which indicated that with a 
protein sample of ~500 µM this would be possible. Mutant 4 was concentrated to a very high 
concentration (~8mg/ml) at the risk of aggregating the protein. The initial raw data (top panel 
of Figure 7.22) suggests that the first binding event is very exothermic and is comparable to 
other two calcium binding titration curves [71]. The difficulty in analysing the ITC curve 
meant that accurate KD values could not be obtained as the heats from one binding site with an 
associated negative enthalpy was masking the heats from the other binding site with an 
associated positive enthalpy. Both calcium-binding sites had similar mM binding affinities for 
calcium as shown in Table 7.3. 
 
Fi ure 7.22 Calorimetric titration of calcium mu ant 4 measured by ITC. Top panel of 
each graph: Heat generated by each injection of titrant at each time interval. Bottom panel 
of each graph: Integration of each peak and the effective amount of heat produced. Red 
squares = 10 mM Ca2+ buffer into Ca2+ free buffer. Black curve and squares = mutant 4.  10 
mM Ca2+ titrated into 500 µM mutant 4 derCD23 measured at 25°C and fitted to a 2:1 binding 





Protein WT derCD23 Mutant B Mutant C 
KD (mM) 0.63 0.22 0.22 ± 0.04 
ΔH (kcal/mol) -2.23 ± 1.23 -2.96 ± 0.99 -6.3 ± 0.2 
ΔG (kcal/mol) -4.4 -5.00 -5.00 
-TΔS (kcal/mol) -2.17 -2.04 1.30 
KD2 (mM)   1.10 ± 0.20 
ΔH2 (kcal/mol)   0.95 ± 0.27 
ΔG2 (kcal/mol)   -4.10 
-TΔS2 (kcal/mol)   -5.05 
    
Table 3-1 The thermodynamic parameters for calcium binding to derCD23 mutants. KD = the 
dissociation equilibrium constant, ΔH = change in enthalpy (heat energy), ΔG = change in free energy, -
TΔS = temperature multiplied by the change of disorder of the system. The second half of the table refers 
to the 2nd phase of mutant C. 
 
3.2.7 X-ray Crystallographic studies of the derCD23 proteins 
 
An ideal method for confirming the presence, location and ligation chemistry of 
calcium to the mutant proteins would be by X-ray crystallography to determine high-
resolution structures. Mutations to a protein can radically alter the crystallisation 
conditions for a protein, so initially commercial screens were set-up for mutant proteins 
B and C. The commercial screens established the initial ‘hit’ from which a matrix grid 
was performed to vary the growing conditions and further optimise the crystals. Figure 
3-15 displays the optimisation process with the protein crystals growing larger each 
time. Potential hits were first scanned for salt detection with the PX scanner, which 
screens crystals with X-rays without the need to remove them from the drop. It collects 
the diffraction pattern of the crystal through the sealed plastic tray in which the crystals 
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grow, as shown in Figure 3-16.  
 
 
Figure 3-15 Optimising mutant B crystallisation conditions.A – The initial E1 hit in the commercial 
screen. The crystals took ~ 2 weeks to grow in conditions of 0.1 M Na-cacodylate pH 6.5 and 1 M tri-
sodium citrate. B – These conditions formed the basis of an optimisation grid where the concentration of 
tri-sodium citrate ranged from 0.8 to 1.3 M and the pH of Na-cacodylate ranged from pH 6 to pH 6.75. C 
– the crystals were optimised further with a finer grid. The crystals are hexagonal rods. A, B and C are 
coloured due to a polarizer attached to the microscope; crystalline objects exhibit bifringence properties 








   
 
Figure 7.14  Optimising mutant 3b crystallisation conditio s  
A – Th  initial E1 hit in the commer ial screen, the crystal took ~ 2 weeks to grow in 
conditions of 0.1 M Na-cacodylate pH 6.5 and 1 M tri-sodiumcitrate. B – These conditions 
formed the basis of an optimisation grid where the concentration of tri-sodiumcitrate ranged 
from 0.8 to 1.3 M and the pH of Na-cacodylate ranged from pH 6 to pH 6.75. C – the crystals 
were optimised further with a finer grid. The crystals are hexagonal rods. A, B and C are 
coloured due to a polarizer attached to the microscope, crystalline objects have bifringence 
properties and change colour as the polarizer is rotated. 
 
 




Figure 3-16 Checking for salt crystals.The large crystal shown in Figure 3-15C was tested on the PX 
scanner (section 2.4.3) for salt detection. A 40 min X-ray exposure has determined that it is a protein 
crystal causing the diffraction pattern seen. Many spots are observed at all distances from the centre, 
which indicates that this is a protein crystal. In contrast, a salt crystal would show relatively few, widely 
spaced spots. The lollipop-shaped space is the beam stop that prevents the X-rays damaging the detector. 
The spots furthest away from the centre give the highest resolution data; the spot indicated by the orange 
arrow corresponds to a resolution of ~ 2.67 Å and the blue arrow, a resolution of ~3.74 Å. It can be 
expected that diffraction will improve by 1-2 Å when the crystal is exposed to the more powerful X-rays 
at the synchrotron. 
 
In order to obtain a calcium-bound structure, two methods were employed; one to set-up 
crystal trials in which the protein dispensed had been incubated with calcium, the other 
with calcium soaks. The protein was initially incubated with CaCl2 to allow calcium to 
bind the C-type lectin at 4mM and then 10 mM, both concentrations which are above 
the KD of the interaction. Calcium soaks were performed with three different solutions 




Figure 7.15  Checking for salt crystals   
The large crystal shown in Figure 7.14C was tested on the PX scanner for salt detection. A 40 
min X-ray exposure has determin d th t it is a protein crystal due to the diffraction pattern 
seen.  Many spots are observed at all distances from the centre indicate this is a protein, in 
contrast, a salt would have a sporadic spots, mostly within mid-range of the centre. The 
lollipop-shaped space is the beam stop that prevents the X-rays damaging the detector. The 
spots furthest away from the centre give the highest resolution data, here the spot indicated by 
the ora ge arrow has a maximum resolution of ~ 2.67 Å and the blue arrow has a resolution 
of ~3.74 Å that will improved upon by 1-2 Å when the crystal is exposed to the more 
powerful X-rays at the Synchrotron. The lower the number of Å, the higher the resolution 








crystal plate reservoir) with calcium concentrations at 10 mM, and incubated for four 
days before cyro-cooling the crystals as explained in chapter 2, sections 2.4.5 and 2.4.6.  
A      B 
  
Figure 3-17 derCD23 mutant B crystal and diffraction pattern. A - The crystal shown in Figure 
3-15C cryocooled and mounted on a loop. The red crosshair is the area where the beam will hit the 
crystal. The red labelled axis is in µm. B – Best diffraction pattern for mutant B, collected at Diamond 
Light Source, beam line I04-1; it has improved resolution to 1.37 Å from Figure 3-16. 
 
The crystal structures of mutant B and C derCD23 were solved to a resolution of 1.37 Å 
and 1.89 Å respectively by molecular replacement using the WT human derCD23 
protein (PDB file: 4G9A with the mutated residues removed, section 2.4.8). Differences 
between the WT human derCD23 structure and the mutant B structure can be seen in 
Figure 3-18A, which shows the mutant B structure superposed on to the WT derCD23 
structure (PDB: 4G96). The overall Cα root mean square deviation (RMSD) is 0.62 Å 
(over 122 Cα pairs, excluding loop 1) indicating the backbone has changed little except 
for loop 1. Loop 1 is expected to have large movements, however, in this case, the loop 
has moved outward to make a crystal contact with a neighbouring molecule as seen in 
Figure 3-18B. This interaction is an artefact from the crystallisation process. Loop 4 is 
not well defined as the protein is very dynamic in this location and no electron density 
could be detected. Three of the four mutated residues had good electron density and 
could be identified for mutant B (Figure 3-18C-E). The mutation T251N had poor 
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electron density since it precedes loop 4, for which no electron density could be found. 
No calcium could be detected at either the primary or the auxiliary calcium-binding site.  
 
Mutant C is superposed on to the WT derCD23 structure (PDB: 4G96) in Figure 3-19A, 
and shows a similar movement of loop 1 as the same crystal contact is formed, as 
depicted in Figure 3-19E. The electron densities for both proteins appear similar with 
good backbone and side-chain electron density identified for mutations N225D and 
K229E (Figure 3-19B and C). T251N had poor side-chain electron density (Figure 
3-19D) and no backbone electron density was found for the S252N, R253G or S254G 






Figure 3-18 Structure of mutant B derCD23 superposed onto WT human derCD23. A) Green = 
mutant B derCD23, mutated residues are shown as sticks. Grey = WT human der CD23. B) New crystal 
contact between E229 (on newly positioned loop 1) and Arg188 of a symmetry equivalent (in yellow). C-
E) Proof of mutations: blue chicken wire = 2Fo-Fc electron density map, light blue = protein backbone, 
green = carbon atoms, red = oxygens, blue = nitrogen. Contoured at 0.5 e/Å3. C) Mutation N225D D) 
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Figure 3-19 Structure of mutant C derCD23 superposed onto WT human derCD23. A) Pink = 
mutant C derCD23, mutated residues are shown as sticks. Grey = WT human der CD23. B-D) Proof of 
mutations: blue chicken wire = 2Fo-Fc electron density map, light blue = protein backbone, green = 
carbon atoms, red = oxygens, blue = nitrogen. Contoured at 0.5 e/Å3. B) Mutation N225D C) Mutation 
K229E D) Mutation T251N. E) New crystal contact between E229 (on newly positioned loop 1) and 





       
Figure	1-18	Structure	of	mutant	C	derCD23	superposed	onto	WT	human	derCD23.	A)	Pink	=	
mutant	C	derCD23,	mutated	r idues	are	shown	as	sticks.	Grey	=	WT	human	der	CD23.	B-D)	
Proof	 of	mutations:	 blue	 chicken	wire	 =	 2Fo-Fc	 electron	 density	map,	 light	 blue	 =	 protein	
backbone,	green	=	carbon	atoms,	red	=	oxygens,	blue	=	nitrogen.	Contoured	at	0.5	e/Å3.	B)	
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Table 3-2 Data Collection and refinement statistics for mutants B and C. a.u. = asymmetric unit. 
R.M.S = Root mean square deviation between B-factors for bonded main chain atoms. Values in 
parentheses are for the outer resolution shell.  
 
 
Protein Mutant B Mutant C 
Space Group P 6 2 2 P 6 2 2  
Unit Cell Parameters (Å, ˚) a = 115.01    D = 90 
b = 115.01    E = 90 
c = 45.67       J = 120 
a = 115.01    D = 90 
b = 115.01    E = 90 
c = 45.67       J = 120 
No. of mol/a.u. 1  1 
Resolution Range (Å) 28.75 -1.37 (1.42-1.37) 32.92–1.89 (1.92–1.89) 
Total reflections 75362 (7406) 29336 (2878) 
Unique reflections 37683 (3703) 14669 (1439) 
Completeness (%) 0.99 (1.00) 0.98 (1.00) 
Multiplicity 2.0 (2.0) 2.0 (2.0) 
Wilson B-factor (Å) 16.01 19.24 
I/ σ(I) 13.08 (2.64) 19.34 (5.33) 
CC1/2 0.992 (0.562) 0.996 (0.714) 
Rmeans 0.03 (0.39) 0.04 (0.46) 
Rmerge  0.02 (0.27) 0.03 (0.32) 
No. of reflections used  37387 (3703) 14442 (1288) 
No. of reflections in Rfree set 1869 (167) 1445 (130) 
Rwork 0.278 (0.403) 0.184 (0.360) 
Rfree 0.273 (0.398) 0.214 (0.379) 
No. of atoms 1035 1249 
No. of protein residues 127 128 
R.M.S bond length (Å) 0.007 0.007 
R.M.S bond angle (˚) 0.98 0.93 
Ramachandran Statistics (%):   
Favoured 97 96 
Allowed 3 2.3 
Outliers 0 0 
   





Despite various attempts to crystallise the mutant derCD23 proteins with calcium, no 
structures with calcium co-ordinated by the protein were obtained. This led to answers 
being sought using a different structural technique. The 1D 1H-NMR spectra had 
already revealed the calcium sensitivity of the mutant proteins (Figure 3-11) and more 
advanced NMR techniques could disclose further information about calcium binding. 
For this, 15N labelled protein had to be produced.  
 
3.2.8 15N Labelled derCD23 protein expression 
 
To perform more complex NMR experiments such as heteronuclear single quantum 
coherence spectroscopy (HSQCs), the protein was initially 15N labelled, and then 
refolded and purified as mentioned previously in sections 2.2.2 and 2.2.10. To generate 
15N labelled recombinant protein, the E.coli was grown in minimal auto-induction 
media containing 15N labelled ammonium sulphate, which provided the only nitrogen 
source, ensuring that 15N was incorporated into the protein backbone and side-chains. 
An expression test of the 15N protein in Figure 3-20 resembled the unlabelled protein in 
Figure 3-5, with the protein solubility unchanged since the protein only expressed as 
inclusion bodies. Figure 3-21 displayed the NMR spectrum of the WT human derCD23 
15N labelled protein, which had folded correctly. The peaks were manually assigned 
based on the peak list in BMRB database entry 6732, (Hibbert, 2005) but re-numbered 





Figure 3-20 15% SDS-PAGE of 15N wild type derCD23 stained with Comassie Stain. M = Molecular 
weight markers, lanes 1 and 2 = insoluble fraction, lanes 3 and 4 = soluble fraction. Expected size of 15N 
labelled WT derCD23 = 16kDa. 
 
A calcium titration performed with 1H 15N-HSQCs in Figure 3-22 revealed a few 
residues with significant chemical shift changes (>0.08 ppm, displaying a progression 
of peaks across the spectrum). The WT derCD23 spectra is in good agreement with 
previous experiments (Hibbert, 2005). Each set of concentric circles denotes one single 
amide peak, representing the hydrogen and nitrogen atoms in an amide group (NH) 
located mostly within the protein backbone amides, or less frequently in the amide 














 15N WT derCD23 





Figure 3-21 1H-15N-HSQC Spectrum of WT human derCD23 with 0 mM calcium. Peaks are labelled according to BMRB database entry 6732, (Hibbert, 2005). The assigned 




































































































































Figure 3-22 Calcium perturbations of WT human derCD23 captured by 1H-15N-HSQCs. A) Colours red through purple to grey show increasing calcium concentration where 
































































































































Most residues are unaffected by calcium in WT derCD23 since the peaks do not move 
upon addition of calcium, it is only the calcium-contact residues that display 
progressive peak shifts. These changes were shown more clearly by contrast with the 
spectrum for mutant B in Figure 3-23A, which showed more extensive changes. D283 
in Figure 3-23B, is an example of a residue unaffected by calcium binding. In the 
mutant B protein spectrum, more peaks were affected by the binding of calcium, in 
particular, W184, I221, L223, W234, G237, N269 and D270. Figure 3-23C displayed 
the uniform movement of residue Trp234 as it experienced different microenvironments 
due to calcium binding. Residue 270 in Figure 3-23D is intriguing as it shows a very 
large proton and chemical shift change (> 0.1 ppm) and changes direction about half-
way through the titration since in the first part of the chemical shift there is a greater 
change in the nitrogen axis while in the second half there is a greater change in the 
hydrogen axis. 15N chemical shifts are sensitive to hydrogen bonding to the carbonyl of 
the preceding residue (the Y angle of the preceeding residue) which has less effect on 
the proton shift (Williamson, 2013). This effect of calcium addition on residue 270 
suggests a two-step process in which the first calcium binding site of higher binding 
affinity binds calcium at lower concentrations causing a conformational change in the 
loop (a change in dihedral angle) and then the second calcium binding site is occupied 
at the higher calcium concentrations which affects the 15N amide by hydrogen bonding 
interactions. The saturation binding curves for each of the identifiable residues (residues 
184, 221, 223, 237, 269 and 270) with large measured chemical shifts, such as those 
depicted in Figure 3-23 could be grouped into 2 sets with each set roughly 
corresponding to the binding of a calcium ion, as shown in Figure 3-24A. The calcium 
binding affinities for mutant B were found to be 1.7 mM and 3.62 mM. From these 





























































































Figure 3-23 Calcium perturbations of mutant B derCD23 captured by 1H-15N-HSQCs. A) Colours 
red through purple to black show increasing calcium concentration where red = 0 mM, coral = 0.1 mM, 
orange = 0.3 mM, gold = 0.6 mM, green = 1 mM, blue = 2 mM, purple = 4 mM, magenta = 10 mM, 
maroon = 25 mM and black = 50 mM CaCl2. B – D) Specific residues B) Residue 283 is unaffected by 
calcium binding C) Residue 234 is affected by higher concentrations of calcium and thus the peaks shift. 
D) Residue 270 exhibits a two-step course with the peaks initially moving downwards as the peak is 
sensitive to low concentrations of calcium along the nitrogen axis. At higher calcium concentrations, the 
peaks more equally affected in both the nitrogen and hydrogen axes and change the trajectory. This 



















































































































































The NMR spectra peaks that exhibit large chemical shifts (DdHN £ 0.1 ppm) can be 
visualised on the structure as shown in Figure 3-24A. The majority of the residues with 
large chemical perturbations in mutant B used to determine the KD of the auxiliary 
calcium binding site lie just below the proposed calcium binding site. The residues in 
loop 1 could not be identified in the spectra as they have not been assigned in the 1H-
15N-HSQC, which may correspond to unlabelled peaks with chemical shifts. To test 
this, a 3D data acquisition leading to a 15N filtered NOESY data set was obtained and 
the protein backbone traced to try to identify further residues, especially residues in 
loops 1 and 4. Unfortunately, this proved to be too difficult because the disorder of loop 
1 could not be traced (data not shown).  
 
A)          B) 
     
 
Figure 3-24 Chemical shifts mapped onto the structure of derCD23 are used to determine calcium 
binding affinities. A) Residues in green = residues in the NMR spectra of Figure 3-23 that displayed the 
largest chemical shifts upon titrating with calcium. Stick residues in grey = residues involved in calcium 
binding. B) Binding isotherm for mutant B based on change in chemical shift position, blue = auxiliary 
site, red = primary site. Results and standard deviations are calculated from residues 184 (backbone and 
sidechain), 221 (backbone and sidechain), 223, 234, 237, 269 and 270. The mutant B KD values for 












Figure 3-25 displays the 1H-15N-HSQC spectra for mutant C which is again different 
from Figure 3-22 and Figure 3-23. The two-step shift of residue 270 of mutant B could 
not be identified in mutant C, but residue Trp234 (around 8.7, 131 ppm on the 
spectrum) showed a larger chemical perturbation with peak splitting occurring as well. 
Despite the structures of mutant B and C being identical (section 3.2.7), the six 
mutations in mutant C have changed local dynamics so that peaks in the spectra are 
harder to identify. Some peaks have a different location in Figure 3-25,  and would not 
be identified without further analysis such as 15N filtered NOESY data, which 





Figure 3-25 Calcium perturbations of mutant C derCD23 captured by 1H-15N-HSQCs. A) Colours red through purple to grey show increasing calcium concentration where red 
= 0 mM, coral = 0.1 mM, orange = 0.2 mM, gold = 0.3 mM, pale green = 0.4 mM, green = 0.6 mM, blue = 0.8 mM, purple = 1 mM, magenta = 2 mM, maroon = 4 mM, grey = 10 































































































































3.2.9 Carbohydrate Binding Assays  
 
Human WT derCD23 contains an ‘EPT’ motif, a variation of the ‘EPN’ carbohydrate 
binding site, which usually preferentially binds to mannose in other CTLs (van den 
Berg et al., 2012). Both mutants B and C had the ‘EPN’ motif restored, and could 
potentially bind to carbohydrate moieties. Earlier studies have suggested that WT 
human CD23 can bind to both mannose and galactose (Kijimoto-Ochiai and 
Toshimitsu, 1995; Wurzburg et al., 2006) but other studies could not detect any binding 
to carbohydrates (Hibbert, 2005) as documented for WT human CD23 on the  
Consortium for Functional Glycomics website: 
http://www.functionalglycomics.org/glycomics/publicdata/selectedScreens.jsp - Glycan 
Array: 634. 
 
To test the sugar binding potential of the mutants, a mannose titration was completed in 
a similar way to the calcium titration. Figure 3-26 displays a 1H-15N-HSQC with mutant 
C, 25 mM CaCl2 and mannose. Chemical shifts for specific residues were recognised, 
which differed from the chemical shifts identified upon calcium titration. This 
suggested specific binding as opposed to non-specific binding. Unfortunately, these 
peaks were unassigned residues, representing new peaks not found in WT human 
derCD23, and most likely belonging to loops that are better structured and less dynamic 
in mutant C than in the WT protein. When the chemical shifts of these unassigned 
residues were measured, as shown in Figure 3-27, they revealed a very weak binding 
affinity to mannose with a KD of around 30 mM, which is outside the expected range 
for a CTL (100 µM – 10 mM) (Weis, 1997). The glycan-binding KD is dependent on the 
presence of calcium in other CTLs, which is why the mannose titrations were performed 
in the presence of 25 mM CaCl2, since calcium is vital for co-ordinating the protein side 
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chains for optimal glycan binding and forming direct co-ordination bonds with the 
glycan (Weis and Drickamer, 1996). The very weak binding of mutant C could be 
accounted for by the lack of an aromatic residue or a histidine in loop 4, which would 
facilitate hydrophobic packing against the non-polar face of a monosaccharide ring 
(Weis and Drickamer, 1996).  
 
 
Figure 3-26 Chemical shifts of mutant C on binding to mannose in the presence of 25 mM CaCl2, 
captured by 1H-15N-HSQC. Colours magenta to black show increasing mannose concentrations where 
magenta is 0 mM mannose (and 0 mM CaCl2), purple is 10 mM mannose and 25 mM Ca2+, maroon is 20 
mM mannose and 25 mM Ca2+ and black is 40 mM mannose and 25 mM Ca2+. Green circles = residues 
































































































































Figure 3-27 Binding isotherm for mutant C based on changes in chemical shift position. Orange = 
average of the glycan binding site. Results and standard deviations are calculated from residues which 
are not involved in oligomerisation, residue identities cannot be definitely identified. The proposed 
mutant C KD value for mannose is 32.4 mM ± 10.2.  
 
Testing for an individually selected monosaccharide was initially preferred to establish 
carbohydrate binding, but longer oligosaccharides as well as a greater variety of other 
monosaccharides needed to be tested with a glycan array. The RayBiotech Human 
Glycan Array 100 contains a range of glycans including N-linked glycans found on 
proteins such as antibodies, milk glycans, Lewis antigens and smaller units of various 
monosaccharides which could be found on pathogens, for testing in parallel. The 
glycans are printed onto a glass slide in quadruplicate via chemical linkers. The 
derCD23 proteins were first prepared by biotinylating them, which allowed for glycan 
binding to be detected via a Cy3 labelled streptavidin. Figure 3-28A displays the results 
of the glycan array without calcium. The strongest binding was to the positive control, 
which consists of a standardized concentration of biotinylated Immunoglobulin G 
printed directly onto the array (in quadruplicate) and is represented by the highest bar 
on the furthest right of Figure 3-28A and Figure 3-29B as expected. The negative 
control (to the right of the positive control) is protein-containing buffer printed onto the 




In Figure 3-28A, the overall pattern of derCD23 proteins binding to glycans can be 
observed. The largest increase in binding was seen in the aminoglycosides (glycans 8, 
96, 98 and 99). The first peak, corresponding to peak 5, is the monosaccharide 
Rhamnose (glycan 5), which only mutant B could bind to. Peak 10 is discounted due to 
high fluorescence intensity from the water control. Figure 3-28B zooms in on the lower 
fluorescence intensities, which reveal other glycan binders above the threshold of 
significance, which is above background level and has an increase in fluorescence 
signal intensity of ≥ 1.5-fold. These include lower peaks such as 56 and 97, which are 
also aminoglycosides. Figure 3-28B also shows how only the mutant derCD23 proteins 
were capable of binding to oligosaccharides 29 and 69. The disaccharides 4-P-GlcNAc-
b-1,4-Man-b-Sp (glycan 28) and Glc-α-1,2-Gal-α-Sp (glycan 48) also resulted in minor 
binding with the mutant derCD23 proteins only, as listed in Table 3-3. Table 3-3 has 
grouped the identified glycans into strong and weak binders dependent on their 
fluorescence intensity signals. For a full list of the glycans in this array, please refer to 
Appendix B. 
 
Figure 3-29A shows the same glycan array repeated in the presence of 4 mM calcium. 
Mutant B appears to bind to many more glycans, although little difference from Figure 
3-28 to Figure 3-29 could be discerned with the WT human derCD23 and mutant C 
proteins. The largest increase in binding for mutant B was seen in the aminoglycosides 
(glycans 8, 56, 96, 97, 98 and 99, which represented binding with more than 50 
normalised fluorescence units). It must be noted that the manufacturer could not 
confirm whether the buffer was PBS free – this was a cause for concern since calcium 
in the presence of PBS forms calcium phosphate and causes proteins to precipitate 




Aminoglycosides are a class of antibiotics derived from the Streptomyces genus used in 
treating Gram negative infections. Aminoglycosides are polycations at physiological 
pH, and might have bound to a positive patch found on derCD23 where lysines (non-
conserved with respect to other CTLs), and arginines clustered. The specificity of the 
binding is not clear, however, aminoglycosides have bactericidal activity against 
mycobacteria, and CD23 is known to mediate antimicrobial activity in human 








Figure 3-28 Glycoarray analysis of binding specificities of WT human derCD23 and mutants B and 
C without calcium. Blue = water (control), red = WT human derCD23, green = mutant B, purple = 
mutant C. Each of the 100 glycans is represented four times on the printed array. The positive and 
negative controls are shown at the end of the graph (glycan 101 and 102). The data is sorted and 
averaged before subtracting the background signal and normalising the data with respect to the positive 
control. The average binding to each glycan is shown as fluorescence intensity ± standard error of the 
mean. A) The complete graph B) Focusing on low fluorescence intensity of 0 – 150.  
 

























































































Figure 3-29 Glycoarray analysis of binding specificities of WT human derCD23 and mutants B and 
C in the presence of 4mM CaCl2. Blue = water (control), red = WT human derCD23, green = mutant B, 
purple = mutant C. Each of the 100 glycans is represented four times on the printed array. The positive 
and negative controls are shown at the end of the graph (glycan 101 and 102). The data is sorted and 
averaged before subtracting the background signal and normalising the data with respect to the positive 
control. The average binding to each glycan is shown as fluorescence intensity ± standard error of the 

















































Name Structure WT B C 
99 Neomycin trisulfate  
 
++ +++ ++ 
98 Geneticin Disulfate 
Salt (G418)  
 
+ + ++ 
97 Kanamycin sulfate 
 
 
 +  
96 Gentamicin Sulfate 
 
 
++ + ++ 
69 Neu5Ac-α-2,6-Gal-β-
1,3-(Neu5Ac-α- 2,6)-
GalNAc-β-Sp   
 + + 
56 Sisomicin Sulfate  
 
 
 + + 
48 Glc-α-1,2-Gal-α-Sp  
 




  ++ 
28 4-P-GlcNAc-b-1,4-
Man-b-Sp   
Continued on next page 
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Table 3-3 The major glycan binding partners in the carbohydrate array. Glycans bound by mutant 
derCD23 proteins with more than 100 normalised fluorescence units. Sp = linker. Glycan Symbol chart 




3.2.10 The effect of the derCD23 mutations on IgE-Fc3-4 binding 
 
Surface plasmon resonance (SPR) was utilised to understand how the mutations altered 
the binding affinity of the CD23 mutant proteins to IgE in the presence, and absence of 
calcium by measuring the equilibrium dissociation constants (KD) as illustrated in 
Figure 3-30A. To ensure a 1:1 binding ratio of derCD23 to Fce3-4, the derCD23 
proteins were immobilised to a CM5 chip by amine coupling at a low density of 
between 70 – 100 resonance units (RU). At high ligand densities, the shorter distance 
between derCD23 molecules meant that the homodimer Fce3-4 could bind to two 
molecules of derCD23, which could ultimately complicate the analysis. KD and Bmax 
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were two main values extracted from the binding experiments. Bmax is defined as the 
maximum signal when all the ligand binding sites are occupied by the analyte. When 
the derCD23 mutants were immobilised on the chip, the Bmax changed from 74.96 RU 
for the WT to 38.17 and 40.23 RU for the mutant proteins as summarised in Table 3-4, 
(sensorgrams displayed in Figure 3-30B-D), suggesting that maximum binding capacity 
had changed. This could be due to the coupling reaction, since amine coupling is 
considered to be random and would immobilise the protein in different orientations or 
even immobilise the protein in such an orientation in which the binding site is no longer 
exposed.  
 
Protein KD (µM) with 4 mM Ca2+ Bmax (RU) 
WT derCD23 0.40 75 
Mutant A 0.82 40 
Mutant B 0.83 40 
 
Table 3-4 Summary of the SPR fitting results of Fce3-4 binding to immobilised derCD23 proteins in 

















Figure 3-30 Steady State SPR analysis of Fcε3-4 binding to immobilised derCD23 proteins in the 
presence of 4mM calcium. A) A diagram of the experimental set up where derCD23 (red) is covalently 
captured on the sensor chip (green) and the analyte, Fcε3-4 (blue) is flowed over the surface of the sensor 
chip, the arrows indicate the direction of the analyte flow. B-D) SPR sensorgrams showing the binding of 
Fcε3-4 to immobilised derCD23 proteins determined over a range of ligand concentrations from 30 nM 
to 8 µM. B) WT derCD23 C) mutant A D) mutant B. E) Steady state binding curve generated from the 
sensorgrams. Blue = WT derCD23, green = mutant A, orange = mutant B. The KD is the concentration of 
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Figure 7.19 Determination of the equilibrium constants of Fcε3-4 binding to derCD23 
proteins in the presence of Calcium. Points taken from equilibrium phase of the association 
phase (the flat line during the last part of the association phase in Figure 7.19B) for each 
conc ntratio  are plotted against the range of IgE Fcε3-4 conc ntrations. WT derCD23 (blue 
dots), 3a (orange dots) and 3b (green triangles) in HBS and 4mM Ca2+, blue fitting curve for 






Table 7.1 Summary of the SPR fitting results in the presence of Ca2+. Rmax = maximum 
binding capacity, Chi2 = average of the squared residuals (a statistical value describing the 
closeness of the fit, values less than 10% of the Rmax are acceptable). 
 
Surprisingly, mutant 4 could only bind to Fcε2-4 in the absence of calcium and bound ~2 fold 
less tightly than WT derCD23 as table 7.3 shows. The restored EPN carbohydrate-binding 
motif combined with the conformation of loop 4 in mutant 4 could be altered such that it is 
positioned optimally for carbohydrate binding and could be interacting with the 
immobilisation matrix of the chip such that the mutant 4 Fcε2-4 binding is not accessible to 
the analyte.  
Protein KD (µM) with Ca2+ Rmax (RU) Chi2 (RU2) 
WT derCD23  0.397 74.96 2.90 
Mutant 3a  0.823 39.17 2.20 







To alleviate the problem, the experiment was performed with an alternative set-up in 
which biotinylated IgE-Fc was immobilised to a streptavidin chip at a high and a low 
density and the prepared derCD23 proteins were the analytes to be flowed over the 
surface. Figure 3-30 displays the equilibrium binding graph and Table 3-5 displays a 
summary of the values obtained from the experiment. Briefly, in the presence of 4 mM 
CaCl2, the KD value altered in a peculiar way; initially the least murine-like protein, 
mutant A, bound 3-fold less strongly to IgE-Fc, however, a trend then emerges in that 
the more mouse-like the protein becomes, the stronger the binding to IgE-Fc so that 
mutant C has a similar KD value as the WT human CD23. This accompanied a change 
in the Bmax value for the mutants indicating that most of the mutant protein molecules 
were unable to bind to IgE-Fc, but a small subset was in a conformation that was able to 
bind. 
 
Protein KD (µM) Bmax (%WT) 
With 4 mM Calcium   
WT human CD23 0.71 100 
Mutant A 2.80 72.4 
Mutant B 1.77 40.3 
Mutant C 0.33 5.37 
Without Calcium   
WT human CD23 22.5 100 
Mutant A 36.0 100 
Mutant C  24.0 34.5 
 









Figure 3-31 Determination of the equilibrium constants of Fcε3-4 binding to derCD23 proteins in 
the presence and absence of calcium. Points taken from equilibrium phase of the association for each 
concentration are plotted against the range of Fcε3-4 concentrations. A) In the presence of 4 mM Ca2+ in 
HBS. B) In the absence of calcium, 10 mM EDTA in HBS running buffer.  
 
 




























To understand why human CD23 has lost its calcium-binding abilities in its “auxiliary” 
calcium-binding site, and how this might affect binding to its most important ligand, 
IgE, the auxiliary calcium-binding site was restored by designing a panel of mutant 
derCD23 proteins. Residues mutated were chosen based on an alignment with mouse 
CD23, an animal crucial to in vivo experiments. This protein panel had binding 
affinities for both calcium and IgE measured by a range of biophysical techniques. 
Greater understanding of why human CD23 distinctively binds to only one calcium ion 
may shed further knowledge into the mechanisms that induce allergic sensitisation in 
humans. 
 
Mutant B clearly demonstrated two calcium-binding sites as recorded by NMR 
experiments (Figure 3-23). One calcium-binding site in mutant B produced a similar 
binding affinity to the WT derCD23 primary calcium-binding site of 1.7 mM, whilst the 
other binding site exhibits 2-fold weaker binding at 3.6 mM. This is in a similar range 
found for CTLs (Weis, 1997). Zelensky and Gready state that from an evolutionary 
point of view, for CTLs, the calcium-binding sites do not act cooperatively despite 
being spatially close to each other (Zelensky and Gready, 2005). It is unclear if mutant 
A has two calcium binding sites, since biophysical studies on the protein were left 
incomplete due to it expressing poorly, and focus was shifted to the other two mutant 
proteins.  
 
Measuring mM binding affinities posed a challenge as most techniques are not sensitive 
enough, however, it is important to keep in mind that weak binding of calcium plays a 
vital role for the functioning of CTLs. Mutant C, despite not having displayed the clear 
two-step progression of residue 270 mutant B in the NMR titrations, also indicates two-
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calcium binding sites as suggested by the unusual HPLC trace as shown in Figure 3-12, 
and the two events in its thermodynamic signature in ITC displayed in Figure 3-14. This 
ITC experiment is unfortunately limited by derCD23 solubility; if the concentration of 
the protein exceeds 500 µM the viscosity of the sample makes it too difficult to load 
into the apparatus, and the poor stability of the protein would cause it to precipitate.  
 
The slight differences in calcium affinities measured by NMR and ITC arise from the 
techniques measuring different properties (Table 3-1 and Figure 3-24). Despite both 
being solution techniques that require no chemical modification or conjugation, ITC 
focuses on the thermodynamic parameters (the macroscopic binding details) whereas in 
NMR, only certain protein residues that display chemical perturbations are focused on 
(the microscopic affinities).  
 
Ongoing crystallisation efforts are trying to reveal greater insight into the calcium co-
ordination of the mutant proteins. Co-crystallising the protein with various 
concentrations of CaCl2 (4 mM – 10 mM CaCl2) added to the protein buffer 24 hr prior 
to distribution in the crystallisation plates did not result in a calcium-bound form of the 
mutant proteins. Although the calcium soaks did not work, they did not destroy the 
crystal as the solution passed through the solvent channels of the crystal. This suggests 
that lattice packing interactions were stronger and would not accommodate calcium-
binding. The crystal of derCD23 mutant B can be seen in Figure 3-17 with the 
collection data and refinement statistics described in  
Table 3-2. In the body, human WT derCD23 would usually bind to calcium in the 
neutral extracellular milieu, and calcium would only be expected to dissociate in an 
acidic endocytic vesicle. The mutant proteins crystallised in slightly acidic pH 
conditions of pH 6 – 6.75, which is equivalent of the environment found in early 
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endosomes, whereas late endosomes have a pH of 4.5-5.5 and this is where ligand 
dissociation occurs. Despite larger crystals growing at pH 6.5, finding conditions closer 
to physiological neutral pH may have resulted in calcium-bound structures. An 
alternative to calcium, would be to substitute lanthanide ions which still leave the CTL 
functional (Weis et al., 1991). If crystallisation conditions could be optimised, then 
structures binding to glycans would be equally interesting.  
 
Restoring the auxiliary calcium binding site also re-instated the ‘EPN’ carbohydrate 
binding motif and this enabled the mutant proteins to bind to several glycans. Except for 
the aminoglycosides found in the glycobiology consortium arrays, WT human derCD23 
was not found to bind to any glycans, in accordance with the findings of Hibbert and 
Jardetzky (Hibbert, 2005; Wurzburg et al., 2006). Perhaps, as Drickamer (Drickamer, 
1999) suggests, although CD23 may be a CTL, its functions diverged earlier than other 
carbohydrate binding proteins, and it never developed the extra structural features on 
the exterior of the protein to facilitate glycan binding. (Drickamer and Taylor, 2015; 
Wurzburg et al., 2006). 
 
Mutant B, however, binds to several glycans containing glucose, rhamnose and 
galactose residues on the array; potentially mutant B might be recognising the 
orientation of the hydroxyl groups on the pyranose ring structure, since D-galactose has 
the same configuration of hydroxyl groups at C2 and C4 as L-rhamnose (Quesenberry 
and Drickamer, 1992; Weis et al., 1998). It is interesting to note that mutant C, which 
contains all the mutations of mutant B, does not recognise the glycans equally well, and 
this could be because the glycines in mutant C cause the loops to become too flexible 




IgE is the most glycosylated immunoglobulin, exhibiting significant interindividual 
variation (Plomp et al., 2014). The several N-linked glycosylation sites contain 
branched glycans composed of mainly mannose, galactose, fucose, N-
acetylglucosamine and N-acetylneuraminic acid. Although the derCD23 mutants did 
bind to some mannose and galactose containing glycans, the lack of binding data in the 
glycan array to fucose, N-acetylglucosamine and N-acetylneuraminic acid suggests that 
the mutant proteins are not capable of binding to human IgE via carbohydrate 
interactions. This finding implies that mouse CD23 is also incapable of binding to 
mouse IgE via carbohydrate interactions, which agrees with previous experiments 
(Richards and Katz, 1990). 
 
The method of glycan presentation is important, and differing results can be generated 
from glycans presented on a protein backbone versus a glass slide with linkers. Most of 
the glycans assessed in the array were considered not to be of human biological 
significance. Although it is interesting to note that the alpha-3 link in glycan 10 of the 
array, which illicits a highly immunogenic response is not found in humans, yet would 
cause a significant immune reaction. The specificity to this linker is called into question 
as number 17 although highly unusual and not found in humans also contains this link 
but no proteins bound to it at all (Personal communication with Prof. Joy Burchell). It 
appears that no true specificity was found with human WT derCD23 or the mutant 
proteins B and C. 
 
The mutant derCD23 proteins are more mouse-like in sequence but not in function since 
murine CD23 can only bind to murine IgE in the presence of calcium, rendering a 
binding affinity of 108 M-1 (Richards and Katz, 1990; Lee et al., 1986). In contrast, 
human WT derCD23 binds more weakly to human IgE with a KD ~ 10-6 – 10-7 M but is 
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not abosolutely dependent on calcium (McCloskey et al., 2007; Hibbert et al., 2005). 
The mutant proteins all displayed weaker binding affinities for IgE than WT derCD23 
in the presence of calcium, except for mutant C as documented in Table 3-5. Despite the 
mutant derCD23 proteins exhibiting a trend of stronger binding to IgE-Fc the more 
mouse-like the protein is, the changes in Bmax suggest a degree of allosteric modulation 
occurring in IgE-Fc (Davies et al., 2017). This allosteric modulation could explain the 
change in the derCD23 proteins’ affinities for IgE-Fc based on the conformation and 
available binding sites of IgE-Fc.  
 
In the absence of calcium, the effect of the allosteric modulation is less apparent. 
Mutant A appears unaffected since it has the same Bmax value as the WT derCD23 while 
mutant C is affected, but the Bmax does not change as much as when calcium is present 
in the experiment. Furthermore, WT human derCD23 displayed the highest calcium 
sensitivity for IgE binding (Table 3-5) with a 32-fold difference in the KD value in the 
presence of, as well as the in the absence of, calcium.  
 
SPR analysis revealed that all the mutants had weaker binding to IgE than WT derCD23 
in the absence of calcium (Table 3-5), and decreased calcium sensitivity thus supporting 
the hypothesis that human derCD23 lost its ability to bind to two calcium ions, which 
led to an increase in binding activity toward IgE. In the context of the whole protein, 
when membrane-bound, this could affect receptor-mediated endocytosis. The calcium-
based gain of function in human CD23 might be enough to tip the scale in favour of an 
allergic response, especially in IgE-mediated antigen presentation. More allergens 
might be processed and displayed to the immune system as pathogens, reducing 
tolerance and this might contribute to the phenomenon that humans experience allergies 




Chapter 4 Molecular Dynamics Simulations Studies of 
derCD23  
4.1 Introduction 
Proteins are very dynamic and most structural studies only permit us to see ‘snapshots’ 
or certain possible protein conformations. In order to escape the constraints of 
experiments and to sample as many protein conformations as possible, Molecular 
Dynamics (MD) simulations were used to understand if it would be possible to predict 
the effects of the mutations in the mutant derCD23 proteins, described previously in 
Chapter 3, in silico. A typical constraint of structural studies, with CD23 in mind, is that 
not all residues of a protein are resolved. The residues of loop 4 in derCD23 couldn’t be 
assigned with experimental techniques such as NMR or X-ray crystallography 
(Dhaliwal et al., 2013; Hibbert et al., 2005), this was overcome with MD simulations. 
The simulations described in this chapter allow for comparison with experimental 
studies in Chapter 3. MD simulations also allow for experiments to be conducted with 
models when the structure of a protein does exist. In this chapter, studies on mouse 
derCD23 (for which no structure currently exists) are also presented to understand 
better the differences between human and mouse CD23.  
 
4.1.1 Introduction to Molecular Dynamics Simulations 
 
MD simulations can explore shorter timescales than that of most laboratory based 
experimental methods, to investigate fast events in protein structural dynamics; such as 
side chain flips as shown in Figure 4-1. In classical molecular mechanics, Newton’s 
second law of motion (F = m.a) is used, which is not as accurate as quantum mechanics, 
154 
 
but is computationally faster and allows for much longer timescales to be observed (1 ns 
-1 µs compared to ps for quantum mechanics) (Dror et al., 2010; Ode et al., 2012). 
 
The starting point for any molecular dynamics simulation is a model of the protein, 
which could have been obtained experimentally by NMR, X-ray crystallography or 
cryo-electron microscopy, or alternatively the model could have been built on a 
homologous structure or by theoretical programs. The model provides a set of Cartesian 
coordinates for each atom in the system (usually in pdb file format) and describes the 
order of the atoms connectivity, therefore considered as the starting conformation for a 
simulation (usually saved as an inpcrd file in Amber notation). The second requirement 
for a MD simulation is topological information that describes how the atoms are 
connected, and their property types such as charge etc. This information is stored on a 
database as part of the Amber software (Case et al., 2014), and in Amber notation this 
information is stored as a prmtop file for the simulation.  
 
 
Figure 4-1 The various timescales covered by biophysical techniques. AFM = atomic force 
microscopy, FRET = fluorescence resonance energy transfer, IR = infrared resonance, NMR = Nuclear 
Magnetic resonance, MD = Molecular Dynamics simulations. The timescale covered by each biophysical 
technique is shown in orange above the timeline. The timescales of some fundamental atomic and 
molecular scale motions are shown below the timescale with purple lines. Image reproduced from (Ode 
et al., 2012). 
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The third condition for setting-up a MD simulation is choosing the force field which 
contains all the parameters to describe how the atoms move and interact in a MD 
simulation, which is a mathematical equation describing the energy in a system. A 
typical force field (FF) is described in Equation 5 and the parameters they control are 
illustrated in Figure 4-2. Additional FFs, for RNA, DNA, lipids and glycans are 




Equation 5 A typical equation for a force field. The first four terms refer to bond stretching, angle 
bending, dihedral and improper torsions, which are intramolecular contributions to the total energy (U) 
while the last two terms describe van der Waals interactions by means of the Lennard-Jones potential and 
electrostatic interactions by Coulombic interactions. 
 
A set of instructions on how to run the MD simulation and its boundaries such as the 
system temperature, pressure and time are saved as a mdin file in Amber notation. All 
this information is fed into a simulation program to run the MD simulation and the 
position, velocity and acceleration of each atom is calculated according to Newton’s 
equations of motion. The initial velocities are chosen randomly but within the 
limitations of temperature stated in the instructions. The atomic coordinates are 
propagated through time using the Verlet algorithm (Verlet, 1967) which are based on 
integrations of Newton’s equations of motion. The Verlet algorithm requires the 
position of atoms at two previous time points in order to calculate the position of atoms 
at the next time step.  
 
Larger time steps within the simulation are allowed with the use of the SHAKE 
algorithm (Ryckaert et al., 1977). SHAKE acts to constrain the Verlet algorithm and 
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system. Ideally this can be done from first principles, solving the electronic structure for a particular
configuration of the nuclei, and then calculating the resulting forces on each atom [12]. Since the
pioneering work of Car and Parrinello [13] the development of ab initio MD (AIMD) simulations has
grown steadily and today the use of the density functional theory (DFT) [14] allows to treat systems
of a reasonable size (several hundreds of atoms) and to achieve time scales of the order of hundreds
of ps, so this is the preferred solution to deal with many problems of interest. However quite often
the spatial and/or time-scales needed are prohibitively expensive for such ab initio methods. In such
cases we are obliged to use a higher level of approximation and make recourse to empirical force field
(FF) based methods. They allow to simulate systems containing hundreds of thousands of atoms during
times of several nanoseconds or even microseconds [15, 16]. On the other hand the quality of a force
field needs to be assessed experimentally. And here again neutrons play a particularly important role
because while many different experimental results can be used to validate some of the FF parameters, the
complementarity mentioned above makes neutron scattering a particularly useful tool in this validation
procedure.
Therefore in the first part of this short review I will introduce briefly what is a FF, which are the
main terms entering into the description of a standard FF, and which are the current lines of research
in order to develop more accurate interatomic potentials. A historical account of the development of
FFs in connection with molecular mechanics is given by Gavezzotti [17]. He also reviews the problems
to derive the terms entering into the FF directly from the electronic density obtained from quantum
mechanical (QM) calculations and the inherent difficulty in assigning a physical meaning to these terms.
General reviews about empirical force fields can be found in references [18–20] and a comprehensive
compilation of available FFs is supplied in [21]. In the second part I will review the principles of MD
simulations and the main concepts and algorithms employed will be introduced. Useful reviews have
been written recently by Allen [22], Sutmann [23–25], and Tuckerman and Martyna [26]. And for a
more comprehensive overview the interested reader is referred to the excellent textbooks of Allen and
Tildesley [27], Haile [28], Rapaport [29] or Frenkel and Smit [30].
2. FORCE FIELDS
2.1 Definition
A force field is a mathematical expression describing the dependence of the energy of a system on
the coordina es of its particles. It consist of an analytic l form f the interatomic potential energy,
U (r1, r2, . . . , rN ), and a set of parameters entering into this form. The parameters are typically obtained
either from ab initio or semi-empirical quantum mechanical calculations or by fitting to experimental
data such as neutron, X-ray and electron diffraction, NMR, infrared, Raman and neutron spectroscopy,
etc. Molecules are simply defined as a set of atoms that is held together by simple elastic (harmonic)
forces and the FF replaces the true potential with a simplified model valid in the region being simulated.
Ideally it must be simple enough to be evaluated quickly, but sufficiently detailed to reproduce the
properties of interest of the system studied. There are many force fields available in the literature,
having different degrees of complexity, and oriented to treat different kinds of systems. However a








































improves its efficiency by removing bond stretching of bound hydrogen atoms. By 
using fixed bond lengths, it freezes the fastest motions in the simulation with negligible 
effect on the accuracy and quality of the simulation while increasing the processing 
speed (Adcock and McCammon, 2006). The atomic coordinates from each time step is 
then connected to become the trajectory of the object which is analysed by a separate 
set of analysis programmes while the trajectory can be visualised by molecular structure 
software e.g. UCSF Chimera or VMD (Case et al., 2014). 
 
 
Figure 4-2 An illustration of the parameters measured. In classical molecular mechanics, atoms are 
treated as spheres (blue) joined by springs. Bonded interactions include Kb for bond length, bond angle 
Kq and dihedral angles Kj. Nonbonded interactions include van der Waals forces(Evdw), and electrostatic 
potential (Ecoulomb). Van der Waals forces are very important in a protein since they affect the secondary 
structure and how the protein organises in a complex or an assembly. Image reproduced from lecture 






4.1.2 derCD23 residues involved in calcium and IgE binding 
 
Chapter 3 describes the difficulty in determining the stoichiometry of calcium binding 
experimentally, and the effect the mutant derCD23 proteins have on IgE-binding.  To 
re-iterate residues of interest in the simulation, Figure 4-3 illustrates the IgE-Fc binding 




Figure 4-3 The structure of WT human derCD23.  Blue carbon atoms = The principal calcium-ion-
binding site, orange = “auxiliary” site, green carbon atoms = E257, a residue involved in both principal 
and “auxiliary” sites, pink carbon atoms = residues involved in IgE binding, yellow carbon atoms = 
additional residues involved in IgE binding upon calcium binding, striped yellow and orange carbon 
atoms = D258 a residue part of the “auxiliary” site and makes additional salt bridges to IgE on calcium 
























4.2 Results  
4.2.1 A Note on Nomenclature  
 
Most molecular dynamics simulation software designates CA to represent a Ca carbon. 
A calcium ion is also represented as either CA, or ca or Ca, which mostly registers as a 
Ca carbon, this unfortunately means that it has been particularly difficult to build and 
analyse a calcium-binding protein system. The systems were all run in Amber14 with 
the Amber ff14SB forcefield (Case et al., 2014). 
 
4.2.2 Summary of Molecular Dynamics Simulations Datasets 
 
 
Table 4-1 provides a summary of all the protein models run for molecular dynamics 
simulations, using the same nomenclature for the derCD23 mutants as chapter 3. All 
simulations were run with, and without calcium. For the calcium simulations, one 
bound calcium ion was modelled for the WT human derCD23 protein, and two ligated 
calcium ions were modelled for the other derCD23 proteins. The calcium-containing 
simulations began with calcium bound to the protein, since WT human derCD23 has 
such a weak binding affinity for calcium at KD ~ 1.5 mM (Yuan et al., 2013). It would 
not be expected to see solution-free calcium bind to the protein within the maximal 
simulation timeframe of 1 µs, due to slow kinetics associated with conformational 








Simulation  Description Time (µs) No. of Runs  
WT_0CA Apo WT derCD23 without calcium 1 3 
WT_1Ca WT derCD23 with 2Ca2+ 1 3 
A_0Ca Triple mutant without calcium µs 1 3 
A_2CA Triple mutant with 2Ca2+ 1 3 
B_0Ca Quadruple mutant without calcium 1 3 
B_2Ca Quadruple mutant with 2Ca2+ 1 3 
C_0Ca Six residue mutant without calcium 1 3 
C_2Ca Six residue mutant with 2Ca2+ 1 3 
Mouse_0Ca Modelled mouse derCD23 without calcium 1 3 
Mouse_2Ca Modelled mouse derCD23 with 2Ca2+ 1 3 
 
Table 4-1 Description of Molecular Dynamics simulations performed in this study. WT = WT 
human derCD23, A = human derCD23 with the following point mutations: N225D, K229E, S252N B= 
human derCD23, with the following mutations: N225D, K229E, T251N, S252N C= WT human 
derCD23 with the following mutations: N225D, K229E, T251N, S252N, R253G, S254G. Mouse = WT 
mouse derCD23 model. 
 
4.2.3 Trajectory Statistics 
 
All the MD simulations remained stable throughout their trajectories as shown by the 
average Cα Root Mean Square Deviation (RMSD), and the small standard deviations as 
shown in Table 4-2. The RMSD measures the structural distance between co-ordinate 
sets in a trajectory, and is defined by Equation 6. Interestingly, the RMSD is always 
smaller in the calcium-bound states, hence in agreement with the observations made for 
mutant C in section 3.2.5, which shows that the calcium adheres to the loops that form 
part of the calcium-binding sites, stabilizing the protein and constraining the loops. The 
stabilizing and protein-shape compacting influence of calcium is also reflected in the 
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total surface area, which is reduced for the calcium-bound proteins; apart from mutant C 
and murine derCD23. This exception may be due to the additional glycines found in the 
loop regions of these most ‘mouse-like’ proteins that may cause the loops to fall into 
conformations not seen in the other proteins, and thus extending the overall surface 
area. Conversely, the difference of compactness between the calcium-bound and apo 
protein simulations do not show any difference in column three of Table 4-2, which 
documents the total radius of gyration across the entire simulation time and is described 
by Equation 7. The change in radius translates to a change of less than 1 % of the 
protein volume. Both the RMSD and Rg confirm that the protein’s tertiary structure 
remained stable because in an unfolding protein these values would increase over the 
course of the simulation.  
 
!"#$ = 	'1)*(,- − /-)12-34  
Equation 6 The Root Mean Square Deviation (RMSD). N = number of atoms, u and v are the vector 
coordinates of two different points in the structure.  
 
!5 =	'16*(7- −	789)1:-34  
Equation 7 The radius of gyration. n = number of visits to location i, ri is the vector of the ith atom’s 
coordinates in space and rcm = position of the centre of mass of the protein. 
 
The exposed surface area (defined by the LCPO algorithm (Weiser et al., 1999)) of both 
calcium-binding sites reported in Table 4-2 also decreased upon calcium-binding as the 
loops bent over the calcium ion. The deeper auxiliary binding site showed greater 
reduction in the surface area compared to the relatively shallow principal site. This was 
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true for all the simulated proteins, except mouse derCD23 which could be due to model 
inaccuracies, since an experimental structure has yet been to be confirmed. The 
individual surface areas of residues involved in IgE binding were expected to increase 
with calcium binding, so that more contacts could be made between derCD23 and IgE-
Fc but with no clear trend for all the simulations, this might be considered a too 
simplistic view as binding is more dependent on atoms being at correct distances and 





Protein RMSD (Å) Rg (Å) Total SA (Å2) IgE-SA (Å2) Ca1-SA (Å2) Ca2-SA (Å2) 
WT 0.99 13.37 6824.1 770.0 218.8 147.1 
 (0.31) (0.036) (123.3) (32.4) (24.5) (17.7) 
WT_1Ca 0.94 13.37 6640.3 701.8 149.9 76.8 
 (0.28) (0.046) (96.4) (27.0) (26.4) (8.6) 
A 1.11 13.40 6820.5 715.1 281.5 135.0 
 (0.14) (0.006) (95.8) (26.5) (16.1) (14.7) 
A_2Ca 0.89 13.33 5113.2 720.8 229.1 79.4 
 (0.11) (0.007) (67.5) (27.6) (14.6) (9.1) 
B 1.12 13.32 6800.5 715.7 279.9 136.2 
 (0.51) (0.082) (100.9) (32.2) (19.7) (22.1) 
B_2Ca 0.95 13.37 6792.7 689.3 232.6 88.0 
 (0.22) (0.017) (89.3) (25.3) (14.6) (8.4) 
C 1.22 13.40 6741.4 694.3 300.0 148.1 
 (0.24) (0.032) (115.7) (38.4) (21.4) (26.2) 
C_2Ca 1.01 13.45 6784.2 743.4 223.2 83.0 
 (0.21) (0.013) (110.5) (34.4) (15.4) (10.1) 
WT Mouse 1.40 13.00 5056.4 218.1 155.0 123.7 
 (0.55) (0.010) (70.9) (16.0) (15.0) (11.0) 
Mouse_2Ca 1.06 13.00 6657.3 326.5 174.3 122.3 
 (0.34) (0.064) (97.9) (18.2) (10.0) (5.2) 
 
Table 4-2 Comparison between average geometric properties of all the MD simulations. Average 
values of three runs displayed taken onwards from frame 30 (1.5 ns) to frame 20000 (1 us). Values in 
parentheses are the standard deviation. Rg = radius of gyration. RMSD and Rg values for Ca atoms only. 
Total SA = Total surface area of protein calculated with the LCPO algorithm. IgE-SA = Surface area of 
IgE-binding residues on CD23 (residues His186, Arg188, Tyr189, Arg224, Asp227, Ser254, Gln255, 
Asp258 and Cys273).  Ca1-SA = Surface Area of the principal calcium binding site (residues Asp 225, 
Glu229, Thr251 and Asp258). Ca2-SA = Surface Area of the auxiliary calcium binding site (residues 





4.2.4 Root Mean Square Fluctuations (RMSF) 
 
Another measurement used to analyse movements of the structure during the simulation 
is root mean square fluctuations (RMSF), defined by Equation 8. It calculates the 
average atomic mobility of each of the Ca atoms during the course of the simulation so 
that portions of the structure that are fluctuating the most can be identified easily. In 
derCD23, the non-secondary structure components of the protein such as the loops 
would be expected to fluctuate the most since a-helices and b-sheets would be held in 
position by a network of hydrogen bonds. Indeed, in Figure 4-4 the regions that 
fluctuate the most are loops 1 and 4, while fluctuations at residues 261-263 and 266-274 
correspond to turns connecting b strands and atomic movement at residues 212-217 
correspond to a turn between b strand 2 and a helix 2 which contains the IgE-binding 
residue His 216.  
 
!"#; =	'1<*(/= −	/)1>=34  
Equation 8 The Root Mean Square Fluctuation (RMSF). T = the number of trajectory frames, / = the 
mean structure and /= = the position of atoms in residue i after superposition on the mean structure. 
 
If calcium is acting to constrain the movements of the loops, it would be expected that 
less mobility is seen in the calcium-bound structures than within the calcium free 
simulations. Accordingly, in the calcium-bound structures displayed in Figure 4-4, there 
is overall less motion (largest fluctuation ~ 2.5 Å) than in the apo-protein in Figure 4-5 
(largest fluctuation ~ 4 Å). In loop 1, Figure 4-4C there is little variance between the 
derCD23 proteins, however, in loop 4, especially for the mouse protein and mutant C, a 
much larger fluctuation can be observed this might be due to the glycines, only found at 
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the base of loop 4 in these two proteins, which allow for greater spatial degrees of 
freedom. 
 
Without calcium, the effect of the altered residues leads to a slightly more pronounced 
movement in loop 1, with all the proteins moving on average 1 Å more than in the 
calcium-bound structures. Mutant C shows the largest increase in RMSF in loop 1 as 
shown in Figure 4-5C, although it is the closest to murine derCD23 by sequence, two 
residues still differ, the aspartic acid and the adjacent leucine are substituted with an 
asparagine and an isoleucine in the mouse protein. The isoleucine may explain why the 
murine derCD23 is less flexible than mutant C in loop 1 due to the branched nature of 
the Cb of the residue, which would restrict the conformations that the main chain could 
adopt. Asp227, a residue found in loop 1 of the WT human and mutant derCD23 
proteins, forms a hydrogen bond with IgE-Fc in the presence of calcium. The greater 
movement of loop 1 could influence the kinetics of the CD23-IgE interaction. In 
general, loop 4 became slightly more flexible, most noticeably in mutant 4, and in the 
mouse protein. Both these proteins contain glycine substitutions, enabling the protein 
backbone to explore more conformational space as the constraints were released. 
 
Another area of difference, is the region containing the calcium co-ordinating residues 
Asn269 and Asp270 of b strand 5 at the principal calcium binding site. All the mutant 
and mouse proteins are less mobile than the WT human protein at this location. The 
reason for this is not clear, since no additional stabilising hydrogen bond could be found 
involving those residues during the MD simulations. Examining solvent accessibility 
(Zhang and Lazim, 2017) or using techniques such as elastic network models 
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Figure 4-4 Structure and RMSF values of the calcium-bound simulations. Black = WT human derCD23, light-blue = mutant A, yellow = B, magenta = C, green = WT 
mouse derCD23, these colours also match those of the graphs. A) displays a cartoon figure of derCD23 with the different residues of each mutant protein highlighted; yellow 
spheres give the position of the two calcium ions. B) shows the RMSF of the Cα of each residue across the whole of the proteins, averaged over triplicate simulations. The 
RMSF is only shown for residues 159-280 which excludes the unstructured N and C terminal domains, residue numbers correspond to the numbering scheme of the protein 
in the pdb file. C) is a zoom-in of panel B focusing on loop 1. D) is a zoom-in of panel B focusing on loop 4.
Loop 1 Loop 4 
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Figure 4-5 Structure and RMSF values of the proteins without calcium. A) A cartoon figure of derCD23 with the different residues of each mutant protein highlighted; 
yellow spheres give the position of the two calcium ions. Light-blue = mutant A, yellow = B and magenta = mutant C, these colours also match those of the graphs. B) black 
= WT human derCD23, green = WT mouse derCD23. The RMSF profile across the whole of the proteins with residue number corresponding to the numbering scheme of the 
protein. C) is a zoom-in of panel B focusing on loop 1. D) is a zoom-in of panel B focusing on loop 4.
Loop 1 Loop 4 
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4.2.5 Comparison of molecular motions seen by Molecular Dynamics Simulations 
and X-ray Crystallography 
 
The MD simulation on average enables a greater freedom of movement for the protein 
to explore more conformations than might be captured experimentally. On comparing 
the crystallographic B-factors with the RMSF from the MD simulations (Kuzmanic and 
Zagrovic, 2010), the RMSF showed more peaks and greater flexibility than the B-
factors as shown in Figure 4-6. This verifies that both techniques can locate the flexible 
regions of the protein and that the protein during simulation does not unfold. There is 
reasonable agreement with peaks at residues 225-230 and 252-258 corresponding to 
loop 1 and loop 4 respectively but there are also local areas of differing mobility. One 
area of discrepancy, in which the RMSF showed an increase and the crystallographic B-
factors did not, is region 210 to 218 matching the end of helix a2 with residues 
connecting to b strand 2 and spatially-close residues 263-266. Within the asymmetric 
unit, these residues are involved in a tight network of hydrogen bonds that have enabled 
the protein to pack tightly (4 separate chains in one asymmetric unit), whereas in the 
MD simulation, these residues are less constrained and show greater mobility as they 
are free to interact with the solvent. This region also contains derCD23 residue His216 
involved in binding to Ce2, but this derCD23- Ce2 interface is not as significant as the 
derCD23/Ce3-4 binding site. The derCD23- Ce2 interface has a 12-fold weaker binding 
affinity than the larger derCD23- Ce3-4 binding site (Dhaliwal et al., 2017). Changes in 
His216 orientation would have minimal impact on IgE binding. The residues of 274-
278, linking b strands 4 and 5 also show a greater amplitude of movement in MD 
simulations than in the crystal structure, because they are involved in a hydrogen-




Another factor to consider that differs between the two sets of experiments, is the 
temperature the experiment is performed at. The protein is crystalline for cryo-X-ray 
crystallography and data is collected at cryo-temperatures ~ 100 K (Pflugrath, 2004) 
while in MD simulations the protein is in simulated solvent for the MD simulation, with 
simulations run at 300 K and subjected to greater thermal motions. It should be noted 
that the thermal settings for the MD simulations could be changed with ease, but are set 
at biologically relevant temperatures. 
 
 
Figure 4-6 Comparison of the average Cα RMSF of the WT-1Ca2+ Cα MD simulation to the B-
factors of chain A pdb:4G9A (derCD23 – calcium bound).  RMSF displayed in black with axis on 
left, B-factors from the PDB file shown in red with axis on the right. Residue numbering matches that of 
the pdb file. 
 
4.2.6 Effect of Calcium on the Protein 
 
Overall, from observations made in Figure 4-7, there is a marked reduction in the 
motion of two regions of the protein backbone on the addition of calcium. It appears 
that calcium is acting to fasten its coordinating residues, and the bulk of the flexible 
loops.  In WT human derCD23, only one calcium was modelled in the principal site 
whereas in the other proteins two calcium ions were modelled, one in the principal site 
and one in the auxiliary site. The calcium coordinating residues, Asn269 and Asp270, 
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which are not part of the loops, also show a difference in peak height as they sample 
conformational space.  A restriction in the motion of loop4 is observed in all the 
proteins, and most pronounced in the mouse protein, although this may be a restriction 
of the model since a crystal structure does not yet exist. Compared to the single-calcium 
binding protein, no additional trends could be observed with the two-calcium binding 
proteins. Residue His216 appears to be unaffected by calcium which matches 
previously made observations of the derCD23/Fce2-4 crystal structure. His216 makes 
one hydrogen bond to Thr260 in Ce2 but it is not close to the calcium binding site of 












Figure continues on next page. 














































Figure 4-7 The effect of calcium binding on the proteins. The RMSFs were measured using the Cα of 
each residue from the entire trajectory (1μs) for both apo-protein in blue and protein + calcium in red, 
and are averaged over triplicate simulations for all proteins. The RMSF is only shown for residues 160 to 
280 which excludes the unstructured and flexible N and C terminal domains. 
 
4.2.7 Calcium Ion Distance Tracking Plots 
 
These Calcium-binding graphs of Figure 4-8 plot the distance between calcium and the 
protein residues throughout the trajectory of the simulation. For the majority of cases, 
the close proximity of calcium to a residue results in a dark colour indicating a calcium 
co-ordinating residue, lighter colours indicate residues involved adjacent to the metal 





























Mouse WT derCD23 
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ion binding residues that move in correlation with it. The smaller inset graph focuses on 
one residue within the calcium-binding site, and plots the distance of calcium over the 
entire 1 µs of the trajectory. A combination of both graphs indicate that the calcium 
remained bound and the darkest marks correspond to the calcium binding residues. In 
the WT graph in panel A, Figure 4-8. The direct calcium-binding residues of the 
principal binding sites D270, E249 and T251 are always displayed in black, indicating 
that they are always co-ordinating the calcium throughout the trajectory. N269, adjacent 
to D270 which in the crystal structure co-ordinates the calcium ion by a water molecule 
is also within a <0.3 nm distance of the calcium ion.   
 
Panels B-E, display an additional graph for the same protein featuring the auxiliary 
calcium site, which shows more variation. There are two clear blocks of colour, the first 
block relating to loop1, whilst block two corresponds with loop 4 and the end of the 
beta strand preceding loop 4. The movement of the loops differs between the proteins; 
with the auxiliary calcium-binding site situated between the principal, and the auxiliary 
site; this calcium would have greater effect on loop movement. T251N in mutant B, C 
and mouse located at the tip of loop 4, does not appear to co-ordinate the calcium ion 
directly, only being within 0.5 nm of the calcium ion (expected calcium-ligation residue 
distance is ~ 0.27 nm).  This residue is involved in the principal binding site, and in 
trying to make the proteins more ‘mouse-like’, the residue was changed to an 
asparagine. Initial model bias in the X-ray structures may account for why this residue 








Figure continues on next page.  
Mutant A 2Ca2+  
WT derCD23 1Ca2+  
Mutant A 2Ca2+ 2nd Calcium 
Mutant B 2Ca2+ Mutant B 2Ca2+ 2nd Calcium 




Figure 4-8 Calcium ion binding graphs. Representative graphs from the molecular dynamics 
simulations, y-axis corresponds to frame. Colour-scheme on right-hand side of the graph, white = 
calcium not within proximity of the calcium, black = calcium within 0.24 nm of the calcium ion. 
Residues corresponds to the numbering scheme of WT human derCD23. Ns = frames throughout 
trajectory. 
 
4.2.8 Principal Component Analysis (PCA) 
 
The RMSF graphs of Figure 4-4, Figure 4-5 and Figure 4-7, highlighted the sections of 
the structure that fluctuated the most (and the least) from the mean structure. To look at 
the most relevant motions of the trajectory, PCA (David and Jacobs, 2014) was applied 
to the backbone atoms in the concatenated simulation models (all repeats for one 
simulation model were concatenated). Eigenvector one describes the largest motions in 
the models and is also known as the principal component.  
 
The first eigenvector was visualised in porcupine plots shown in Figure 4-9 and Figure 
4-10, in which the arrows describe the direction and magnitude of the dominant motion 
of eigenvector 1. Several of the models express a ‘breathing’ motion in which loops 1 
and 4 are moving to and fro from each other. The WT human derCD23 model without 
any calcium is the only model which displays movement around the principal calcium 
binding site with a lifting of the b4 strand and loop 4 only as shown in Figure 4-9. 
Calcium bound-mutant A displays the opposite behaviour to apo-WT model in which 
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the principal calcium binding site is occupied, and the area does not move, however 
loop 1 still expresses some flexing motion despite the auxiliary calcium site being 
occupied as well. The predicted auxiliary binding site would sit deep in the pocket 
compared the shallower principal binding site and depending on the backbone, could 
still exhibit some flexibility in the residues surrounding the calcium. 
 
The other simulation models display this ‘breathing’ motion, as well as a slight twisting 
motion. The largest movement in loop 4 is exhibited by apo-mutant C, which might be 
due the point mutations since the glycines at the base of loop 4 would allow for greater 
conformational flexibility. Interestingly, the WT mouse model without calcium also 
displays movements like that of the calcium-free WT human protein. It too displays 
movements in loop 4 but of a larger magnitude. This finding might be due to the extra 
loop mobility provided by the glycine residues found at the base of loop 4 in the mouse, 
but not human sequence. With calcium added to the mouse derCD23 protein displayed 
in Figure 4-10, the movement in loop 4 is reduced, however, there is also pronounced 
flexibility in loop 1, not seen in the calcium-free simulation. Perhaps, binding of a 
calcium ion to the principal site stabilises loop 4 but the second calcium ion binding site 
might be less defined with the calcium ion associating and dissociating to cause the 











Figure 4-9 Porcupine plot of the largest motions described by the first eigenvector of the human 
and mutant derCD23 proteins. Ca backbone displayed as a green backbone trace, red arrows depict the 
direction and magnitude of motion. The direction of the arrows is an indication of the range of motions 
experienced by those atoms, it does not signify a final conformation. Left hand side shows simulations 









Mouse_0Ca     Mouse + Ca 
    
Figure 4-10 Porcupine plot of the largest motions described by the first eigenvector of mouse 
derCD23 proteins. Ca backbone displayed as a green backbone trace, red arrows depict the direction 
and magnitude of motion. The direction of the arrows is an indication of the range of motions 
experienced by those atoms, it does not signify a final conformation. Left hand side shows simulations 
without calcium. Right hand side shows simulations with calcium. 
 
4.2.9 The Effect on IgE-binding residues  
 
New conformations of derCD23 proteins were found during the trajectories as shown in 
Figure 4-11.  Previously, molecule D of PDB file 4J6P contained a conformation of WT 
human derCD23 with the loops closest together (Dhaliwal et al., 2013), whereas the 
MD simulation has provided at least one new conformation, shown in Figure 4-11A. 
This conformation has been designated the ‘closed’ conformation due to the proximity 
of the calcium-binding loops. A new conformation in which the loops 1 and 4 are 
furthest apart is displayed in panel B of Figure 4-11, designated the ‘open’ 
conformation. The advantage with the MD simulations is that the loops are always well 
defined and the atom co-ordinates can always be distinguished since there is no absent 





Figure 4-11 Demonstrations of new conformations discovered through MD simulations compared 
to the most extreme conformations found by X-ray crystallography. A) The most ‘closed’ 
conformation observed in the MD simulations. An alignment of a single MD trajectory frame (green) to 
PDB file: 4J6P (grey). B) The most ‘open’ conformation observed in the MD simulations. An alignment 
of a single MD trajectory frame (blue) to PDB file: 4J6Q (grey). 
 
The binding site between human derCD23 and IgE-Fc3-4 involves the base of loop4, and 
helix a1 of derCD23 and the loops AB, CD and EF of IgE-Fc. The conformation from 
Figure 4-11 B has been superposed onto the crystal structure of apo and calcium bound 
derCD23/IgE-Fc3-4 complex, and several steric clashes are seen, indicating that this 
conformation would not be amenable for binding. For comparison, the 
crystallographically solved complex is shown in Figure 4-13, which displays minimal 
clashes. It is important to note, however, that the loops of both proteins are highly 






      A)                  B) 
      
Figure 4-12 Clashes arising from superimposing the most ‘open’ WT human CD23 MD simulation 
structure on IgE-Fc3-4. A) An alignment of a single MD trajectory frame (blue) to IgE-Fc3-4 PDB file: 
4EZM (grey). B) An alignment of a single MD trajectory frame (blue) to calcium-bound-IgE-Fc3-4 PDB 
file: 4GKO (grey). The red disks display van der Waals overlaps or steric clashing. 
 
                 A)                                                   B) 
    
Figure 4-13 The calcium-free and calcium-bound crystallographic structures of the CD23/IgE-Fc3-4 
complex. Green = derCD23, grey = IgE-Fc3-4 A) The calcium-free complex, PDB file: 4EZM. B) The 




These clashes are also seen for the most ‘closed’ conformation (Figure 4-11A) depicted 
in the MD trajectories in Figure 4-14. It is interesting to note that the hydrogen bond 
that bridges loop 4 and loop 1 between Asn 225 and Asp 258 in WT human derCD23 
remains in all the mutations as this involves the backbone and not side chain atoms.  
 
A)         B) 
     
Figure 4-14 Clashes arising from superimposing the most ‘closed’ WT human CD23 MD simulation 
structure on IgE-Fc3-4. A) An alignment of a single MD trajectory frame (blue) to IgE-Fc3-4 PDB file: 
4EZM (grey). B) An alignment of a single MD trajectory frame (blue) to calcium-bound-IgE-Fc3-4 PDB 
file: 4GKO (grey). The red disks display van der Waals overlaps or steric clashing.  
 
4.2.10 Modelling Three Calcium Ions in derCD23  
 
Mutant C contains the same calcium ligating residues as DC-SIGNR, and it is possible 
for CTLs to bind to more than 2 calcium ions in general. In the case of derCD23, 
sequence analysis, molecular dynamics simulations and ITC results point to two 
calcium binding events in mutant C. Superpositioning mutant C onto the IgE-Fce3-4 
complex reveals another reason why a third calcium ion would be unlikely to bind as 
shown in Figure 4-15. A conserved arginine residue (Arg 440) in IgE occupies the site 
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of the third calcium ion and the positively charged side chain would repel the third 
calcium ion.  
 
 
Figure 4-15 Mutant C modelled with 3 calciums and superpositioned onto the derCD23/IgE-Fce3-4 
complex. Yellow spheres = calcium ions modelled on DC-SIGNR, pdb file: 1K9J. Grey = mutant C, blue 
= IgE-Fce3-4 pdb file: 4GKO. 
 
4.2.11 Predictions on Mouse derCD23 binding to Mouse IgE-Fc3-4 
 
Currently, there is no structure of the mouse proteins, thus the impact of loop movement 
on binding to murine IgE-Fc is only speculative. For both mouse CD23 and mouse IgE, 
the overall fold of the proteins is similar, but there are some disparities between the 
sequences of the human and mouse protein. Small changes include H186 mutated to 
Q186 in humans, and H216 in human CD23 mutated to lysine in mouse, this residue is 
involved in binding to Thr260 in Ce2 (Dhaliwal et al., 2017). These histidine mutations 
have a similar backbone and the H216K mutation would not weaken the His216-Thr260 
salt bridge.  The change from Y189 in humans to F189 still maintains the aromatic 
nature of the residue, whereas the R224Q mutation found in mice would disrupt the salt 




Further analysis of the modelled complex, shown in Figure 4-16 illustrates the mouse 
structure from the MD simulations and a SWISS Model of mouse-IgE aligned to pdb 
file 4EZM (human X-ray structure). The most striking difference is the lack of 
hydrogen bonds (only 4 hydrogen bonds are predicted for the mouse CD23 to mouse 
IgE interaction), especially those involving residue E412. This finding might 
significantly reduce the affinity of mouse CD23 to mouse IgE. Mouse derCD23 
contains similar electrostatics as human WT derCD23, so it is to be expected that 
interactions of mouse derCD23 and its ligands, and self-association will be similar to 
that seen in human WT derCD23. It is likely that the flexible regions and side-chains of 
both proteins alter in ways that the computer model cannot predict, to still allow for 
similar affinity interaction. 
 
A)                   B) 
  
Figure 4-16 Model of the human derCD23/IgE-Fc3-4 complex and a model of mouse-derCD23 
binding to mouse-IgE. Predicted hydrogen bonds shown with yellow dashes with residues involved in 
hydrogen bonds labelled. Glu412 is circled in orange. A) Human derCD23 (grey) bound to human Fce3-
4 (green). Pdb file: 4EZM. B) A model of m-derCD23 (grey) modelled on PDB file: 1S14 and a model of 


















4.3 Discussion  
 
Half of the calcium-facilitated IgE-binding residues in derCD23 are found in loops 1 
and 4, with Asn269 and Asp270 of b strand 4 also co-ordinating calcium ions. The 
proximity of ligand-binding residues and the allostery caused in IgE by calcium-bound 
derCD23 might be involved in the mechanism that releases IgE-allergen complexes in 
endosomes and recycles the receptors back to the plasma membrane. This mechanism 
could be involved in the processes that exacerbate the symptoms of allergies such as 
facilitated-antigen presentation.  
 
These loop-dwelling residues are difficult to examine experimentally due to a lack of 
electron density in X-ray structures and poor definition in NMR; thus in this chapter, 
with the drawbacks experienced in experiments such as poor protein expression, 
precipitating protein and crystal-packing constraints, these challenges are overcome in 
MD simulations, which explore the role calcium plays in the highly mobile loops and 
IgE-binding regions of derCD23. These simulations were run with the WT human 
derCD23 proteins, as well as the mutations documented in Chapter 3 to see if an in 
silico prediction tool could be built.   
 
The MD simulation systems built were stable, as summarised in Table 4-1 and Table 4-
2 and allowed for greater space and protein conformations to be explored as recorded by 
the extra motions caught by the RMSF in Figure 4-4 and Figure 4-5. Figure 4-6 shows 
good correlation between the crystallographic B-factors that reflect the mobility of the 
crystalline protein, and the RMSD of the simulation protein with the simulation 
showing greater flexibility than the X-ray structure, this is in good agreement with 




The addition of calcium to the structures does not affect the global conformational 
flexibility of the protein. Surprisingly, this addition only has a minor effect on the local 
flexibility of the calcium binding loops as shown in Figure 4-9. Perhaps the averaging 
of the motions for the analysis has distorted any subtle insights into the protein’s 
dynamics. 
 
Flexibility of the IgE-binding site of derCD23 has been documented with a range of 
Ce3-Ce4 interdomain angles compatible with CD23 binding (Dhaliwal et al., 2014, 
2012; Yuan et al., 2013; Dhaliwal et al., 2013). It is vital to remember than in solution 
or in vivo, IgE would be bending and sampling several of these conformations. Unlike 
the crystallographically solved structures of derCD23 (Dhaliwal et al., 2013), 
superimposing the most extreme structures found in the MD simulations on the 
derCD23/IgE-Fce3-4 complex, does result in clashes with the antibody as shown in 
Figure 4-11, Figure 4-12 and Figure 4-14. This suggests that there are some 
conformations of derCD23 that are not capable of binding directly to IgE and expands 
on the work reported by Dhaliwal et al.   
 
The effects of the mutations posed a challenge to elucidate in this system, as an equal 
amount of flexibility is found within the calcium binding loops, suggesting that other 
compensatory mechanisms are at work. Other in silico systems as documented by Yang 
et al. (Sang et al., 2014)(Yang et al., 2014b), suggest that the effect of individual 
mutations can be interpreted, but unfortunately these computational studies do not 




Despite the MD system not being able to act as an in silico prediction model for 
mutations in derCD23, force fields are constantly improving (Beauchamp et al., 2012; 
Maier et al., 2015) and using more advanced approaches to MD could result in a greater 
depth of understanding. For example, a system for derCD23 in which calcium binds, 
unbinds and binds again could yield binding affinities that could be used to predict ITC 
results. Greater integration between the MD simulations and experimental findings 
could lead to virtual tool to screen protein mutant before they are generated in vitro.  
 
Despite NMR being an in-solution technique, the loops of derCD23 could not be 
observed in NMR due to the intermediate exchange timescale while in X-ray 
crystallography, crystals contacts may occur as documented in Figure 3-18B or poor or 
no electron density can be found for mobile loop regions. MD simulations was able to 
provide insight to the loop movements with new conformations being observed in 
addition to those found by Dhaliwal et al. Understanding this plasticity is an important 
factor in small molecule drug design and new binding pockets could be exposed etc. 
Alternatively stabilising an unfavourable IgE-binding conformation of derCD23 could 





Chapter 5 Generation of the surface membrane IgE-Fc 
display library 
5.1 Introduction 
IgE in solution is usually found in a bent state (the acute angle between the two-fold 
axes of symmetry of the (Cε2)2 and (Cε4)2 domain pairs is at 62°), and is in an even 
more acutely bent state when bound to its receptor FceRI (54°) (Holdom et al., 2011). 
IgE is very flexible, and can ‘flip’, passing through a fully extended state with the Cε2-4 
domains aligned (as shown in Figure 1-5, Drinkwater et al., 2014). This dynamic 
movement has been proposed to allow the Cε2 domains of the immunoglobulin to flip 
over from one side of the Cε3-4 domains to the other, allowing the Fabs to occupy the 
optimal space for allergen binding (Drinkwater et al., 2014). Although, this 
conformational flexibility may hamper the conventional structure-activity relationship 
of drug development, it allows possibilities for allosteric intervention (Wurzburg and 
Jardetzky, 2009; Dhaliwal et al., 2013; Davies et al., 2017). 
 
Although we know the protein interfaces between IgE and its receptors, shown in 
Figure 5-1 and Figure 5-2, the large range of conformational states and allosteric 
binding sites makes the rational process of protein engineering challenging. Previous 
mutational studies, in which individual interface residues were mutated to alanine, had 
their energetic contributions measured by an SPR assay and resulted in less than a 10 
fold effect on the KD value of the IgE-CD23 interaction (Borthakur et al., 2012). 
Combining several of these mutations has resulted in an unfolded protein (data not 
shown). This finding prompted a new mutagenesis approach, which proved less 
laborious and rendered a higher through-put with a greater chance of success. A library 
display approach, in which IgE-Fc molecules could be selected, was proposed as a 
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method to overcome this problem. Therefore, the aim was to design and construct a 
surface membrane IgE-Fc (memIgE-Fc) mutant library that could be screened to select 
mutants that could only bind to one receptor, and not the other. This library could then 
be used to yield research reagents to explore processes such as epitope spreading, or 
yield potential theranostics.  
 
A)                                                     B) 
  
Figure 5-1 IgE binding to FceRI; interactions at both subsites. Green = IgE-Fc, blue = FceRI, orange 
= hydrogen bonds. A) Ce3 domain binds via two salt bridges (Arg334-Glu132 and Asp362-Lys117) to a 
chain of FceRI. B) The proline sandwich at site 2, with Pro426 of Ce3 packed between Trp87 and 



















Figure 5-2 IgE binding to derCD23. Red = derCD23, green = IgE, yellow = salt bridges, green = 
hydrogen bonds, blue = a hydrogen bond found in 5 out of 6 molecules in the crystallographic unit cells. 
PDB file: 4EZM. 
 
5.1.1 Introduction to Display Technologies 
 
Display technologies such as phage display allow for the efficient presentation, 
screening and selection of protein or antibody fragment libraries on the surface of a 
range of scaffolds or hosts (e.g. mRNA, bacteriophage, a prokaryotic cell or a 
eukaryotic cell) against a specific target in a high-throughput manner. Phenotype (i.e. 
specificity/affinity) is linked to the genotype (i.e. DNA/RNA sequences) to enable 
complete identification of lead hits. The diversity of display technologies reflects their 
potency in a range of applications.  
 
mRNA display libraries have the largest potential library size since they can present any 
protein secretable to the periplasmic space of E.coli. Yeast display libraries, although 












specific glycosylation. For complete expression of mammalian-specific post-
translational modifications and properly folded multi-domain protein, mammalian cells 
are required. The size of a display library is limited by the transformational efficiency 
of the cells. Even within mammalian cell display libraries, there is a range of presenting 
proteins that can be utilised, with the protein of interest (P.O.I) being expressed as a 
GPI-anchored-fusion protein for example on CHO cells (Armour et al., 2010; Soga et 
al., 2015), or as a full-length antibody (Akamatsu et al., 2007). Tethering the P.O.I to 
the cell membrane means that it is less constrained by orientation and the binding of 
accessory proteins. IgE is already expressed as an existing membrane-bound protein 
when part of the B-cell Receptor (BCR), in the later stages of B-cell maturation, and 
thus this construct can be used for the display library. Naïve B-cells express membrane-
bound IgM and IgD as part of the BCR and express other isotypes upon activation. 
 
5.1.2 Differences between membrane and soluble IgE  
 
Membrane IgE differs from secreted IgE in that it contains three additional structural 
features encoded by exons M1 and M2, as shown in Figure 5-3. M1 encodes the 
extramembrane proximal domain (EMPD), which in humans can be either of the short 
(IgEs) or long isoforms (IgEL). Mice only express IgE with a short isoform, whilst 
human IgEs is reported to be 52 amino acids shorter than IgEL, and has more efficient 
transport to the plasma membrane (Batista et al., 1996). Findings from some studies 
suggest that the EMPD is a control element of apoptotic signalling when the B cell 
receptor (BCR) of an IgE expressing cell is engaged by antigen (Poggianella et al., 
2006). The transmembrane and cytoplasmic domain are the other two structural features 
encoded by exons M1 and M2, while the cytoplasmic tail of IgE has no specific role on 





Figure 5-3 Membrane and soluble Immunoglobulin E. TM = transmembrane domain, CT = 
cytoplasmic tail. The two forms of IgE are produced by different cells: class-switched B-cells express 
membrane IgE while plasma cells secrete IgE.  
 
5.1.3 Chaperone proteins 
 
Membrane-bound IgE forms part of the BCR in which the antibody is obligatorily 
associated with other membrane proteins: CD79-a and CD79-b (Ig-a/Ig-b) as shown in 
Figure 5-3. These proteins are not only vital for signalling, but also for transporting and 
assembling the BCR within the plasma membrane. Experimental evidence suggest that 
without the extracellular and transmembrane domains of CD79, the BCR will not 
assemble in a B cell (Dylke et al., 2007); thus it is not clear whether membrane IgE-Fc 



























5.1.4 The strategy for the generation of the surface memIgE-Fc display library  
 
The first step in designing a library was to decide on the format and framework that 
would express well and accommodate mutations. My strategy was to generate a library 
consisting of the Fc region (Ce2 to Ce4) of the heavy chains solely, as it is this region 
that binds to the two receptors. This took into consideration the fact that the light chains 
or the Fab regions of the antibody are not required for binding to the IgE receptors and 
might obstruct the binding of the selection assay reagents to the membrane-bound 
protein. In addition, library selection does not depend on antigen capture or signalling, 
so these parts were omitted in order to simplify the construct; since the light and heavy 
chains no longer need to pair up, only the heavy chains need to homodimerise. This still 
presents a level of complexity since the two chains need to dimerise and form 
disulphide bonds between the Ce2 domains of each chain.  
 
A single mutation in IgE-Fc (R334S) is known to significantly reduce binding of 
soluble IgE to FceRI. This mutation is involved in two hydrogen bonds in subsite 1 
(Figure 5-1A).  R334S reduces IgE affinity for FceRI ~50-fold and in vivo reduces the 
passive cutaneous anaphylaxis response by 75% (Henry et al., 1997; Hunt et al., 2008). 
Additional mutations in IgE-Fc acting co-operatively with R334S could further decrease 
the affinity for FceRI such that cross-linking of IgE molecules on a mast cell is no 
longer able to occur, and the allergic cascade is not triggered. Therefore, a stable cell 
line with the R334S mutation was generated to act as a benchmark against which 
additional mutant IgE-Fcs could be assessed.  
 
A small-scale surface memIgE-Fc display library was created as a proof-of-principle 
study, in which two IgE - FceRI interface residues were mutated to all the other amino 
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acids. Residue, P426 (Figure 5-1B) at the second IgE subsite was chosen because it is 
involved in a ‘proline sandwich’, a dominant feature of FceRI binding subsite 2. P462 
makes several van der Waals contacts with Trp87 and Trp110 of the FceRI a2 domain 
(Holdom et al., 2011) and mutating it would disrupt the buried hydrophobic surface area 
of the binding site. In addition, residue R334 was selected to determine if an alternative 
amino acid at position 334 (compared to the R334S mutation) may further decrease 
binding to FceRI. The two residues were mutated and transfected into FlpIn™ HEK293 
cells for membrane surface expression. FlpIn™ cells contain one Flp Recombination 
Target (FRT) site in a specific genomic location, so that when the cells are co-
transfected with the expression vector containing the gene of interest and the vector 
encoding the Flp recombinase, the expression vector is integrated at the FRT site. It is 
vital that only one mutant IgE-Fc is displayed per cell otherwise it will not be possible 
to maintain the phenotype-genotype link. The hygromycin gene in the expression vector 
contains no promoter nor start codon and therefore it can only be expressed when 
integrated successfully into the host cell’s genome at the FRT site. The FlpIn™ cells 
enable the generation of a stable cell line in only a month, compared to six months to a 
year for conventional stable cell line production (Lai et al., 2013).  
 







Figure 5-4 The mammalian cell surface IgE-Fc display platform pipeline. Mutations are introduced 
into the expression vector by degenerate primers. The library of expression vectors is then co-transfected 
with pOG44, which expresses the recombinase necessary for creation of the stable cell line, into Flp-In™ 
HEK293 cells. This bipartite vector system generates a stable high expressing cell-line within one month. 
Stably transfected cells are positively selected by hygromycin. Single cell clones displaying one type of 
mutant per clone with binding specific to one IgE-receptor are then isolated by flow cytometry employing 













Immunoglobulin E (IgE) is mediates the allergic response via it’s two receptors, 
















Immunoglobulin E (IgE) mediates the allergic response via its two receptors, 
FcεRI and FcεRII (also known as CD23) as shown in figure 1. This network of 
proteins have obscured the unique role each individual receptor plays in the 
processes of antigen presentation and epitope spreading; both processes are 
responsible for spreading allergy from one allergen to multiple allergens1. 
 
Disrupting the interactions between IgE and its receptors may reduce allergic 
disease. The R334S mutation has been shown to reduce binding to FcεRI by 
50 fold and reduced mast cell degranulation in vitro proportionately2; additional 
mutations are needed to completely ablate binding, however, existing rational 
approaches to this problem have only resulted in unfolded protein and the 
allosteric nature of IgE makes it impossible to predict the effect of mutations.  
 
Figure 1. IgE mediates the allergic response via interaction with its two receptors. A) 
Cross-linking of FcεRI-bound-IgE by allergens (brown) on mast cells triggers degranulation 
and the release of allergy-causing mediators. B) IgE (blue) synthesis is controlled by CD23 












•  To generate engineered IgE antibodies with selective and 
exclusive binding to each of the IgE receptors to further 
characterise the individual role of each receptor.  
 
This will be accomplished by: 
 
•  Creating a mammalian cell-display library similar to phage display, 
in which, mutant IgE proteins are expressed on the surface of 
mammalian cells. 
•  Selecting single-receptor binding knock-out proteins.  
•  Characterising receptor binding kinetics of the proteins. 




Beavil, Sutton, McDonnell and Gould groups. 
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 2) Hunt et al. Attenuation of IgE affinity for FcεRI radically reduces the allergic response in vitro and in vivo. JBC. 2008;44:29882-7 
 3) Wright et al. Structural and Physical Basis for Anti-IgE Therapy. Scientific Reports. 2015;5:11581	
In order to generate an IgE-Fc mammalian-cell-display 
library, first a membrane-tethered construct of the IgE-Fc 
had to be created as shown in figure 2.A. Due to the 
allosteric nature of IgE (figure 2.B), rationally choosing 
residues in the IgE-Fc-receptor binding site to mutate 
might lead to dysfunctional protein, to overcome this 
problem, a library approach was taken. 	
 
	
Figure 4. Generation and Screening of IgE-Fc stable-cell-line 
library expressed in Flp-InTM HEK293 cells. Mutations are 
rationally cho n and introduc d into the expression vector by 
degenerate primers. The library of expression vectors is then co-
transfected with pOG44, which expr sses the recombinase 
necessary for creation of the stable cell line, into Flp-InTM HEK293 
cells. This dipartite vector system generates a stable high expressing 
cell-line within one month compared to the traditional 6 months-1 
year. Stably transfected cells are positively selected by hygromycin. 
Si gle cell clones display ng on  type of mutant per clone with 
binding specific to one IgE-receptor are then isolated by flow 
cytometry employing a fluorescently labeled receptor as bait. The 
sequence of the proteins are retrieved by single-cell sequencing 
followed by protein validation. Protein binding kinetics will be 
measured by surface Plasmon resonance (SPR).    
Figure 3. An overview of the Flp-In system. HEK-293 Flp-InTM 
cells (in red wells) are transfected with two plasmids; pcDNA5/FRT 
contains the gene of interest (GOI) and the other, pOG44, expresses 











Selection Antibiotic Optimisation 
 
Hygromycin, the selection antibiotic, was 
optimised based on a kill curve to identify the 
best concentration as well as temporarily, to 
determine the best day to add it.  
	
Transfection reagent : DNA  
 
A range of transfection reagent to DNA ratios were 
tested to find optimum delivery of DNA to the 
mammalian cells without causing cytotoxicity.  
Recombinase DNA: Protein DNA  
 
In this system, two expression 
plasmids are mandatory for expression 
and selection of stable cell lines. One 
plasmid expresses Flp recombinase; 
the DNA ratio of this can also be varied 
to control expression levels of the Flp-
recombinase which integration of the 







Presence of other Antibiotics  
 
Mammalian cells are usually grown in the 
presence of penicillin and streptomycin. It 
was hypothesised these might have 
interfered with the selection antibiotics but 
this was found to be untrue.	
Temperature 
 
The Flp-recombinase gene 
originates from Yeast, which is 
shown to have optimum activity at 
30°C but mammalian cells grow 
at 37°C.The temperature of the 
incubator was altered under 
varying lengths of t ime to 
determine effects on efficiency. 
	
Plasmid Purification Kits  
 
Different plasmid purification kits 
and their age were found to have 
various qualities of supercoiled 
D N A w h i c h a f f e c t e d t h e 
transfection efficiency.  	
Figure 5. Optimisation of the Flp-InTM transfections. A few of the 
















Figure 2. IgE-Fc membrane construct and whole IgE. A) A 
cartoon depiction of C terminus GFP tagged membrane-IgE-Fc 
protein used in the mammalian cell-display library in blue, pink = cell 
membrane, Cε2 = constant domain 2, EMPD = extra membrane 
proximal domain. B) A cartoon depiction of the IgE domains, with 
disulphide bridges and the sites of N-linked glycosylation pictured. 
The green and purple domains correspond to the blue domains in A. 
A library would be dependent on generating stable cell 
lines with guaranteed surface expression of only a single 
type of mutant protein per cell, which was only possible 
with the Flp-InTM system; described in figure 3.  
This set-up would enable me to create the following 
methodology described in figure 4. Transfection of the Flp-
InTM system required a great deal of optimisation as 
described in figure 5.  Each experiment took on average 1 
month to complete but it is still the fastest method of 
generating stable cell lines. A representative successful 
transfection is shown in figure 6. 
   
Figure 6. Successful Flp-InTM transfections A) Brightfield B) GFP and 
C) merged epifluorescence images of successfully transfected cells in 
6-well plates growing in phenol-red containing media, imaged at 20x 
magnification. The necrotic, untransfected cells do not express GFP. 
Live cells express GFP-tagged IgE-Fc.  
Figure 7. Development of the Selection Assay. Flow cytometry 
results, grey= unstained control, blue = fluorescently labeled IgE 
receptor, results analysed in FlowJ. The labeled FcεRI receptor works 
well while the CD23 bait needs to be improved by creating a multimeric 
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5.2 Results  
5.2.1 Design and Construction of the membrane IgE vector 
 
Proteins destined for the secretory pathway such as IgE usually contain a signal peptide 
at their N-terminus, which directs them to the correct pathway for secretion. The native 
signal sequence of IgE was chosen (GenBank: AAB59424.1, Figure 5-5A), as IgE is 
naturally secreted by plasma cells, which should be sufficient to shuttle the protein to 
the cell surface, rather than being directed to the proteasome for degradation.  
 
In previous studies carried out by our laboratory, the soluble form of IgE-Fc had two of 
its surface glycosylation sites removed to ease crystallisation (the N265Q, N371Q 
construct)(Young et al., 1995). These glycosylation sites were re-introduced to the new 
construct to enable proper folding of the ectodomain of the protein. This is especially 
important to IgE since it is the most glycosylated antibody (Plomp et al., 2014). Another 
factor taken into consideration was the expression of the two human memIgE isoforms, 
which differ in the length of their EMPD. The short form of memIgE was chosen as it 
has been shown to be more stable and express better than the memIgE long form 
(Batista et al., 1996). 
 
No changes were made to the native transmembrane domain sequence or the 
cytoplasmic tail, which acted as a linker for GFP and enabled space for the b-barrel 
protein to fold. Enhanced GFP (eGFP), which is 35 times brighter than WT GFP (Zhang 
et al., 1996), folds fast and matures quickly, was chosen as the transfection marker and 
to also provide semi-quantitative analysis for the FACS selection assay (see section 
200). The expected protein construct and its vector is displayed in Figure 5-5B while 






Figure 5-5 A map of the memIgE-Fc-GFP construct and protein. A) An overview of the designed 
protein. 1923 bp in length, numbers under the black line correspond to bp. Red = Native signal peptide, 
purple = IgE-Fc, blue = extramembrane-proximal domain (EMPD), navy = transmembrane domain, lilac 
= intracellular tail and green = GFP.  B) The new Flp-In vector containing the designed protein. Features 
labelled and the two residues to be mutated are highlighted in red as R334 and Pro426. Images created in 
Snapgene. C)  A cartoon representation of the proposed protein drawn linearly for ease. Blue = IgE 












Immunoglobulin E (IgE) is mediates the allergic response via it’s two receptors, 
















Immunoglobulin E (IgE) mediates the allergic response via its two receptors, 
FcεRI and FcεRII (also known as CD23) as shown in figure 1. This network of 
proteins have obscured the unique role each individual receptor plays in the 
processes of antigen presentation and epitope spreading; both processes are 
responsible for spreading allergy from one allergen to multiple allergens1. 
 
Disrupting the interactions between IgE and its receptors may reduce allergic 
disease. The R334S mutation has been shown to reduce binding to FcεRI by 
50 fold and reduced mast cell degranulation in vitro proportionately2; additional 
mutations are needed to completely ablate binding, however, existing rational 
approaches to this problem have only resulted in unfolded protein and the 
allosteric nature of IgE makes it impossible to predict the effect of mutations.  
 
Figure 1. IgE mediates the allergic response via interaction with its two receptors. A) 
Cross-linking of FcεRI-bound-IgE by allergens (brown) on mast cells triggers degranulation 
and the release of allergy-causing mediators. B) IgE (blue) synthesis is controlled by CD23 












•  To generate engineered IgE antibodies with selective and 
exclusive binding to each of the IgE receptors to further 
characterise the individual role of each receptor.  
 
This will be accomplished by: 
 
•  Creating a mammalian cell-display library similar to phage display, 
in which, mutant IgE proteins are expressed on the surface of 
mammalian cells. 
•  Selecting single-receptor binding knock-out proteins.  
•  Characterising receptor binding kinetics of the proteins. 
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In order to generate an IgE-Fc mammalian-cell-display 
library, first a membrane-tethered construct of the IgE-Fc 
had to be created as shown in figure 2.A. Due to the 
allosteric nature of IgE (figure 2.B), rationally choosing 
residues in the IgE-Fc-receptor binding site to mutate 
might lead to dysfunctional protein, to overcome this 
problem, a library approach was taken. 	
 
	
Figure 4. Generation and Screening of IgE-Fc stable-cell-line 
library expressed in Flp-InTM HEK293 cells. Mutations are 
rationally chosen and introduced into the expression vector by 
degenerate primers. The library of expression vectors is then co-
transfected with pOG44, which expresses the recombinase 
necessary for creation of the stable cell line, into Flp-InTM HEK293 
cells. This dipartite vector system generates a stable high expressing 
cell-line within one month compared to the traditional 6 months-1 
year. Stably transfected cells are positively selected by hygromycin. 
Single cell clones displaying one type of mutant per clone with 
binding specific to one IgE-receptor are then isolated by flow 
cytometry employing a fluorescently labeled receptor as bait. The 
sequence of the proteins are retrieved by single-cell sequencing 
followed by protein validation. Protein binding kinetics will be 
measured by surface Plasmon resonance (SPR).    
Figure 3. An overview of the Flp-In system. HEK-293 Flp-InTM 
cells (in red wells) are transfected with two plasmids; pcDNA5/FRT 
contains the gene of interest (GOI) and the other, pOG44, expresses 











Selection Antibiotic Optimisation 
 
Hygromycin, the selection antibiotic, was 
optimised based on a kill curve to identify the 
best concentration as well as temporarily, to 
determine the best day to add it.  
	
Transfection reagent : DNA  
 
A range of transfection reagent to DNA ratios were 
tested to find optimum delivery of DNA to the 
mammalian cells without causing cytotoxicity.  
Recombinase DNA: Protein DNA  
 
In this system, two expression 
plasmids are mandatory for expression 
and selection of stable cell lines. One 
plasmid expresses Flp recombinase; 
the DNA ratio of this can also be varied 
to control expression levels of the Flp-
recombinase which integration of the 







Presence of other Antibiotics  
 
Mammalian cells are usually grown in the 
presence of penicillin and streptomycin. It 
was hypothesised these might have 
interfered with the selection antibiotics but 
this was found to be untrue.	
Temperature 
 
The Flp-recombinase gene 
originates from Yeast, which is 
shown to have optimum activity at 
30°C but mammalian cells grow 
at 37°C.The temperature of the 
incubator was altered under 
varying lengths of t ime to 
determine effects on efficiency. 
	
Plasmid Purification Kits  
 
Different plasmid purification kits 
and their age were found to have 
various qualities of supercoiled 
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Figure 2. IgE-Fc membrane construct and whole IgE. A) A 
cartoon depiction of C ter i us GFP tagged membrane-IgE-Fc 
prot in use  in the mammalia  cell-display library  bl , pink = cell 
membrane, Cε2 = constant domain 2, EMPD = extra membrane 
proximal domain. B) A cartoon depiction of the IgE domains, with 
disulphide bridges and the sites of N-linked glycosylation pictured. 
The green and purple domains correspond to the blue domains in A. 
A library would be dependent on generating stable cell 
lines with guaranteed surface expression of only a single 
type of mutant protein per cell, which was only possible 
with the Flp-InTM system; described in figure 3.  
This set-up would enable me to create the following 
methodology described in figure 4. Transfection of the Flp-
InTM system required a great deal of optimisation as 
described in figure 5.  Each experiment took on average 1 
month to complete but it is still the fastest method of 
generating stable cell lines. A representative successful 
transfection is shown in figure 6. 
   
Figure 6. Successful Flp-InTM transfections A) Brightfield B) GFP and 
C) merged epifluorescence images of successfully transfected cells in 
6-well plates growing in phenol-red containing media, imaged at 20x 
magnification. The necrotic, untransfected cells do not express GFP. 
Live cells express GFP-tagged IgE-Fc.  
Figure 7. Development of the Selection Assay. Flow cytometry 
results, grey= unstained control, blue = fluorescently labeled IgE 
receptor, results analysed in FlowJ. The labeled FcεRI receptor works 
well while the CD23 bait needs to be improved by creating a multimeric 
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5.2.2 Proof-of-principle library generation – mutating the memIgE-Fc protein 
using the trick-22 method 
 
This proof-of-principle library focused on mutating two residues, P426 and R334, 
within the Fce region of the heavy chains, involved in IgE-FceRI binding. The residues 
at these positions were mutated to all the other amino acids to create a library size of 
potentially 400 different memIgE-Fc mutant proteins for screening against selective 
binding to either CD23 or FceRI. To create a ‘smarter’ library, the ‘22-c trick’ was 
employed to reduce codon redundancy. The 22-c trick is so-called because it consists of 
a 22:20 codon to amino acids ratio as illustrated in Figure 5-6, and uses a mix of three 
degenerate-base containing primers (detailed in section 2.1.14) to create intelligent 
libraries and reduce subsequent screening efforts (Kille et al., 2013; Sanchis and 
Fernández, 2008). A mammalian display library would be smaller than a phage display 
library, hence it is important to maximise the sampling of the library. If 15 amino acid 
positions were chosen and mutated to all the canonical amino acids, this would result in 
2015 = 3.27 x 1019 possible combinations, too many to sample or transfect efficiently.  
 
 
Figure 5-6 An example of the redundancy of the genetic code using in the 22-c trick. Codons are read 
from the most inner circle to the outside. The 20 amino acids for which the 22 codons code for are 





5.2.3 Validation of the surface memIgE-Fc display libraries at the DNA level 
 
The mutational rate of the library was assessed using the semi-quantitative quick quality 
control (QQC) method, for which twenty colonies were randomly chosen and 
sequenced (Acevedo-Rocha et al., 2015). It was vital to check that the WT clones were 
not over-represented as this would reduce library quality. Figure 5-7 displays the results 
of the QQC. For the first nucleotide chart a distribution of 27%(A), 19%(T), 27%(G) 
and 27%(C) is expected, as detailed in section 2.1.15. R334S clones corresponded 
closely to the expected distribution with a slight bias for the wild type codon. A similar 
pattern was observed for the third position (expected 55%(T) and 45%(G)). The second 
nucleotide is expected to have a distribution of 32%(A), 32%(T), 18%(G) and 18% (C) 
which was not observed by either set of clones. Overall, the primers appeared more 
efficient for the R334 residue, which showed greater diversity than the P426 residue, as 





       
 
 
Figure 5-7 Quick quality control of the library generated with the 22c-trick. Obtained distribution of 
nucleotides for residues R334 and P426. The wild-type codon is presented above the pie-charts.  
 
 
5.2.4 Generation of the membrane IgE cell line 
 
FlpIn™HEK293 cells were co-transfected with the constructed plasmid library as 
described in Figure 5-5, and pOG44, which codes for the Flp recombinase. After 
selection with hygromycin, successfully transfected cells expressed GFP, whereas the 
non-transfected cells either turned necrotic or did not express the GFP of the protein 
construct. The green cells in Figure 5-8 show that the designed protein is being 
expressed and that at least the intracellular part folded correctly. To test whether the 
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extracellular portion of the membrane protein has folded, the cells were stained with 
anti-human-IgE polyclonal antibodies and analysed by two-colour flow cytometry.  
 
 
Figure 5-8 Successful Flp-In transfections. A) Brightfield B) GFP and C) merged epifluorescence 
images of successfully transfected cells in 6-well plates growing in phenol-red containing media, imaged 
at 20x magnification on the Axiovert 200 M inverted microscope. The necrotic, untransfected cells do not 
express GFP. Live cells express GFP-tagged IgE-Fc. 
 
 
Figure 5-9 shows double positive cells for GFP and anti-human IgE PerCP Cy5.5, 
indicating that the polyclonal antibodies recognise the IgE-Fc and thus it can be 
concluded that the designed protein has been accurately targeted to the cell membrane 
and is fully folded. Non-transfected FlpIn™HEK293 cells did not express GFP, and the 




      




Figure 5-9 Validation of the WT memIgE-Fc-GFP cell line. Cells were gated for live cells first, based 
on forward and side scatter. Transfected FlpIn ™ cells in Q2 express GFP (cytoplasmic part of the 
protein construct is folded correctly and functioning) and bind to anti-human IgE polyclonal antibody 
(cells express the fully folded ectodomain). In Q4, untransfected FlpIn™ cells do not express GFP and 
do not stain for PerCP 5.5.  
 
5.2.5 Production of selection assay reagents: derCD23-Alexa488  
 
The first reagent to test was the fluorescently labelled WT human derCD23 protein, the 
production of which is detailed in section 3.2.1, and the fluorescent labelling detailed in 
section 2.2.26. Monomeric WT human derCD23 has a relatively low affinity for IgE 
with a Ka of 106 -107 M-1. It was not known whether the protein would have to be an 
oligomer to work as a reliable flow cytometry reagent since the avidity effect increases 
the affinity of trimeric CD23 to a Ka of 108 -109 M-1(Gould and Sutton, 2008). Figure 




































Figure 5-10 Labelling of derCD3 with Alexa488. 15% SDS-PAGE captured with multichannel 
fluorescence; pale blue = brightfield channel to capture markers, green= Alexa488 channel. Lane 1 = WT 
protein, lane 2 = derCD3-Alexa488, expected size = 17 KDa.  
 
While the transfections were in progress, a pilot study was performed with WEHI cells 
(Batista et al., 1996), which are mouse B-cells able to express full-length short isoform 
of membrane-bound human IgE, to test binding of the derCD23-Alexa488 to memIgE. 
Figure 5-11A demonstrates how monomeric derCD23-Alexa488 did not have sufficient 
affinity to bind to the membrane-IgE-Fc protein. 
 
To address this problem, a trimeric CD23 protein (triCD23) was produced, and 
conjugated to Alexa647, which was then bound to WEHI cells and these were tested by 
flow cytometry. The next section describes the production of triCD23, whilst Figure 
5-11B demonstrates that triCD23 conjugated to Alexa647 was able to bind to WEHI 
cells. The larger shift to the right gives a larger window to observe any decreases in 














 Figure 5-11 Binding of Alexa647-conjugated monomeric derCD23 and trimeric triCD23 to WEHI 
cells. Grey = unstained cells, coloured lines = stained cells. A) Cells stained with monomeric derCD23-
FITC. B) Cells stained with triCD23-Alexa647. 
 
5.2.6 Production of selection assay reagents: Expression, refolding and purification 
of recombinant triCD23 
 
Soluble triCD23 contains the C-type lectin domain and an engineered stalk with a 
synthetic trimerisation sequence (Cooper et al., 2012). TriCD23 has a greater affinity 
for IgE-Fc than derCD23 due to its avidity (Shi et al., 1997; Cooper et al., 2012; 
Borthakur et al., 2012). The pET151-GA-tri vector was kindly provided by Rebecca 
Beavil and BL21 star DE3 cells were transformed with the vector for protein 
expression. The expression test in Figure 5-12 shows an induced band at 30 kDa, which 































Immunoglobulin E (IgE) is mediates the allergic response via it’s two receptors, 











Immunoglobulin E (IgE) mediates the allergic response via its two receptors, 
FcεRI and FcεRII (also known as CD23) as shown in figure 1. This network of 
proteins have obscured the unique role each individual receptor plays in the 
processes of antigen presentation and epitope spreading; both processes are 
responsible for spreading allergy from one allergen to multiple allergens1. 
 
Disrupting the interactions between IgE and its receptors may reduce allergic 
disease. The R334S mutation has been shown to reduce binding to FcεRI by 
50 fold and reduced mast cell degranulation in vitro proportionately2; additional 
mutations are needed to completely ablate binding, however, existing rational 
approaches to this problem have only resulted in unfolded protein and the 
allosteric nature of IgE makes it impossible to predict the effect of mutations.  
 
Figure 1. IgE mediates the allergic response via interaction with its two receptors. A) 
Cross-linking of FcεRI-bound-IgE by allergens (brown) on mast cells triggers degranulation 
and the release of allergy-causing mediators. B) IgE (blue) synthesis is controlled by CD23 












•  To generate engineered IgE antibodies with selective and 
exclusive binding to each of the IgE receptors to further 
characterise the individual role of each receptor.  
 
This will be accomplished by: 
 
•  Creating a mammalian cell-display library similar to phage display, 
in which, mutant IgE proteins are expressed on the surface of 
mammalian cells. 
•  Selecting single-receptor binding knock-out proteins.  
•  Characterising receptor binding kinetics of the proteins. 




Beavil, Sutton, McDonnell and Gould groups. 
		
	
References:										1) Gould and Sutton. IgE in allergy and asthma today. Nat Rev Immunol. 2008;8:205–17 
                              2) Hunt et al. Attenuation of IgE affinity for FcεRI radically reduces the allergic response in vitro and in vivo. JBC. 2008;44:29882-7 














In order to generate an IgE-Fc mammalian-cell-display 
library, first a membrane-tethered construct of the IgE-Fc 
had to be created as shown in figure 2.A. Due to the 
allosteric nature of IgE (figure 2.B), rationally choosing 
residues in the IgE-Fc-receptor binding site to mutate 
might lead to dysfunctional protein, to overcome this 
problem, a library approach was taken. 	
 
	
Figure 4. Generation and Screening of IgE-Fc stable-cell-line 
library expressed in Flp-InTM HEK293 cells. Mutations are 
rationally chosen and introduced into the expression vector by 
degenerate primers. The library of expression vectors is then co-
transfected with pOG44, which expresses the recombinase 
necessary for creation of the stable cell line, into Flp-InTM HEK293 
cells. This dipartite vector system generates a stable high expressing 
cell-line within one month compared to the traditional 6 months-1 
year. Stably transfected cells are positively selected by hygromycin. 
Single cell clones displaying one type of mutant per clone with 
binding specific to one IgE-receptor are then isolated by flow 
cytometry employing a fluorescently labeled receptor as bait. The 
sequence of the proteins are retrieved by single-cell sequencing 
followed by protein validation. Protein binding kinetics will be 
measured by surface Plasmon resonance (SPR).    
Figure 3. An overview of the Flp-In system. HEK-293 Flp-InTM 
cells (in red wells) are transfected with two plasmids; pcDNA5/FRT 
contains the gene of interest (GOI) and the other, pOG44, expresses 
the recombinase required for integrating the GOI DNA into the cell’s 
genome. 
Selection Antibiotic Optimisation 
 
Hygromycin, the selection antibiotic, was 
optimised based on a kill curve to identify the 
best concentration as well as temporarily, to 
determine the best day to add it.  
	
Transfection reagent : DNA  
 
A range of transfection reagent to DNA ratios were 
tested to find optimum delivery of DNA to the 
mammalian cells without causing cytotoxicity.  
Recombinase DNA: Protein DNA  
 
In this system, two expression 
plasmids are mandatory for expression 
and selection of stable cell lines. One 
plasmid expresses Flp recombinase; 
the DNA ratio of this can also be varied 
to control expression levels of the Flp-
recombinase which integration of the 







Presence of other Antibiotics  
 
Mammalian cells are usually grown in the 
presence of penicillin and streptomycin. It 
was hypothesised these might have 
interfered with the selection antibiotics but 
this was found to be untrue.	
Temperature 
 
The Flp-recombinase gene 
originates from Yeast, which is 
shown to have optimum activity at 
30°C but mammalian cells grow 
at 37°C.The temperature of the 
incubator was altered under 
varying lengths of t ime to 
determine effects on efficiency. 
	
Plasmid Purification Kits  
 
Different plasmid purification kits 
and their age were found to have 
various qualities of supercoiled 
D N A w h i c h a f f e c t e d t h e 
transfection efficiency.  	
Figure 5. Optimisation of the Flp-InTM transfections. A few of the 
















Figure 2. IgE-Fc membrane construct and whole IgE. A) A 
cartoon depiction of C terminus GFP tagged membrane-IgE-Fc 
protein used in the mammalian cell-display library in blue, pink = cell 
membrane, Cε2 = constant domain 2, EMPD = extra membrane 
proximal domain. B) A cartoon depiction of the IgE domains, with 
disulphide bridges and the sites of N-linked glycosylation pictured. 
The green and purple domains correspond to the blue domains in A. 
A library would be dependent on generating stable cell 
lines with guaranteed surface expression of only a single 
type of mutant protein per cell, which was only possible 
with the Flp-InTM system; described in figure 3.  
This set-up would enable me to create the following 
methodology described in figure 4. Transfection of the Flp-
InTM system required a great deal of optimisation as 
described in figure 5.  Each experiment took on average 1 
month to complete but it is still the fastest method of 
generating stable cell lines. A representative successful 
transfection is shown in figure 6. 
   
Figure 6. Successful Flp-InTM transfections A) Brightfield B) GFP and 
C) merged epifluorescence images of successfully transfected cells in 
6-well plates growing in phenol-red containing media, imaged at 20x 
magnification. The necrotic, untransfected cells do not express GFP. 
Live cells express GFP-tagged IgE-Fc.  
Figure 7. Development of the Selection Assay. Flow cytometry 
results, grey= unstained control, blue = fluoresce tly labeled IgE 
receptor, results analysed in FlowJ. The labeled FcεRI r ceptor works 
well while the CD23 bait needs to be improved by creating a multimeric 






Instead	 of	 using	 anIbodies,	 soluble	 ﬂuorescently-labeled	 IgE-
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[ rpmi8866 Veronica6 052.fcs ]
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Sample Name Subset Name Count
[ rpmi8866 Veronica6 052.fcs ] APC-A+ 1197 




Figure 5-12 15 % SDS-PAGE expression test of triCD23 stained with Comassie stain. M = Marker, 1 
and 2 = insoluble fraction, lane 3 = supernatant. Samples are reduced, and a band representing triCD23 
can be observed in 1 and 2 indicating that triCD23 is expressed in inclusion bodies. 
 
Next, triCD23 was refolded in a buffer similar to the refold buffer of WT human 
derCD23, except that imidazole was added to the refold buffer since the protein is His-
tagged. During the refold, the protein was diluted much less than the monomeric 
derCD23 so that it could trimerise. The protein was purified by passing it over a Histrap 
column and concentrated prior to further purification by size exclusion chromatography 
(SEC). Fractions for peak PN4 were pooled and concentrated as shown in Figure 5-13. 




Figure 5-13 Size exclusion chromatographic profile of triCD23 using a Superdex 200 column. 
Fractions for peak PN4 were collected on a Superdex 200 column equilibrated with 0.5M Tris, 100 mM 
NaCl pH 7.5, flow rate = 0.75ml/min. 


















Figure 5-14 15 % SDS-PAGE of purified triCD23 stained with Comassie stain. M = marker, lane 1 = 
purified reduced triCD23, expected size = 28 kDa. 
 
5.2.7 Conjugating fluorophores to triCD23 and the ag-fusion protein 
 
TriCD23 was conjugated to Alexa-647, a photostable red dye with a high quantum 
yield. This fluorophore was chosen in order to minimise the possibility of spectral 
overlap with the transfected GFP. Figure 5-15 displays the spectra of Alexa647 and 




Figure 5-15 Fluorophore spectrum. Created by Biolegend website. Dotted and solid lines represent the 
excitation and emission spectra, respectively. Solid vertical lines represent the laser line while the thicker 
shaded vertical lines represent the flow cytometer’s filters. The emission spectrum of GFP and Alexa647 
do not overlap.  
 
















Alexa 647 was conjugated to triCD23 by amine coupling (Figure 5-16). In addition, 
IgG-sFceRIa, the extracellular region of FceRIa fused to an IgG4-Fc (ag-fusion 
protein; kindly provided by Rebecca Beavil) (Shi et al., 1997) was also conjugated to 
Alexa647 by amine coupling. To optimise the degree of labelling with the ag-fusion 
protein, varying molar excesses of dye were tried as documented in Figure 5-16. 
 
 
Figure 5-16 Labelling of ag-fusion protein and triCD3 with Alexa647. 12% SDS-PAGE gel captured 
with multichannel fluorescence; green = brightfield channel to capture markers, red= Alexa647 channel. 
1 = WT ag-fusion protein, 2 = 20x molar dye excess, 3 = 10 x molar dye excess, 4 = 5x molar dye 
excess, 5= WT triCD23, 6 = labelled triCD23.   
 
The ag-fusion protein-Alexa647 was stable (no degradation bands in Figure 5-16) and 
had expressed at high yield. In contrast triCD23 had a low yield and a longer production 
time. Subsequent experiments therefore employed the ag-fusion protein to assess the 
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5.2.8 Validation of selection assay reagents: ag-fusion protein-Alexa647 and 
FceRI-Alexa647 
 
The IgE-FceRI binding site had two potential assay reagents, the ag-fusion protein-
Alexa647 and the labelled high affinity IgE binding receptor, FceRI. Both of these 
reagents were tested on WEHI B cells expressing the short isoform (Batista et al., 1996) 
by flow cytometry as shown in Figure 5-17. Both Alexa-647 labelled reagents could 
bind to IgE expressed on the WEHI B-cells suggesting that membrane IgE spends more 
time bent, rather than fully extended on the cell surface for it to accommodate binding 
of these reagents. The ag-fusion protein-Alexa647 showed greater binding to the cells 
in panel B of Figure 5-17 and thus was chosen for further experiments. 
 
A)                                                                         B) 
 
Figure 5-17 Binding of Alexa64-conjugated FceRI and ag-fusion protein to WEHI cells. Grey = 








5.2.9 Validation of the WT memIgE-Fc-GFP and R334S memIgE-Fc-GFP cell 
lines… 
 
To analyse the memIgE-Fc-GFP library, two main control cell lines were required. 
These were the WT memIgE-Fc-GFP cell lines, and a known effective mutation: R334S 
(the R334S memIgE-Fc-GFP cell line), which served as a benchmark for the library. All 
the cells were positive for GFP. Figure 5-18 shows the addition of the Alexa-647 
conjugated ag-fusion protein to the cell lines and a clear difference can be seen in the 
histograms with the R334S cell line mean fluorescence intensity (MFI) binding 4x less 
well than the WT cell line. In previous studies, it is known that the R334S mutation is 
responsible for a 50-fold decrease in affinity for FceRI (Hunt et al., 2008) so any cells 
from the library that express a better than a 4-fold decrease in MFI would be expected 







Colour Sample MFI - Alexa647 
 WT cells only 121 
 R334S cells only 84.8 
 R334S cells and ag-fusion protein-Alexa647  1092 
 WT cells and ag-fusion protein-Alexa647 4695 
 
Figure 5-18 Histogram of ag-fusion protein-Alexa647 binding to the WT and R334S cell lines. Red = 
WT memIgE-Fc-GFP cell line with ag-fusion protein-Alexa647 at 1 ug/ml, magenta = R334S memIgE-
Fc-GFP cell line with ag-fusion protein-Alexa647 at 1 ug/ml, grey = R334S memIgE-Fc-GFP cells only, 
black = WT memIgE-Fc-GFP cells only. Table below: The MFI for each sample. 
 
5.2.10 Selection assay of memIgE-Fc-GFP library and its validation 
 
The selection assay for the memIgE-Fc-GFP library is a flow-cytometry based assay in 
which cells are first gated on GFP and then binding to Alexa-647 labelled IgE-receptors 
is measured. A typical analysis method is shown in Figure 5-19. The memIgE-Fc-GFP 





library with results shown in Figure 5-20. The FlpIn™ untransfected cells (red) do not 
express the memIgE-Fc-GFP and thus no GFP or Alexa647 MFI was measured. The 
WT memIgE-Fc-GFP cells (grey) bind to ag-fusion protein-Alexa647 with the highest 
MFI of 40963. The library (green) shows distinct populations which bind to ag-fusion 
protein-Alexa647 protein with apparent lower affinity than R334S memIgE-Fc-GFP 
cell line (Figure 5-20). The library has one negative peak that does not appear to bind to 
ag-fusion protein-Alexa647 protein. Another broader peak binds with reduced MFI 
compared to the R334S memIgE-Fc-GFP cell line, and overall the library had a 6-fold 
reduction in binding compared to the WT cell line. 
 
 
Figure 5-19 Representative Flow Cytometry analysis with gating and selection strategies displayed. 
Live WT memIgE-Fc-GFP cells are gated of which only GFP positive cells are chosen for further 
analysis. The main graph displays a histogram of the Alexa647 positive cells indicating that they are 
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Colour Sample Name Subset Name Count MFI – Alexa647 
 MemIgE-Fc-GFP mutant library GFP 5861 7474 
 R334SmemIgE-Fc-GFP cells GFP 6469 25680 
 WTmemIgE-Fc-GFP cells GFP 6222 40963 
 Untransfected FlpIn™HEK cells GFP 0 n/a 
 
Figure 5-20 Histogram values of ag-fusion protein-Alexa647 binding to the WT, R334S and library 
memIgE-Fc-GFP proteins and the untransfected FlpIn™HEK cells. Grey = WT memIgE-Fc-GFP 
cells, orange = R334SmemIgE-Fc-GFP cells, green =mutant library memIgE-Fc-GFP cells, red = 
untransfected FlpIn™HEK cells. MFI counts listed below histogram. Table displays MFI values, error 
bars = standard error of mean (SEM), n =3.  
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Sample Name Subset Name Count Median : RL1-H
[ VI_200617_Group_LIB_ag.fcs ] GFP 5861 7474 
[ VI_200617_Group_R334S_ag.fcs ] GFP 6469 25680 
[ VI_200617_Group_memIgE_ag.fcs ]  6222 40963 
[ VI_200617_Group_FlpIn_ag.fcs ] GFP 0 n/a 
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Sample Name Subset Name Count Median : RL1-H
[ VI_200617_Group_LIB_aIgE.fcs ] GFP 4626 572 
[ VI_200617_Group_R334S_aIgE.fcs ] GFP 6532 1303 
[ VI_200617_Group_memIgE_aIgE.fcs ] GFP 6068 1637 























5.3 Discussion  
Despite knowing the residues involved in binding at the IgE-FceRI and IgE-CD23 
interface, the exact roles of both IgE receptors in the normal physiology of IgE is not 
complete. The mechanisms of antigen presentation and epitope spreading that involve 
the IgE receptors could also be improved upon. The problem is further compounded by 
the highly flexible nature of IgE since it can twist from an acutely bent conformation (in 
which the constant domains are bent over one another) to an extended one (where the 
constant domains are fully extended) (Drinkwater et al., 2014; Holdom et al., 2011). 
These conformational changes result in two spatially separate receptor binding sites 
which are allosterically linked (Dhaliwal et al., 2012). These structural features have 
complicated the development of IgE inhibitors, since biologics are intrinsically complex 
and allosteric proteins are deemed a challenging target for small molecules. Targeting 
individual residues at the IgE receptor-binding interface has resulted in either little 
change in binding affinity or unfolded protein (Borthakur et al., 2012). 
 
To overcome these challenges, the Fc portion of IgE itself was engineered to create a 
library of IgE-Fc mutants, and a selection assay was developed and validated to identify 
single receptor-binding mutants. This mammalian cell-surface display library is the first 
to employ engineering of antibody constant domains with respect to receptor binding. 
Previous mammalian cell-surface antibody display libraries, despite expressing full-
length antibodies, have focused on expanding the diversity of variable domains 
(Waldmeier et al., 2016; Zhou et al., 2010; King et al., 2014). Those studies have also 
focused on IgG, which has a very different conformation in solution compared to the 
acutely bent IgE (Zheng et al., 1992) and has fewer glycosylation sites than IgE. This 
mem-IgE-Fc-GFP library also maintains the linked phenotype to genotype feature found 
in phage display since each cell only expresses one type of mutant Fc, and the 
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conservation of this feature in this display system is vital for the enrichment of proteins 
or the directed evolution of lead proteins.  
 
The size of mammalian cells (~100x larger than phage) impose a limit on the size of the 
library, and thus when creating a small library, it is vital to maximise diversity. The 
approach to make a ‘smarter’, less empirically-driven library was to utilise the ‘22c-
trick’ to limit codon degeneracy so that each amino acid was represented more evenly 
(Kille et al., 2013). Figure 5-7 indicates the diversity of the memIgE-Fc-GFP library, 
which was more successful for the R334 site than the P426 site, although this could just 
reflect the small sample size. The degenerate primers could have had a bias while being 
manufactured and the mutagenesis protocol could be optimised further by altering 
annealing temperatures of the primers or by changing the ratio of the degenerate 
primers in the PCR mix. This small proof-of-concept study has however produced a 
maximal protein diversity size of 400.  
 
For these studies, several stable cell lines were generated: WT memIgE-Fc-GFP and 
R334S memIgE-Fc-GFP as controls and the memIgE-Fc-GFP DNA library was 
successfully generated by a batch transfection. Figure 5-20 demonstrates the library 
contains mutant proteins with a range of apparent affinities for ag-fusion-protein-
Alexa647, however, a non-uniform distribution was observed.  
 
The two-colour FACS selection assay designed here to analyse the stable cell lines is 
adaptable and alternative fluorophores could be used. If the emission and excitation 
spectra do overlap then it would be best to create control cell lines, similar to that of 
flow cytometry compensation beads. In reference to Figure 5-5C, this would entail 
expressing only the transmembrane domain and the GFP portion of the protein and none 
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of the extracellular protein to create an internal standard. Figure 5-16 shows how 
different molar dye ratios were tested; this is important to obtain a greater sample range 
in the flow cytometry (Figure 5-18) so that reductions in binding can be observed more 
clearly, but it is also important to note that a brighter labelled protein does not 
necessarily mean a better reporter, since the dyes could conjugate to residues important 
for binding.  
 
When generating the selection assay reagents, it became clear (Figure 5-11) that the best 
method of increasing the affinity of CD23 would be to increase the avidity of the 
protein. There are many approaches to oligomerising proteins, such as biotinylating the 
protein and joining it to streptavidin, however, repeated need to purify the protein and 
dialyse it after each step would significantly reduce protein yield. The best solution was 
to produce a soluble trimeric CD23 protein and conjugate it directly to a fluorophore, 
reducing the number of processing steps and maximising yield of the reagent. A further 
possibility to optimise the reagent assay would be to redesign the protein construct and 
incorporate a fluorescent protein tagged to the terminus of the protein to avoid the need 
for conjugation. 
 
The potential assay reagents for the Fce-FceRI receptor binding site demonstrated a 
clear preference for ag-fusion protein-Alexa647 over FceRI-Alexa647 (Figure 5-17). 
This might be due to the heterogeneous glycosylation patterns of FceRI-Alexa647, 
which is heavily glycosylated (Kanellopouloss et al., 1980) although not a requirement 
for binding to IgE, which is based on protein-protein interactions (Garman et al., 2000). 
The carbohydrates on FceRI are required for efficient folding and solubility of the 
receptor (Robertson, 1993; Letourneur et al., 1995). In these results the FceRI-Alexa647 
may have caused greater steric hindrance than that of the ag-fusion protein. Another 
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reason for the better binding observed by the ag-fusion protein is that it is a dimer, and 
a possible avidity effect might allow for 2:1 binding not seen with FceRI-Alexa647. The 
greater availability of the ag-fusion protein also led to the decision to choose ag-fusion 
protein-Alexa647 for future experiments. 
 
This pipeline project could be converted to high-throughput in many ways. First, instead 
of a batch co-transfection for the library, individual transfections in 24-well plates could 
be conducted (transfections in 96-well plates were found to be inefficient, data not 
shown). The transfected cells could then be sorted on their ability to bind to the 
fluorescently labelled reagents. If the order is maintained, then the identity of the cells is 
known post-sorting if the plate layout is known. 
 
Alternatively, with novel emerging technology that could soon be applied, the sorted 
repertoire of mutant IgE-Fc cells could be analysed by next-generation sequencing and 
protein mass spectrometry instead of single-cell PCR analysis (Lavinder et al., 2015). 
This method builds on single-cell PCR analysis, to provide a low-cost technology. It 
uses a flow-focusing device like flow cytometry to capture individual cells in a single 
drop of fluid containing mRNA captures beads and lysis solution. The mRNA from the 
lysed cells anneals to the beads which are then purified and emulsified with reverse-
transcription solution. After reverse-transcription, the product is purified and sequenced 
by Ilumina sequencing technology (DeKosky et al., 2016; McDaniel et al., 2016). 
Thereafter, the DNA sequences could be recovered for analysis leading to further 
rounds of mutagenesis, or further protein production in order to better characterise the 




The selected mutant IgE-Fcs generated in the library can act as tools to examine the role 
of IgE receptor in antigen presentation and epitope spreading as well as discovering 
new ways of inhibiting the allergic response. This potentially could lead to the 
development of new therapeutics for allergen immunotherapy (to induce allergen 




Chapter 6 Summary and Future Work 
The pathophysiological role of IgE in allergy had been the focus of immunoglobulin E 
studies for several decades. The exact roles of this elusive antibody in normal 
physiology and homeostasis are still not fully known. Historically, IgE was known to be 
involved in mediating a type 2 immune response against macroparasites such as 
helminths, ticks and certain parasites, although IgE is not critical to clear infections 
naturally (Harris and Gause, 2011). Nowadays, IgE is more commonly associated with 
allergies, a misdirected immune response against common environmental stimuli. 
Recent studies have also associated IgE with tumour surveillance (Jensen-Jarolim et al., 
2010; Nigro et al., 2016). To better understand the true function of IgE and its role 
within a network of IgE receptors and proteins, new tools are required to investigate 
IgE.  
 
In chapter 5, I present a toolbox of new human IgE-Fc mutant proteins that can used to 
further investigate the functional role of IgE. The toolbox is presented as a surface 
display library, in which mutant membrane IgE-Fc proteins are displayed on 
mammalian HEK293 cells. The IgE-Fc domains have been mutated at receptor binding 
sites to modulate the Fc effector functions to disable binding to one or other of the two 
IgE receptors. This library has a proven diversity as indicated by the QQC controls 
described in section 5.2.3, which can be further expanded upon in the future. The 
surface display library and designed FACS screen have demonstrated a range of binding 
affinities for FceRI as shown in Figure 5-20. 
 
The known R334S mutant (Henry et al., 1997), which acted as benchmark for these 
studies, has shown a 50-fold reduction in IgE affinity for FceRI and a proportionate 
reduction of degranulation in vitro when compared to WT IgE (Hunt et al., 2008). The 
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developed FACS assay demonstrated IgE-Fc mutants with a lower affinity for FceRI 
than the known R334S mutant. These IgE-Fc mutants have the possibility of being even 
more effective than the R334S mutant at reducing mast cell degranulation in vitro. The 
R334S mutant resulted in a 75% reduction in passive cutaneous anaphylaxis response in 
vivo (Hunt et al., 2008); the new mutant-Fc proteins might be able to surpass this 
reduction and might indeed be below the affinity limit required to trigger mast cell 
degranulation in vivo.  
 
The designed pipeline for the surface display library uses laboratory equipment 
commonly found in molecular biology and cell culture laboratories, making it an 
accessible protocol. This library also makes it significantly easier to study IgE, studies 
of which are usually hampered by the low serum concentration (Dullaers et al., 2012) 
and the rarity of IgE-producing B-cells (Zuidscherwoude and van Spriel, 2012), as well 
as the dynamics of the protein itself (Drinkwater et al., 2014). The memIgE-Fc library 
produced a range of human IgE-Fc proteins in vitro with modulated Fc effector 
function. This small proof-of-principle study can be used to build a more complex 
library allowing for greater screening power, which can then be applied to defining 
IgE’s parameters in FAP and epitope spreading. This demonstration of Fc engineering, 
which is less common then Fab engineering, could also be used in an industrial setting 
since Fc optimisation is critical for antibody pharmacokinetics and pharmacodynamics 
(Tiller and Tessier, 2015).  
 
The membrane IgE-Fc protein construct I designed and created, has made it possible for 
the group to study membrane-bound IgE and its signalling. The memIgE-Fc construct 
has been adapted to express light chains and the remainder of the heavy chains, so that 
an entire membrane-IgE, capable of binding to allergens, is presented on the membrane 
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surface of B cells. The same protein construct contains the EMPD, a region for which 
researchers have a very limited knowledge. With the advent of monoclonal antibodies 
targeting this region (Feichtner et al., 2008; Vigl et al., 2017), this could be a chance to 
further explore its role. The crystal structure of IgE-Fc and FceRI provided great insight 
into IgE biology and the triggering of the allergic response, and perhaps a crystal 
structure of the EMPD will also reveal more about its role, and the epitope being 
targeted by the anti-IgE-EMPD monoclonal antibodies.  
 
With the exact role of IgE in the immune system being debated, the role of its receptors 
is also under examination. The low affinity receptor for IgE, CD23, can control IgE 
synthesis, dependent on whether it is membrane-bound or soluble, and on its 
oligomerisation status (Gould and Sutton, 2008). This regulation might be further 
modulated by the metal ion, calcium (Yuan et al., 2013). In chapters 3 and 4, I present 
in vitro experimental results and theoretical in silico simulations of CD23 to investigate 
further the role of calcium. To explore if human CD23 lost its ability to bind a second 
calcium ion and whether this uniquely affects its binding to human IgE, I created human 
CD23 mutants that ought to bind to two calcium ions.  
 
C-type lectins do not have high affinities for calcium like antibodies do for their 
antigens; the affinity of a CTL for calcium is within the mM range. The difficulty of 
measuring mM interactions with biophysical techniques, which are usually employed 
for tighter binding properties, made the task of elucidating calcium’s role challenging. 
Calcium titrations with NMR confirmed that a second calcium binding site had been 
introduced into mutant C, as shown in figure 3-22. Many previous studies of calcium in 
CTLs have been conducted by X-ray crystallography (Drickamer, 1999). Unfortunately, 
X-ray crystallographic studies with the mutant derCD23 proteins could not reveal the 
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co-ordination of the calcium ions since only the metal-free form of the protein 
crystallised. Despite various attempts to crystallise the calcium-bound protein, a task 
already found difficult with the WT human derCD23 protein (Yuan, 2012), the new 
crystal contact formed between molecules of the mutant proteins was more 
energetically favourable than binding of calcium (Figures 3-17 and 3-18). 
 
The mutant derCD23 proteins demonstrated lower calcium sensitivity and reduced IgE-
Fc binding affinities as shown by the SPR experiments in Figure 3-31. WT human 
derCD23 was the most sensitive to calcium with a 20-fold difference in KD in the 
presence of calcium, while mutant C was unable to bind to IgE with calcium present. 
This data supports the notion that the loss of binding to a second calcium ion in human 
CD23, resulted in a gain-of-function, in which human CD23 binds to human IgE with 
greater affinity and sensitivity to calcium.  
 
In C-type lectins, calcium plays a vital role in co-ordinating carbohydrate binding, 
although CD23 is unusual in its carbohydrate-independent interaction with IgE. A 
carbohydrate array reported in section 3.2.9, corroborates previous findings that WT 
human derCD23 is unable to bind to glycans (Hibbert 2005 and array 634 conducted by 
the Consortium for Functional Glycomics). Mutant B and C which contain the ‘EPN’ 
carbohydrate binding motif, displayed limited binding to some glycans (Figures 3-26 
and 3-27), however, this appeared to be non-specific. A NMR mannose titration with 
mutant C (Figure 3-26) revealed very weak binding to mannose ~ 30 mM, outside the 
expected range for a CTL (with dissociation constants usually in the 0.1 – 10 mM 
range) (Weis, 1997), and perhaps not within a functionally relevant range. This low 
affinity might be due to lack of an aromatic residue in loop 4, which would facilitate 




It was thought that the MD simulations might be able overcome challenges faced by 
experimental approaches, and predict the effect of the mutations on calcium binding to 
CD23. Only predictions for mutant B binding to two calcium ions matched the 
experimental data. Although MD simulations could provide insight into the calcium-
coordinating loop activities, these could not be compared to the experimental data, as 
the loops could not be identified in structural studies such as NMR or X-ray 
crystallography (Hibbert et al., 2005; Dhaliwal et al., 2012). MD simulations did 
however identify effects on loop 4 (which contain residues involved in both calcium-
binding sites, figure 5-2), that lead to reduced loop mobility when calcium bound. 
Unfortunately, this MD system was not well characterised enough to be used as an in 
silico prediction tool.  
 
There are various other types of MD simulations that could be used to estimate binding 
affinities, which could complement SPR studies. Alternatively, more complex types of 
MD simulations such as the MM-PBSA approach (Case et al., 2014) and the Free 
Energy Workflow Tool (Case et al., 2014), could be used to calculate binding energies. 
 
The mutant proteins described in both chapters 3 and 4, are an attempt to further our 
knowledge of mouse CD23 and the differences between mouse and human CD23. 
Studies on murine derCD23 could advance our understanding of the different calcium 
binding and dissociation properties between the species. For example, could the calcium 
sensitivity have implications for the efficiency of FAP and epitope spreading? In 
humans, is IgE homeostasis more sensitive to calcium levels and thus more prone to 
dysregulation and allergy? Hopefully the tools created and described in this thesis can 
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Appendix B. List of glycans on the RayBio Glycan Array  
 
1 β-Glc-Sp  51 GlcNAc-β-1,4-GlcNAc-β-Sp1  
2 β-Gal-Sp  52 β-D-GlcA-Sp  
3 α-Man-Sp  53 Gal-β-1,4-(6S)GlcNAc-β-Sp  
4 α-Fuc-Sp  54 GlcNAc-α-1,3-(Glc-α-1,2-Glc-α-1,2)-Gal- α-
1,3-Glc-α-Sp  
5 α-Rha-Sp  55 Gal-β-1,3-GalNAc-β-1,4-(Neu5Gc-α-2,3)- Gal-
β-1,4-Glc-β-Sp1 
6 β-GlcNAc-Sp  56 Sisomicin Sulfate 
7 β-GalNAc-Sp  57 GalNAc-α-1,3-(Fuc-α-1,2)-Gal-β- [Blood A 
antigen trisaccharide]-Sp1  
8 Tobramycin  58 Fuc-α-1,2-Gal-β-1,4-GlcNAc-β- [Blood H 
antigen trisaccharide]-Sp1  
9 Gal-β-1,3-GlcNAc-β-Sp  59 Gal-α-1,3-(Fuc-α-1,2)-Gal-β- [Blood B antigen 
trisaccharide]-Sp1  
10 Gal-α-1,3-Gal-β-1,3-GlcNAc-β-Sp  60 Fuc-α-1,2-Gal-β-1,3-GlcNAc-β-1,3-Gal-β- 1,4-
Glc-β- [LNFP I]-Sp1  
11 Neu5Ac-α-2,3-Gal-β-1,3-GlcNAc-β-Sp  61 Fuc-α-1,2-Gal-β-1,4-Glc-β- [Blood H antigen 
trisaccharide]-Sp1  
12 Neu5Ac-α-2,6-Gal-β-1,3-GlcNAc-β-Sp  62 Gal-α-1,3-(Fuc-α-1,2)-Gal-β-1,4-Glc-β- [Blood 
B antigen tetrasaccharide]-Sp1  
13 Neu5Gc-α-2,3-Gal-β-1,3-GlcNAc-β-Sp  63 (Fuc-α-1,2)-Gal-β-1,4-(Fuc-α-1,3)- GlcNAc-β- [ 
Lewis Y]-Sp1  
14 Neu5Gc-α-2,6-Gal-β-1,3-GlcNAc-β-Sp  64 (Fuc-α-1,2)-Gal-β-1,3-(Fuc-α-1,4)- GlcNAc-β- [ 




1,4-(Fuc-α-1,4)-Glc-β- [Lewis A]-Sp1 
16 Gal-β-1,4-Glc-β-Sp  66 Gal-β-1,3-GalNAc-β-Sp1  
17 Gal-α-1,3-Gal-β-1,4-Glc-β-Sp  67 Gal-β-1,3-(Neu5Ac-α-2,6)-GalNAc-β-Sp  
18 Gal-α-1,4-Gal-β-1,4-Glc-β-Sp  68 Neu5Ac-α-2,6-Gal-β-1,3-GalNAc-β-Sp  
19 GlcNAc-β-1,3-Gal-β-1,4-Glc-β-Sp  69 Neu5Ac-α-2,6-Gal-β-1,3-(Neu5Ac-α- 2,6)-
GalNAc-β-Sp  




21 Neu5Ac-α-2,3-Gal-β-1,4-Glc-β-Sp  71 Neu5Ac-α-2,6-(Neu5Ac-α-2,3)-Gal-β- 1,3-
GalNAc-β-Sp  
22 Neu5Ac-α-2,6-Gal-β-1,4-Glc-β-Sp  72 GalNAc-β-1,4-(Neu5Ac-α-2,3)-Gal-β-1,4- Glc-
β- [GM2]-Sp  
23 Neu5Gc-α-2,3-Gal-β-1,4-Glc-β-Sp  73 GalNAc-β-1,4-(Neu5Ac-α-2,8-Neu5Ac-α- 2,3)-
Gal-β-1,4-Glc-β- [GD2]-Sp  
24 Neu5Ac-α-2,6-Gal-β-1,4-Glc-β-Sp  74 Gal-α-1,4-Gal-β-1,4-GlcNAc-β-Sp1  





27 GlcNAc-β-1,6-GlcNAc-β-Sp  77 Glc-α-1,6-Glc-α-1,6-Glc-β-Sp1  
28 4-P-GlcNAc-b-1,4-Man-b-Sp  78 Maltotriose-β-Sp1  
29 Glc-α-1,2-Gal-α-1,3-Glc-α-Sp  79 Glc-α-1,6-Glc-α-1,6-Glc-β-Sp1  
30 Gal-β-1,3-GalNAc-α-Sp  80 Maltotetraose-β-Sp1  
27 GlcNAc-β-1,6-GlcNAc-β-Sp  77 Glc-α-1,6-Glc-α-1,6-Glc-β-Sp1  
28 4-P-GlcNAc-b-1,4-Man-b-Sp  78 Maltotriose-β-Sp1  
29 Glc-α-1,2-Gal-α-1,3-Glc-α-Sp  79 Glc-α-1,6-Glc-α-1,6-Glc-β-Sp1  
30 Gal-β-1,3-GalNAc-α-Sp  80 Maltotetraose-β-Sp1  





82 Maltohexaose-β-Sp1  
 
33 Neu5Ac-α-2,3-Gal-β-1,4-(Fuc-α-1,3)- 
GlcNAc-β- [Sialyl Lewis X]-Sp  83 Maltoheptaose-β-Sp1  
34 Neu5Ac-α-2,3-Gal-β-1,3 -(Fuc-α-1,4)- 
GlcNAc-β- [Sialyl Lewis A]-Sp  84 Acarbose-β-Sp1  
35 Neu5Gc-α-2,3-Gal-β-1,3-(Fuc-α-1,4)- 
GlcNAc-β- [Sialyl Lewis A]-Sp  85 D-pentamannuronic acid-β-Sp1  
36 Gal-α-1,4-Gal-β-1,3-GlcNAc-β-Sp  86 L-pentaguluronic acid-β-Sp1  
37 Gal-β-1,4-GlcNAc-β-1,3-Gal-β-1,4-Glc-β- 
[LNnT]-Sp  87 D-cellose-β-Sp1  
38 GlcA-β-1,4-GlcNAc-α-1,4-GlcA-β-Sp  88 Gal-α-1,3-Gal-β-Sp1  
39 GlcNAc-β-1,6-(Gal-β-1,3)-GalNAc-α-O- 
Ser- Sp4  89 β-1,4-Xylotetrose-Sp1  




41 GalNAc-β-1,4-GlcNAc-β-Sp2  91 KDN-α-2,8-Neu5Ac-α-2,3-Gal-β-1,4-Glc- β-Sp  









β- [Blood A antigen tetrose]-Sp1  
94 Neu5Ac-a-2,8-Neu5Ac-a-2,6-Gal-b-1,4- Glc-
Sp5  
45 GlcNAc-β-1,2-Man-α-Sp  95 Gal-β-1,3-GalNAc-β-1,4-(Neu5Ac-α-2,3)- Gal-
β-1,4-Glc-β-Sp1  
46 Neu5Ac-α-2,3-Gal-β-Sp1  96 Gentamicin Sulfate 
47 Gal-β-1,3 -GalNAc-β-1,3-Gal-β-Sp1  97 Kanamycin sulfate 
48 Glc-α-1,2-Gal-α-Sp  98 Geneticin Disulfate Salt (G418)  
49 Gal-β-1,4-(Fuc-α-1,3)-GlcNAc-β-1,3-Gal- 
β-Sp1  99 Neomycin trisulfate SGP  
50 Neu5Ac-α-2,3-Gal-β-1,4-(Fuc-α-1,3)-Glc- 
β- [3-Sialyl-3-fucosyllactose/ F-SL]-Sp1  100 SGP 
 
Table 6-1 A list of the glycans printed on the RayBio Glycan Array. Sp = linkers used to bind glycan 
to the glass slide. Sp: OCH2CH2CH2NH2. Sp1: NH(CH3)OCH2CH2NH2. Sp2: OCH2CH2NH2. Sp3: 







Appendix C. Input files for the Molecular Dynamics 
Simulations…. 
 
System minimization, minimize only the water and restrain the protein: 
System minimization:  
  &cntrl #Namelist for basic controls 
  imin=1,  
  ntmin=1,  
   
 
  nmropt=0,  
  drms=0.1 
#Choose a minimization run 
#Method of minimization = steepest 
descent for ncyc cycles then switch to 
conjugate gradient 
#No NMR-specific analysis 
#Convergence criterion for energy 
gradient 
  maxcyc=2000,  
  ncyc=1500,  
#Maximum number of minimization cycles 
#Switch to conjugate gradient algorithm  
  ntx=1,  
  irest=0, 
#Input: read formatted inpcrd file 
#Run new simulation 
  ntpr=100,  
   
  ntwr=100,  
   
  iwrap=0, 
#Output: print energy information every 
100 steps 
#Output: print restart file every 100 
steps 
#Output: do not wrap coordinates in 
restart/trajectory files  
  ntf=1,  
  ntb=1,  
   
  cut=10.0,  
  nsnb=20, 
#Complete force evaluation 
#Equilibrate at constant volume with 
periodic box boundaries 
#Nonbonded cut-off (Angstroms) 
#Nonbonded list update frequency 
  igb=0, #No generalised Born solvation model 
  ibelly=0,  
   
  ntr=1, 
#No groups of independently restrained 
atoms (belly type dynamics) 
#Use restraints (harmonic potential) on 




#Force constant (kcal/mol-Å2) for 
restrained atoms 
&end #End of instructions 
 
Let the water move while restraining the protein: 
LET WATER MOVE:  
  &cntrl #Namelist for basic controls 
  timlim=999999.,  
  nmropt=0,        
  imin=0, 
#Time limit 
#No NMR-specific analysis 
#No minimization: molecular dynamics run 
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  ntx=1,        
  irest=0,       
  ntrx=1,       
  ntxo=1, 
#Input: read formatted inpcrd file 
#Run new simulation 
#Formatted (ASCII) Cartesian coordinate 
#Formatted (ASCII) restart file 
  ntpr=500,      
   
  ntwx=500,      
   
  ntwv=0,       
  ntwe=0, 
#Output: print energy information every 500 
steps 
#Output: print trajectory file every 500 
steps 
#Output: no velocity trajectory file 
#Output: no energy and temperature file 
  ntwr=5000, #Output: print restart file every 5000 steps 
  ntf=2,        
  ntb=2, 
#No force evaluation for bonds with H atoms 
#Constant pressure with periodic box 
boundaries 
  cut=10.0,     
  nsnb=20, 
#Nonbonded cut-off (Angstroms) 
#Nonbonded list update frequency 
  nstlim=10000,    
  nscm=2500, 
    
  iwrap=1, 
#Number of molecular dynamics steps 
#Remove translational center-of-mass motion 
every 2500 steps 
#Output: wrap coordinates in 
restart/trajectory files 
  t=0.0,      
  dt=0.002, 
#Start time 
#Time step (ps) 
  temp0=300.0,      
  tempi=200.0,     
  tautp=0.5, 
#Reference temperature to be kept at 
#Initial temperature 
#Time constant (ps) for heat bath coupling 
  ntt=1,  #Constant Temperature (Berendsen thermostat) 
  ntp=1,        
   
  taup=1.0, 
#Constant pressure with periodic boundary 
conditions 
#Pressure relaxation time (ps) 
  ntc=2,        
  tol=0.00001, 
#H atom bond lengths are SHAKE constrained 
#Relative geometrical tolerance for 
 coordinate resetting in shake 
  ibelly=0,  
   
  ntr=1, 
#No groups of independently restrained atoms 
(belly type dynamics) 
#Use restraints (harmonic potential) on 







#Force constant (kcal/mol-Å2) for restrained 
atoms 
&end #End of instructions 
 
Minimize the water and the protein: 
System minimization:  
  &cntrl #Namelist for basic controls 
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  imin=1,  
  ntmin=1,  
   
 
  nmropt=0,  
  drms=0.1 
#Choose a minimization run 
#Method of minimization = steepest descent 
for ncyc cycles then switch to conjugate 
gradient 
#No NMR-specific analysis 
#Convergence criterion for energy gradient 
  maxcyc=2000,  
  ncyc=1500, 
#Maximum number of minimization cycles 
#Switch to conjugate gradient algorithm 
  ntx=1, 
  irest=0, 
#Input: Read formatted inpcrd file 
#Run new simulation 
  ntpr=100, 
   
  ntwr=100, 
   
  iwrap=0, 
#Output: print energy information every 
100 steps 
#Output: print restart file every 100 
steps 
#Output: do not wrap coordinates in 
restart/trajectory files 
  ntf=1, 
  ntb=1, 
   
  cut=10.0, 
  nsnb=20, 
#Complete force evaluation 
#Equilibrate at constant volume with 
periodic box boundaries 
#Nonbonded cut-off (Angstroms) 
#Nonbonded list update frequency 
  igb=0, #No generalised Born solvation model 
  ibelly=0, 
   
  ntr=0, 
#No groups of independently restrained 
atoms (belly type dynamics) 
#No positional restrains 
&end #End of instructions 
 
Heat the system while restraining the protein:  
Heating System:  
&cntrl #Namelist for basic controls 
  imin=0, 
  nmropt=1, 
#No minimization: molecular dynamics run 
#NMR restraints 
  ntx=1, 
  irest=0, 
#Input: read formatted inpcrd file  
#Input: run new simulation 
  ntpr=500, 
   
  ntwr=500, 
  ntwx=500, 
  iwrap=1, 
#Output: print energy information every 500 
steps 
#Output: print restart file every 500 steps 
#Output: trajectory file every 500 steps 
#Wrap coordinates in restart/trajectory files 
  ntf=2, 
  ntb=1, 
   
  cut=10.0, 
  nsnb=20, 
#No force evaluation for bonds with H atoms 
#Equilibrate at constant volume with periodic 
box boundaries 
#Nonbonded cut-off (Angstroms) 
#Nonbonded list update frequency 
  igb=0, #No generalised Born solvation model 
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  ibelly=0, 
   
  ntr=1, 
#No groups of independently restrained atoms 
(belly type dynamics) 
#Use restraints (harmonic potential) on atoms 
specified by restraintmask 
  nstlim=250000,  
  nscm=500, 
 
#Number of molecular dynamics steps 
#Remove translational center-of-mass motion 
every 500 steps 
  dt=0.002, #Time step (ps) 
  ntt=1, 
  temp0=0.0, 
  tempi=0.0, 
  tautp=0.5 
#Constant Temperature (Berendsen thermostat) 
#Reference temperature to be kept at 
#Initial temperature 
#Time constant (ps) for heat bath coupling 
  ntc=2, 
restraintmask=':1-
135', 
#H atom bond lengths are SHAKE constrained 
#Restraint information 
restraint_wt=10.0, #Force constant (kcal/mol-Å2) for restrained 
atoms 
&end  
  &wt type='REST',   
   
  istep1=0, 
  istep2=0, 
  value1=1.0, 
  value2=1.0,&end 
#relative NMR restraint energy term weights 
are varied 
#Apply change in conditions  
#Conditions maintained until end of the run 
#Value of istep 1 change 
#Value of istep 2 change 
  &wt 
type='TEMP0',  
  istep1=0,  
  istep2=250000,    
  value1=0.0,  
  value2=300,&end 
#Varying target temperature 
 
#Apply change in conditions 
#End conditions at istep2 
#Value of istep 1 change 
#Value of istep 2 change 
  &wt type='END'  
&end 
#End varying conditions 
#End of instructions 
 
Relax the system, restraining the protein heavy atoms: 
heat:  
  &cntrl #Namelist for basic controls 
  imin=0, 
  irest=1, 
  ntx=5, 
#No minimization: molecular dynamics run 
#Input: restart previous MD  
#Input: read formatted coordinates and 
velocities 
  nstlim=250000, 
  dt=0.002, 
#Number of molecular dynamics steps 
#Time step (ps) 
  ntc=2, 
  ntf=2, 
#H atom bond lengths are SHAKE constrained 
#No force evaluation for bonds with H atoms 
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  cut=10.0,  
  ntb=2,  
   
 
  ntp=1,  
   
  taup=1.0, 
#Nonbonded cut-off (Angstroms) 
#Constant pressure with periodic box 
boundaries 
#Constant pressure with periodic boundary 
conditions 
#Pressure relaxation time (ps) 
  ntpr=500,  
   
  ntwx=500, 
#Output: print energy information every 500 
steps 
#Output: trajectory file every 500 steps 
  ntt=3,  
  gamma_ln=2.0, 
#Temperature control (Langevin dynamics) 
#Collision frequency (ps-1) 
  temp0=300.0, 
  iwrap=1, 
#Reference temperature to be kept at 
#Output: wrap coordinates in 
restart/trajectory files 




#Use restraints (harmonic potential) on atoms 
specified by restraintmask 
#Restraint information 
restraint_wt=10.0, #Force constant (kcal/mol-Å2) for restrained 
atoms 
 /  
 
Relax the system: 
Equilibrate:  
  &cntrl #Namelist for basic controls 
  imin=0, 
  irest=1, 
  ntx=5, 
#No minimization: molecular dynamics run 
#Input: restart previous MD 
#Input: read formatted coordinates and 
velocities 
  nstlim=2500000, 
  dt=0.002, 
#Number of molecular dynamics steps 
#Time step (ps) 
  ntc=2, 
  ntf=2, 
  ig=-1, 
#H atom bond lengths are SHAKE constrained 
#No force evaluation for bonds with H atoms 
#Random seed for pseudo-random number  
 generator based on date and time 
  cut=10.0,  
  ntb=2,  
   
  ntp=1,  
   
  taup=2.0, 
#Nonbonded cut-off (Angstroms) 
#Constant pressure with periodic box 
boundaries 
#Constant pressure with periodic boundary 
conditions 
#Pressure relaxation time (ps) 
  ntpr=1000,  
   
  ntwx=1000, 
#Output: print energy information every 1000 
steps 
#Output: trajectory file every 1000 steps 
  ntt=3,  
   
#Temperature control (Langevin dynamics) 
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  gamma_ln=2.0, #Collision frequency (ps-1) 
  temp0=300.0, #Reference temperature to be kept at 




ntpMD - Langevin Temp, Monte Carlo P,2fs steps, 50ps saves: 
  &cntrl #Namelist for basic controls 
  imin=0, 
  irest=1, 
  ntx=5, 
#No minimization: molecular dynamics run 
#Input: restart previous MD 
#Input: read formatted coordinates and 
velocities 
  nstlim=100000000, 
  dt=0.002, 
#Number of molecular dynamics steps 
#Time step (ps) 
  ntc=2, 
  ntf=2, 
  ig=-1, 
#H atom bond lengths are SHAKE constrained 
#No force evaluation for bonds with H atoms 
#Random seed for pseudo-random number  
 generator based on date and time 
  cut=10.0,  
  ntp=1, 
   
  barostat=2 
#Nonbonded cut-off (Angstroms) 
#Constant pressure with periodic boundary 
conditions 
#Monte Carlo barostat used for pressure 
control 
  ntpr=25000, 
  ntwx=25000,  
  ntwr=25000, 
#Output: print data every 25000 steps 
#Output: trajectory file every 25000 steps 
#Output: print restart file every 25000 
steps 
  ntt=3, 
  gamma_ln=5.0, 
#Temperature control (Langevin dynamics) 
#Collision frequency (ps-1) 
  temp0=300.0, 
  ioutfm=1, 
   
  iwrap=1, 
#Reference temperature to be kept at 
#Coordinates and velocities written in 
NetCDF format 
#Output: wrap coordinates in 
restart/trajectory files 











import numpy as np # import pyemma modules 





import pyemma.coordinates as coor 
import pyemma.msm as msm 
import pyemma.plots as mplt 
from pyemma import config 
import matplotlib.pyplot as plt 
import pyemma.coordinates as coor 
 
trajfile = './WT/trj/WT_Ca1.nc' # renamed mdcrd trajectory file 
topfile = './WT/WT_Ca3.pdb' # pdb file 
 
feat = coor.featurizer(topfile)# just use all xyz-coordinates 
feat.add_all() 
 
feat.describe()[:5] # print output 
 
inp = coor.source(trajfile, feat) 
print ('trajectory length = ' , inp.trajectory_length(0)) 
print ('number of dimension = ',inp.dimension()) 
 
feat = coor.featurizer(topfile) 
 
n_res = 135 # number of residues 
ben_ind = 136 # Calcium index (with residues starting at 1) 
ind_arr = np.zeros((n_res,2)) 
for i in range(n_res): 
    ind_arr[i][0] = ben_ind-1 




feat.describe()[:5] # print output 
 
inp = coor.source(trajfile, feat) 
print ('number of trajectories = ',inp.number_of_trajectories()) 
print ('trajectory length = ',inp.trajectory_length(0)) 
print ('trajectory time step = ',200.0 / 
(inp.trajectory_length(0)),'ns') 






RES = inp.get_output() # get results 
print ('number of trajectories = ', np.shape(RES)[0]) 
print ('number of frames = ', np.shape(RES)[1]) 




print (XY[1500,70:77])  
# check Ca residue distance for res70 to res77 at frame 1500 
 
# plot one residue to Ca separation 
matplotlib.rcParams.update({'font.size': 18}) 
plt.figure(figsize(15,5)) 




plt.plot(XY[:,(72)-1 linewidth=2) # residue to plot 
 







# residues numbered according to mouseCD23 instead of 1 to 135 
# colour of plot used is CMRmap 
plt.colorbar(); imgplot.set_clim(0.2,1.0)  
# plot from 0.2nm to 1nm only 
plt.title('WT m-derCD23') # rename graph for mutants 
# CA binds at res 72 aka E252 OR res 92 aka E272 
 
# Combining both graphs 
figure(figsize(18,12)) 
matplotlib.rcParams.update({'font.size': 18}) 





plt.title('WT m-derCD23') # rename graph for mutants 
plt.ylabel('ns') 
plt.xlabel('Residue') 
left, bottom, width, height = [0.2, 0.6, 0.2, 0.2] 
ax1 = fig.add_axes([left, bottom, width, height]) 
ax1.plot = plt.plot(XY[:,(72)-1],linewidth=1)  
plt.xticks(np.arange(0,4001,1000))  
plt.yticks(np.arange(0,4,1)) # adjust y axis as required 
plt.title('E252') 
plt.ylabel('Ca-Protein Separation (nm)')  
plt.xlabel ('Frame') 




Appendix E. Trajectory Analysis script in R 
 
#Veronica's automated analysis for MD Simulations 
for I in 1 2 3 
do 
echo "Analysis Beginning" $I 
 
#Load and read the files and environment 
R --save <<EOF 
library(bio3d) 
library(igraph) 
dcd <- read.dcd("PROTEIN_NAME_run$I.dcd") 
pdb <- read.pdb("CA.pdb") 
print(pdb) 
print(dcd) 
ca.inds <- atom.select(pdb,"calpha", resno=4:125) 




dim(xyz) == dim(dcd) 
 
#Generate a new PDB with renumbered residues 
nums <- as.numeric(pdb\$atom[,"resno"]) 
nums <- nums - (nums[1] - 159) 
write.pdb(pdb=pdb, resno=nums, file="renum.pdb") 
 
#RMSD 
rd <- rmsd(xyz[1,ca.inds\$xyz], xyz[,ca.inds\$xyz]) 
plot(rd, typ="l", ylab="RMSD", xlab="Frame No.") 
points(lowess(rd), typ="l", col="red", lty=2, lwd=2); dev.copy((png), file = "RMSD\$I.png") 
write.table(rd, file="RMSD\$I.csv", col.names=FALSE, sep = ",") 
dev.off() 
 
hist(rd, breaks=40, freq=FALSE, main="RMSD_Histogram", xlab="RMSD") 
lines(density(rd), col="gray", lwd=3); dev.copy((png), file = "Hist\$I.png") 
dev.off() 
 
#Radius of gyration 
rg <- rgyr(xyz[,ca.inds\$xyz]) 
plot(rg, typ="l", ylab="Rgyr", xlab="Frame No.") 
points(lowess(rg), typ="l", col="red", lty=2, lwd=2); dev.copy((png), file = "Rgyr\$I.png") 







rf <- rmsf(xyz[,ca.inds\$xyz]) 
plot(rf, ylab="RMSF", xlab="Residue Position", typ="l"); dev.copy((png), file = 
"RMSF\$I.png") 




pc <- pca.xyz(xyz[,ca.inds\$xyz]) 
plot(pc, col=bwr.colors(nrow(xyz)) ); dev.copy((png), file = "PCA\$I.png") 
dev.off() 
 
hc <- hclust(dist(pc\$z[,1:2])) 
grps <- cutree(hc, k=2) 
plot(pc, col=grps); dev.copy((png), file = "Clusters\$I.png") 
dev.off() 
 
plot.bio3d(pc\$au[,1], ylab="PC1 (A)", xlab="Residue Position", typ="l") 
points(pc\$au[,2], typ="l", col="blue"); dev.copy((png), file = "PCA1_2res\$I.png") 
dev.off() 
p1 <- mktrj.pca(pc, pc=1, b=pc\$au[,1], file="pc1.pdb") 
p2 <- mktrj.pca(pc, pc=2,b=pc\$au[,2], file="pc2.pdb") 




plot.bio3d(pc\$au[,2], ylab="PC2 (A)", xlab="Residue Position", typ="l") 
points(pc\$au[,3], typ="l", col="blue"); dev.copy((png), file = "PCA2_3res\$I.png") 
dev.off() 
plot.bio3d(pc\$au[,1], ylab="PC1 (A)", xlab="Residue Position", typ="l") 
points(pc\$au[,3], typ="l", col="blue"); dev.copy((png), file = "PCA1_3res\$I.png") 
dev.off() 
 
#Residue Cross Correlation 
cij <- dccm(xyz[,ca.inds\$xyz]) 
plot(cij); dev.copy((png), file = "CrossCorrel\$I.png"); dev.copy((png), file = 
"CrossCorrel\$I.png") 




#Calculate suboptimal network paths 
net <- cna(cij, cutoff.cij=0.3) 
print(net) 
x <- summary(net) 
par(mfcol = c(1, 2), mar = c(0, 0, 0, 0)) 
plot(net, pdb, full = TRUE, vertex.label.cex=0.7) 
plot(net, pdb) 




print(pa, label="HIVP", plot=TRUE); dev.copy((png), file = "HIVP\$I.png") 
view.cnapath(pa, pdb=pdb, spline=TRUE, col='cyan', launch=FALSE) 
write.table(net\$cij, quote=FALSE, row.names=FALSE, col.names=FALSE, 
file="adj_forWISP.txt") 
 
node.betweenness <- betweenness(net\$network) 








view.dccm(cij, pdbshort, type="pdb", launch=FALSE) 
write.pdb(pdb=NULL, xyz=pdbshort\$xyz, file="RMSF-Bfactors.pdb", b=rf) 






#Move files to Folder 
 
mkdir Analysis_res4-125_Run$I 
mv *.csv NaAnalysis_res4-125_Run$I 
mv pc1.pdb Analysis_res4-125_Run$I 
mv pc2.pdb Analysis_res4-125_Run$I 
mv pc3.pdb Analysis_res4-125_Run$I 
mv betweenness.pdb Analysis_res4-125_Run$I 
mv renum.pdb Analysis_res4-125_Run$I 
mv trj_pc1.nc Analysis_res4-125_Run$I 
mv trj_pc2.nc Analysis_res4-125_Run$I 
mv trj_pc3.nc Analysis_res4-125_Run$I 
mv Rplots.pdf Analysis_res4-125_Run$I 
mv corr.inpcrd.pdb Analysis_res4-125_Run$I 
mv corr.pdb Analysis_res4-125_Run$I 
mv RMSF-Bfactors.pdb Analysis_res4-125_Run$I 
mv view.cnapath.pdb Analysis_res4-125_Run$I 
mv view.cnapath.vmd Analysis_res4-125_Run$I 
mv adj_forWISP.txt Analysis_res4-125_Run$I 
mv CrossCorrel$I.png Analysis_res4-125_Run$I 
mv HIVP\$I.png Analysis_res4-125_Run$I 
 
done 
 
 
262 
 
 
 
 
 
 
